RM
301.45
.A66
1993
Oct
Suppl

ST. LOUIS COLLEGE OF PHARMACY LIBRARY
JAN 10 1994

CUMULATIVE SUPPLEMENT 10

JAN'93-OCT'93

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

RM301.45 .A66 1993 Oct Suppl

Approved drug products with therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

RM301.45 .A66 1993 Suppl 10

Approved drug products with therapeutic equivalence
C:368627 M:154953 O:12771735

SUBCRIBE NOW!

Available in March 1994

New 14th Edition



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION 1994

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Cumulative Supplement 10

OCTOBER 1993

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Products Requiring Revised Labeling for Full Approval	v
1.3	Applicant Name Changes	vi
1.4	USP Monograph Title Additions or Changes	viii
1.5	Report of Counts for the Prescription Drug Product List	ix
2.0	DRUG PRODUCT LISTS	
2.1	Prescription Drug Product List	1
2.2	OTC Drug Product List	77
2.3	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	81
2.4	Orphan Drug Product Designations	82
2.5	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	87
2.6	Biopharmaceutic Guidance Availability	88
2.7	ANDA Suitability Petitions	89
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
	A. Exclusivity Terms	90
	B. Patent and Exclusivity Lists	91

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

CUMULATIVE SUPPLEMENT 10

OCTOBER 1993

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 13th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line containing overstruck print. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 13th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 14th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AH ROBINS CO (ROBINS)	AH ROBINS CO (ROBINS AH)
ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC (ALLERGAN HERBERT)	ALLERGAN HERBERT DIV ALLERGAN INC (ALLERGAN INC)
ASTRA PHARMACEUTICAL PRODUCTS INC (ASTRA)	ASTRA USA INC (ASTRA)
BAKER CUMMINS PHARMACEUTICALS INC (BAKER CUMMINS)	BAKER NORTON PHARMACEUTICALS INC (BAKER NORTON)
BENEDICT NUCLEAR PHARMACEUTICALS INC (BENEDICT)	NORTH AMERICAN CHEMICAL CORPORATION (NORTH AM CHEM)
BOLAR PHARMACEUTICAL CO INC (BOLAR)	CIRCA PHARMACEUTICALS INC (CIRCA)
CIS US INC (CIS)	CIS US INC (CIS) **formerly** (CIS US)
CUTTER BIOLOGICAL DIV MILES LABORATORIES INC (CUTTER)	MILES LABORATORIES INC (MILES LABS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DANBURY PHARMACAL INC (DANBURY)	DANBURY PHARMACAL INC (DANBURY PHARMA)
FUJISAWA PHARMACEUTICAL CO (FUJISAWA)	FUJISAWA USA INC (FUJISAWA)
HERBERT LABORATORIES DIV SMITH KLINE AND FRENCH CO (HERBERT)	ALLERGAN HERBERT DIV ALLERGAN INC (ALLERGAN HERBERT)
ICI PHARMACEUTICALS GROUP DIV ICI AMERICAS (ICI)	ZENECA PHARMACEUTICALS GROUP DIV ZENECA INC (ZENECA) **formerly** ZENECA PHARMACEUTICALS GROUP
LEMMON CO (LEMMON)	LEMMON CO SUB TEVA PHARMACEUTICALS (LEMMON)
LYPHOMED DIV FUJISAWA USA INC (LYPHOMED)	FUJISAWA USA INC (FUJISAWA)
OWEN GALDERMA LABORATORIES INC (OWEN GALDERMA)	GALDERMA LABORATORIES INC (GALDERMA)
PIONEER PHARMACEUTICALS INC (PIONEER PHARMS)	PIONEER PHARMACEUTICALS CO INC (PIONEER PHARMS)
ROXANE LABORATORIES INC (ROXANE)	ROXANE LABORATORIES INC (ROXANE) **formerly** (ROXANE LABS)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV MCNEILAB (JOHNSON RW)	RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)
SCHIAPPARELLI SEARLE (SCHIAPPARELLI SEARLE)	SCS PHARMACEUTICALS (SCS PHARMS)
SCHWARZ PHARMA KERMERS URBAN (SCHWARZ PHARMA)	SCHWARZ PHARMA DIV KREMERS URBAN CO (SCHWARZ PHARMA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
SOMERSET PHARMACEUTICALS INC (SOMERSET)	SOMERSET PHARMACEUTICALS INC (SOMERSET PHARMS)
STERLING DRUG INC (STERLING)	STERLING WINTHROP INC (STERLING WINTHROP)

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF OCTOBER 1993.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1992) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1992	MAR 1993	JUN 1993	SEP 1993
DRUG PRODUCTS LISTED	9488	9392	9194	9142
SINGLE SOURCE	2245 (23.7%)	2243 (23.9%)	2119 (23.0%)	2151 (23.5%)
MULTISOURCE	7243 (76.3%)	7149 (76.1%)	7075 (77.0%)	6991 (76.5%)
THERAPEUTICALLY EQUIVALENT	6516 (68.6%)	6432 (68.5%)	6357 (69.1%)	6276 (68.7%)
NOT THERAPEUTICALLY EQUIVALENT	577 (6.1%)	562 (5.9%)	555 (6.1%)	532 (5.8%)
EXCEPTIONS[1]	150 (1.6%)	155 (1.7%)	163 (1.8%)	183 (2.0%)
NEW MOLECULAR ENTITIES APPROVED	--	3	2	9
NUMBER OF APPLICANTS	477	484	508	515

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

/AA/ /MALLARD/ /325MG;50MG;40MG/ /N87628/001/ /OCT/01,/1986/

AB ROBERTS HAUCK 325MG;50MG;40MG N87628 001 OCT 01, 1986

TABLET; ORAL

/ESGIC/

/AB/ /FOREST/PHARMS/ /325MG;50MG;40MG/ /N89660/001/ /DEC/23,/1988/

∂ FOREST PHARMS 325MG;50MG;40MG N89660 001 DEC 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

COMPAL

AA PURDUE FREDERICK 356.4MG;30MG;16MG N88584 001 MAR 04, 1986

/AA/ /SOLVAY/ /356.4MG;30MG;16MG/ /N88584/001/ /MAR/04,/1986/

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

∂ LEMMON 300MG;30MG N88324 001 DEC 29, 1983

/ACETAMINOPHEN/W/CODEINE/H3/

/LEMMON/ /300MG;30MG/ /N88324/001/ /DEC/29,/1983/

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA PENNEX PHARMS 120MG/5ML;12MG/5ML N87006 001

/AA/ /PHARM/BASICS/ /120MG/5ML;12MG/5ML/ /N87006/001/

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ALLAY

/AA/ /LUCHEM/ /500MG;5MG/ /N89907/001/ /JAN/13,/1989/

AA NORTON HN 500MG;5MG N89907 001 JAN 13, 1989

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

/BANCAP HC/

/AA/ /FOREST/PHARMS/ /500MG;5MG/ /N87961/001/ /MAR/17,/1983/

∂ FOREST PHARMS 500MG;5MG N87961 001 MAR 17, 1983

TABLET; ORAL

ANEXSIA

AA BOEHRINGER MANNHEIM 500MG;5MG N89160 001 APR 23, 1987

/AA/ /SKCP/ /500MG;5MG/ /N89160/001/ /APR/23,/1987/

ANEXSIA 7.5/650

AA BOEHRINGER MANNHEIM 650MG;7.5MG N89725 001 SEP 30, 1987

/AA/ /SKCP/ /650MG;7.5MG/ /N89725/001/ /SEP/30,/1987/

/DURADYNE DHC/

/AA/ /FOREST/PHARMS/ /500MG;5MG/ /N87809/001/ /MAR/17,/1983/

∂ FOREST PHARMS 500MG;5MG N87809 001 MAR 17, 1983

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

/AA/ /LUCHEM/ /500MG;5MG/ /N89696/001/ /APR/21,/1988/

AA NORTON HN 500MG;5MG N89696 001 APR 21, 1988

/NORCET/

/AA/ /ABANA/ /500MG;5MG/ /N88871/001/ /MAY/15,/1986/

∂ ABANA 500MG;5MG N88871 001 MAY 15, 1986

/TYCOLET/

/AA/ /JOHNSON/RW/ /500MG;5MG/ /N89385/001/ /AUG/27,/1986/

∂ JOHNSON RW 500MG;5MG N89385 001 AUG 27, 1986

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN		
/AB/	/HALSEY/	/325MG;50MG/	/N72105/001/ /MAY/13,/1988/
/AB/		/650MG;100MG/	/N72106/001/ /MAY/13,/1988/
	∂ HALSEY	325MG;50MG	N72105 001 MAY 13, 1988
	∂	650MG;100MG	N72106 001 MAY 13, 1988

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	/ACETAZOLAMIDE SODIUM/		
/AP/	/QUAD/	/EQ 500MG/VIAL/	/N89619/001/ /JAN/13,/1988/
	∂ QUAD	EQ 500MG/VIAL	N89619 001 JAN 13, 1988
	DIAMOX		
/AP/	/LEDERLE/	/EQ 500MG/VIAL/	/N09388/001/ /DEC/05,/1990/
	LEDERLE	EQ 500MG/VIAL	N09388 001 DEC 05, 1990

ACETYLCHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC

	MIOCHOL-E		
	+ IOLAB	20MG/VIAL	N20213 001 SEP 22, 1993

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ZOVIRAX		
	+ BURROUGHS WELLCOME	EQ 1GM BASE/VIAL	N18603 002 JUN 29, 1989
	∂	EQ 250MG BASE/VIAL	N18603 003 AUG 30, 1983

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE		
AN	COPLEY	EQ 0.083% BASE	N73495 001 MAY 28, 1993

SYRUP; ORAL

	ALBUTEROL SULFATE		
AA	WATSON LABS	EQ 2MG BASE/5ML	N73165 001 APR 29, 1993

TABLET; ORAL

	ALBUTEROL SULFATE		
AB	NOVOPHARM	EQ 2MG BASE	N72779 001 JUN 25, 1993
AB		EQ 4MG BASE	N72780 001 JUN 25, 1993

TABLET, EXTENDED RELEASE; ORAL

	PROVENTIL		
/BC/+//SCHERING/		/EQ/4MG/BASE/	/N19383/001/ /JUL/13,/1987/
BC	SCHERING	EQ 4MG BASE	N19383 001 JUL 13, 1987
	VOLMAX		
/BC/	/GLAXO/	/EQ/4MG/BASE/	/N19604/002/ /DEC/23,/1992/
/+/		/EQ/8MG/BASE/	/N19604/001/ /DEC/23,/1992/
BC +	MURO	EQ 4MG BASE	N19604 002 DEC 23, 1992
+		EQ 8MG BASE	N19604 001 DEC 23, 1992

ALPRAZOLAM

CONCENTRATE; ORAL

>ADD>	ALPRAZOLAM		
>ADD>	ROXANE	1MG/ML	N74312 001 OCT 31, 1993
>ADD>			
>ADD>			

SOLUTION; ORAL

>ADD>	ALPRAZOLAM		
>ADD>	ROXANE	0.5MG/5ML	N74314 001 OCT 31, 1993
>ADD>			
>ADD>			

ALPRAZOLAM

TABLET; ORAL

> ADD >		ALPRAZOLAM		
> ADD >	AB	ALPHAPHARM	0.25MG	N74046 001 OCT 19, 1993
> ADD >				
> ADD >	AB		0.5MG	N74046 002 OCT 19, 1993
> ADD >				
> ADD >	AB		1MG	N74046 003 OCT 19, 1993
> ADD >				
> ADD >	AB	LEDERLE	0.25MG	N74174 001 OCT 19, 1993
> ADD >				
> ADD >	AB		0.5MG	N74174 002 OCT 19, 1993
> ADD >				
> ADD >	AB		1MG	N74174 003 OCT 19, 1993
> ADD >				
> ADD >	AB		2MG	N74174 004 OCT 19, 1993
> ADD >				
> ADD >	AB	PUREPAC	0.25MG	N74342 001 OCT 31, 1993
> ADD >				
> ADD >	AB		0.5MG	N74342 002 OCT 31, 1993
> ADD >				
> ADD >	AB		1MG	N74342 003 OCT 31, 1993
> ADD >				
> ADD >	AB		2MG	N74342 004 OCT 31, 1993
> ADD >				
> ADD >	AB	ROXANE	0.25MG	N74199 001 OCT 19, 1993
> ADD >				
> ADD >	AB		0.5MG	N74199 002 OCT 19, 1993
> ADD >				
> ADD >	AB		1MG	N74199 003 OCT 19, 1993
> ADD >				
		XANAX		
> ADD >	AB	UPJOHN	0.25MG	N18276 001
> ADD >	AB		0.5MG	N18276 002
> ADD >	AB	+	1MG	N18276 003
> ADD >	AB		2MG	N18276 004
> ADD >				NOV 27, 1985

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

		AMANTADINE HCL		
/AB/		/CIRCA/	/100MG/	/N71382/001/ /JAN/21,/1987/
		∂ CIRCA	100MG	N71382 001 JAN 21, 1987

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

		AMANTADINE HCL		
AA		MIKART	50MG/5ML	N74028 001 JUN 28, 1993
		/TABLET;/ORAL/ /SYMMETREL/ /+//DUPONT/	/100MG/	/N18101/001/
		∂ DUPONT	100MG	N18101 001

AMDINOCILLIN

	/INJECTABLE;/INJECTION/ /COACTIN/ /ROCHE/	/250MG/VIAL/	/N50565/001/ /DEC/21,/1984/
		/500MG/VIAL/	/N50565/002/ /DEC/21,/1984/
		/1GM/VIAL/	/N50565/003/ /DEC/21,/1984/
	∂ ROCHE	250MG/VIAL	N50565 001 DEC 21, 1984
	∂	500MG/VIAL	N50565 002 DEC 21, 1984
	∂	1GM/VIAL	N50565 003 DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION

		AMIKACIN		
AP		DUPONT MERCK	EQ 50MG BASE/ML	N63350 001 JUL 30, 1993
AP			EQ 250MG BASE/ML	N63350 002 JUL 30, 1993
AP		GENSIA	EQ 50MG BASE/ML	N64045 001 SEP 28, 1993
AP			EQ 250MG BASE/ML	N64045 002 SEP 28, 1993
		AMIKIN		
/AP/		/BRISTOL/	/EQ 250MG BASE/ML/	/N50495/002/
AP	+	BRISTOL	EQ 250MG BASE/ML	N50495 002

AMIKACIN SULFATE

INJECTABLE; INJECTION

/AMIKIN/IN/SODIUM/CHLORIDE/0.9%/IN/PLASTIC/CONTAINER/
/BRISTOL/ /EQ/5MG/BASE/ML/ /N50618/002/
/NOV/30,/1987/
/EQ/10MG/BASE/ML/ /N50618/001/
/NOV/30,/1987/

@ BRISTOL EQ 5MG BASE/ML N50618 002
NOV 30, 1987

@ EQ 10MG BASE/ML N50618 001
NOV 30, 1987

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER
BAXTER 15% N20107 001
FEB 05, 1993

/NOVAMINE/8.5%/
/KABIVITRUM/ /8.5%/ /N17957/002/
/AUG/09,/1982/

@ KABIVITRUM 8.5% N17957 002
AUG 09, 1982

TRAVASOL 10% IN PLASTIC CONTAINER
BAXTER 10% N18931 003
AUG 23, 1984

/10%/ /N18931/004/
/APR/27,/1988/

/TRAVASOL/10%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /10%/ /N18931/003/
/AUG/23,/1984/

TRAVASOL 5.5% IN PLASTIC CONTAINER
BAXTER 5.5% N18931 001
AUG 23, 1984

/TRAVASOL/5.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /5.5%/ /N18931/001/
/AUG/23,/1984/

TRAVASOL 8.5% IN PLASTIC CONTAINER
BAXTER 8.5% N18931 002
AUG 23, 1984

/TRAVASOL/8.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /8.5%/ /N18931/002/
/AUG/23,/1984/

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

/AMINOSYN/II/7%/W//ELECTROLYTES/
/ABBOTT/ /7%;102MG/100ML;45MG/100ML;/
/522MG/100ML;410MG/100ML/ /N19437/006/
/APR/03,/1986/

@ ABBOTT 7%;102MG/100ML;45MG/100ML;
522MG/100ML;410MG/100ML N19437 006
APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

/AMINOSYN/II/3.5%/W/
/ABBOTT/ /3.5%;30MG/100ML;97MG/100ML;/
/120MG/100ML;49MG/100ML/ /N19437/007/
/APR/03,/1986/

@ ABBOTT 3.5%;30MG/100ML;97MG/100ML;
120MG/100ML;49MG/100ML N19437 007
APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

> ADD > AP + IMMUNEX 250MG/ML N15229 002
> DLT >/AP/ /LEDERLE/ /250MG/ML/ /N15229/002/

AMINOCAPROIC ACID

/AP/ /LYPHOMED/ /250MG/ML/ /N70522/001/
/JUN/17,/1986/

@ LYPHOMED 250MG/ML N70522 001
JUN 17, 1986

SYRUP; ORAL

AMICAR

> ADD > IMMUNEX 1.25GM/5ML N15230 002
> DLT > /LEDERLE/ /1.25GM/5ML/ /N15230/002/

TABLET; ORAL

AMICAR

> ADD > + IMMUNEX 500MG N15197 001
> DLT > /*//LEDERLE/ /500MG/ /N15197/001/

AMINOPHYLLINE

/ENEMA;/RECTAL/
/SOMOPHYLLIN/
/FISONS/ /300MG/5ML/ /N18232/001/
/APR/02,/1982/
@ FISONS 300MG/5ML N18232 001
APR 02, 1982

INJECTABLE; INJECTION
AMINOPHYLLINE
/AP/ /BRISTOL/ /25MG/ML/ /N87431/001/
AP FUJISAWA 25MG/ML N88407 001
JAN 25, 1984
@ 25MG/ML N87431 001
/AP/ /LYPHOMED/ /25MG/ML/ /N88407/001/
/JAN/25,/1984/

SOLUTION; ORAL
AMINOPHYLLINE
@ PENNEX PHARMS 105MG/5ML N88156 001
DEC 05, 1983
/AA/ /PHARM/BASICS/ /105MG/5ML/ /N88156/001/
/DEC/05,/1983/
>_DLT_> /SOMOPHYLLIN/
>_DLT_>/AA/ /FISONS/ /105MG/5ML/ /N86466/001/
>_ADD_> @ FISONS 105MG/5ML N86466 001
>_DLT_> /SOMOPHYLLIN-DF/
>_DLT_>/AA/ /FISONS/ /105MG/5ML/ /N87045/001/
>_ADD_> @ FISONS 105MG/5ML N87045 001

TABLET; ORAL
/AMINOPHYLLIN/
/AB//+//SEARLE/ /100MG/ /N02386/002/
/AB//+/ /200MG/ /N02386/003/
@ SEARLE 100MG N02386 002
@ 200MG N02386 003

AMINOPHYLLINE
/AB/ /ROXANE/ /100MG/ /N87500/001/
/FEB/09,/1982/
AB + ROXANE 100MG N87500 001
FEB 09, 1982
/AB/ /200MG/ /N87501/001/
/FEB/09,/1982/
AB + 200MG N87501 001
FEB 09, 1982

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION
ELAVIL
/AP/ /MSD/ /10MG/ML/ /N12704/001/
AP ZENECA 10MG/ML N12704 001

TABLET; ORAL
ELAVIL
/AB/ /MSD/ /10MG/ /N12703/001/
/AB//+/ /25MG/ /N12703/003/
/AB/ /50MG/ /N12703/004/
/AB/ /75MG/ /N12703/005/
/AB/ /100MG/ /N12703/006/
/AB/ /150MG/ /N12703/007/
AB ZENECA 10MG N12703 001
AB + 25MG N12703 003
AB 50MG N12703 004
AB 75MG N12703 005
AB 100MG N12703 006
AB 150MG N12703 007

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL
>_DLT_>/AB/ /PAR/ /10MG;2MG/ /N70565/001/
>_DLT_> /SEP/11,/1986/
>_DLT_>/AB/ /10MG;4MG/ /N70620/001/
>_DLT_> /SEP/11,/1986/
>_DLT_>/AB/ /25MG;2MG/ /N70621/001/
>_DLT_> /SEP/11,/1986/
>_DLT_>/AB/ /25MG;4MG/ /N70595/001/
>_DLT_> /SEP/11,/1986/
>_DLT_>/AB/ /50MG;4MG/ /N70574/001/
>_DLT_> /SEP/11,/1986/
>_ADD_> @ PAR 10MG;2MG N70565 001
>_ADD_> SEP 11, 1986
>_ADD_> @ 10MG;4MG N70620 001
>_ADD_> SEP 11, 1986
>_ADD_> @ 25MG;2MG N70621 001
>_ADD_> SEP 11, 1986
>_ADD_> @ 25MG;4MG N70595 001
>_ADD_> SEP 11, 1986
>_ADD_> @ 50MG;4MG N70574 001
>_ADD_> SEP 11, 1986

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

> DLT >	/AMMONIUM CHLORIDE/		
> DLT >/AP/	/ABBOTT/	/5MEQ/ML/	/N83130/001/
> ADD >	∂ ABBOTT	5MEQ/ML	N83130 001

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

> DLT >/AP/	/ABBOTT/	/5MEQ/ML/	/N88366/001/
> DLT >			/JUN/13,/1984/
> ADD >	+ ABBOTT	5MEQ/ML	N88366 001
> ADD >			JUN 13, 1984

AMOXICILLIN

CAPSULE; ORAL

	/POLYMOX/		
/AB/	/BRISTOL/	/250MG/	/N61885/001/
/AB/		/500MG/	/N61885/002/
	/TRIMOX/		
/AB/	/SQUIBB/	/250MG/	/N62098/001/
/AB/		/250MG/	/N62152/001/
/AB/		/500MG/	/N62098/002/
/AB/		/500MG/	/N62152/002/
	TRIMOX		
AB	APOTHECON	250MG	N61885 001
AB		500MG	N61885 002
	∂ APOTHECON	250MG	N62098 001
	∂	250MG	N62152 001
	∂	500MG	N62098 002
	∂	500MG	N62152 002

POWDER FOR RECONSTITUTION; ORAL

	AMOXICILLIN		
AB	CLONMEL	125MG/5ML	N62927 001
			NOV 25, 1988
AB		250MG/5ML	N62927 002
			NOV 25, 1988
/BX/		/125MG/5ML/	/N62927/001/
			/NOV/25,/1988/
/BX/		/250MG/5ML/	/N62927/002/
			/NOV/25,/1988/
	/POLYMOX/		
/AB/	/BRISTOL/	/125MG/5ML/	/N61886/002/
/AB/		/50MG/ML/	/N61886/001/
/AB/		/250MG/5ML/	/N61886/003/
/AB/	/BRISTOL/MYERS/	/125MG/5ML/	/N62885/001/
			/MAR/08,/1988/
/AB/		/250MG/5ML/	/N62885/002/
			/MAR/08,/1988/

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL

	/TRIMOX/		
/AB/	/SQUIBB/	/125MG/5ML/	/N62099/001/
/AB/		/125MG/5ML/	/N62154/001/
/AB/		/250MG/5ML/	/N62099/002/
/AB/		/250MG/5ML/	/N62154/002/
	TRIMOX		
AB	APOTHECON	125MG/5ML	N61886 002
AB		125MG/5ML	N62885 001
			MAR 08, 1988
AB		50MG/ML	N61886 001
AB		250MG/5ML	N61886 003
AB		250MG/5ML	N62885 002
			MAR 08, 1988
	∂ APOTHECON	125MG/5ML	N62099 001
	∂	125MG/5ML	N62154 001
	∂	250MG/5ML	N62099 002
	∂	250MG/5ML	N62154 002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

/CAPSULE;/ORAL/			
	/DELCOBESE/		
	/LEMMON/		
		/1.25MG;1.25MG;1.25MG;/	
		/1.25MG/	/N83564/001/
		/2.5MG;2.5MG;2.5MG;2.5MG/	/N83564/002/
		/3.75MG;3.75MG;3.75MG;/	
		/3.75MG/	/N83564/003/
		/5MG;5MG;5MG;5MG/	/N83564/004/
	∂ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83564 001
	∂	2.5MG;2.5MG;2.5MG;2.5MG	N83564 002
	∂	3.75MG;3.75MG;3.75MG; 3.75MG	N83564 003
	∂	5MG;5MG;5MG;5MG	N83564 004
/TABLET;/ORAL/			
	/DELCOBESE/		
	/LEMMON/		
		/1.25MG;1.25MG;1.25MG;/	
		/1.25MG/	/N83563/004/
		/2.5MG;2.5MG;2.5MG;2.5MG/	/N83563/003/
		/3.75MG;3.75MG;3.75MG;/	
		/3.75MG/	/N83563/002/
		/5MG;5MG;5MG;5MG/	/N83563/001/

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

/TABLET;/ORAL/
/DELCOBESE/

∂ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83563 004
∂	2.5MG;2.5MG;2.5MG;2.5MG	N83563 003
∂	3.75MG;3.75MG;3.75MG; 3.75MG	N83563 002
∂	5MG;5MG;5MG;5MG	N83563 001

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

> DLT >	/CAPSULE;/EXTENDED/RELEASE;/ORAL/		
> DLT >	/BIPHETAMINE/12.5/		
> DLT >	/FISONS/	/EQ/6.25MG/BASE;/	
> DLT >		/EQ/6.25MG/BASE/	/N10093/007/
> ADD >	∂ FISONS	EQ 6.25MG BASE;	
> ADD >		EQ 6.25MG BASE	N10093 007
> DLT >	/BIPHETAMINE/20/		
> DLT >	/+//FISONS/	/EQ/10MG/BASE;/	
> DLT >		/EQ/10MG/BASE/	/N10093/003/
> ADD >	∂ FISONS	EQ 10MG BASE;	
> ADD >		EQ 10MG BASE	N10093 003

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE		
+ APOTHECON	3%	N50314 001
/SQUIBB/	/3%/	/N50314/001/

INJECTABLE; INJECTION

	FUNGIZONE		
AP	+ APOTHECON	50MG/VIAL	N60517 001
/AP/	/SQUIBB/	/50MG/VIAL/	/N60517/001/

LOTION; TOPICAL

FUNGIZONE		
+ APOTHECON	3%	N60570 001
/SQUIBB/	/3%/	/N60570/001/

OINTMENT; TOPICAL

FUNGIZONE		
+ APOTHECON	3%	N50313 001
/SQUIBB/	/3%/	/N50313/001/

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	AMPICILLIN SODIUM		
AP	HANFORD	EQ 125MG BASE/VIAL	N63143 001 APR 15, 1993
AP		EQ 250MG BASE/VIAL	N63145 001 APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63146 001 APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63147 001 APR 15, 1993
AP		EQ 1GM BASE/VIAL	N62772 001 APR 15, 1993
AP		EQ 1GM BASE/VIAL	N63139 001 APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63140 001 APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63141 001 APR 15, 1993
AP		EQ 10GM BASE/VIAL	N63142 001 APR 15, 1993
AP	IBI	EQ 125MG BASE/VIAL	N62797 001 JUL 12, 1993
AP		EQ 2GM BASE/VIAL	N62797 002 JUL 12, 1993
/AP/	/LILLY/	/EQ 500MG BASE/VIAL/	/N62565/001/ /APR/04,/1985/
/AP/		/EQ 1GM BASE/VIAL/	/N62565/002/ /APR/04,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62565/003/ /JUN/24,/1986/
	∂ LILLY	EQ 500MG BASE/VIAL	N62565 001 APR 04, 1985
	∂	EQ 1GM BASE/VIAL	N62565 002 APR 04, 1985
	∂	EQ 2GM BASE/VIAL	N62565 003 JUN 24, 1986
	PENBRITIN-S		
	/WYETH/AYERST/	/EQ/4GM/BASE/VIAL/	/N50072/006/
	∂ WYETH AYERST	EQ 4GM BASE/VIAL	N50072 006

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	/POLYCILLIN-N/		
/AP/	/BRISTOL/	/EQ 125MG BASE/VIAL/	/N61395/001/
/AP/		/EQ 125MG BASE/VIAL/	/N62860/001/ /FEB/05,/1988/
/AP/		/EQ 250MG BASE/VIAL/	/N61395/002/
/AP/		/EQ 250MG BASE/VIAL/	/N62860/002/ /FEB/05,/1988/
/AP/		/EQ 500MG BASE/VIAL/	/N61395/003/
/AP/		/EQ 500MG BASE/VIAL/	/N62860/003/ /FEB/05,/1988/
/AP/		/EQ 1GM BASE/VIAL/	/N61395/004/
/AP/		/EQ 1GM BASE/VIAL/	/N62738/001/ /FEB/19,/1987/
/AP/		/EQ 1GM BASE/VIAL/	/N62860/004/ /FEB/05,/1988/
/AP/		/EQ 2GM BASE/VIAL/	/N61395/005/
/AP/		/EQ 2GM BASE/VIAL/	/N62738/002/ /FEB/19,/1987/
/AP/		/EQ 2GM BASE/VIAL/	/N62860/005/ /FEB/05,/1988/
/AP/		/EQ 10GM BASE/VIAL/	/N61395/006/

	PRINCIPEN		
AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001
AP		EQ 125MG BASE/VIAL	N62860 001 FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002
AP		EQ 250MG BASE/VIAL	N62860 002 FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003
AP		EQ 500MG BASE/VIAL	N62860 003 FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004
AP		EQ 1GM BASE/VIAL	N62738 001 FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004 FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005
AP		EQ 2GM BASE/VIAL	N62738 002 FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005 FEB 05, 1988
AP	+	EQ 10GM BASE/VIAL	N61395 006

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

	UNASYN		
	/PFIZER/	/EQ/500MG/BASE/VIAL;/ /EQ/250MG/BASE/VIAL/	/N50608/003/ /DEC/31,/1986/
	∂ PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N50608 003 DEC 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	/POLYCILLIN/		
/AB/	/+//BRISTOL/	/EQ 250MG BASE/	/N61392/001/
/AB/		/EQ 500MG BASE/	/N61392/002/
/AB/	/BRISTOL/MYERS/	/EQ 250MG BASE/	/N62888/001/ /MAR/04,/1988/
/AB/	/+/	/EQ 500MG BASE/	/N62888/002/ /MAR/04,/1988/

	PRINCIPEN		
AB	+ APOTHECON	EQ 250MG BASE	N61392 001
AB		EQ 250MG BASE	N62888 001 MAR 04, 1988
AB		EQ 500MG BASE	N61392 002
AB	+	EQ 500MG BASE	N62888 002 MAR 04, 1988
	/PRINCIPEN '250'/		
/AB/	/SQUIBB/	/EQ 250MG BASE/	/N50056/001/
/AB/		/EQ 250MG BASE/	/N62157/002/
	∂ APOTHECON	EQ 250MG BASE	N50056 001
	∂	EQ 250MG BASE	N62157 002
	/PRINCIPEN '500'/		
/AB/	/SQUIBB/	/EQ 500MG BASE/	/N50056/002/
/AB/		/EQ 500MG BASE/	/N62157/001/
	∂ APOTHECON	EQ 500MG BASE	N50056 002
	∂	EQ 500MG BASE	N62157 001
	TOTACILLIN		
/AB/	/SMITHKLINE/BEECHAM/	/EQ 250MG BASE/	/N60060/001/
/AB/		/EQ 500MG BASE/	/N60060/002/
	∂ SMITHKLINE BEECHAM	EQ 250MG BASE	N60060 001
	∂	EQ 500MG BASE	N60060 002

POWDER FOR RECONSTITUTION; ORAL

	/POLYCILLIN/		
/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N61394/002/
/AB/		/EQ 250MG BASE/5ML/	/N61394/003/
		/EQ/100MG/BASE/ML/	/N61394/001/

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL
PRINCIPEN

AB	APOTHECON	EQ 125MG BASE/5ML	N61394 002
AB		EQ 250MG BASE/5ML	N61394 003
AB		EQ 100MG BASE/ML	N61394 001
	/PRINCIPEN 125/		
/AB/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N60127/002/
/AB/		/EQ 125MG BASE/5ML/	/N62151/001/
	∂ APOTHECON	EQ 125MG BASE/5ML	N60127 002
	∂	EQ 125MG BASE/5ML	N62151 001
	/PRINCIPEN 250/		
/AB/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N60127/001/
/AB/		/EQ 250MG BASE/5ML/	/N62151/002/
	∂ APOTHECON	EQ 250MG BASE/5ML	N60127 001
	∂	EQ 250MG BASE/5ML	N62151 002

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

/CAPSULE;ORAL/
/PRINCIPEN/W//PROBENECID/

/+//SQUIBB/	/EQ/389MG/BASE;111MG/	/N50488/001/
	/EQ/389MG/BASE;111MG/	/N62150/001/
∂ APOTHECON	EQ 389MG BASE;111MG	N50488 001
∂	EQ 389MG BASE;111MG	N62150 001

POWDER FOR RECONSTITUTION; ORAL
POLYCILLIN-PRB

AB	+ APOTHECON	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001
/AB//+//BRISTOL/		/EQ 3.5GM BASE/BOT;/ /1GM/BOT/	/N61898/001/

ANISOTROPINE METHYLBROMIDE

/TABLET;ORAL/
/VALPIN/50/

/DUPONT/	/50MG/	/N13428/001/
∂ DUPONT	50MG	N13428 001

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
IOPIDINE

+ ALCON	EQ 0.5% BASE	N20258 001 JUL 30, 1993

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

/INJECTABLE;/INJECTION/
/M.V.I.-12/LYOPHILIZED/

/ASTRA/	/100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL/ /15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;/ /40MG/VIAL;4MG/VIAL;3.6MG/VIAL;/ /3MG/VIAL;1MG/VIAL;/ /10MG/VIAL/	/N18933/002/ /AUG/08,/1985/
∂ ASTRA	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL 15MG/VIAL;5UGM/VIAL;0.4MG/VIAL; 40MG/VIAL;4MG/VIAL;3.6MG/VIAL; 3MG/VIAL;1MG/VIAL; 10MG/VIAL	N18933 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.C. 943

AP FUJISAWA	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18440 002 AUG 08, 1985
/AP/ /LYPHONED/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS/ML;1 IU/ML/	/N18440/002/ /AUG/08,/1985/

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL

/+//ADRIA/	/650MG;50MG/	/N88305/001/ /OCT/13,/1983/
+ SAVAGE	650MG;50MG	N88305 001 OCT 13, 1983

ASPIRIN; PROPOXYPHENE NAPSYLATE

> DLT >	/TABLET;/ORAL/		
> DLT >	/DARVON-N/W/ASA/		
> DLT >	/+//LILLY/	/325MG;100MG/	/N16863/001/
> ADD >	∂ LILLY	325MG;100MG	N16863 001

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	MUTUAL PHARM	50MG	N73475 001 MAR 30, 1993
AB		100MG	N73476 001 MAR 30, 1993
AB	NOVOPHARM	50MG	N73315 001 MAY 28, 1993
AB		100MG	N73316 001 MAY 28, 1993

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

	AB	MUTUAL PHARM	50MG;25MG	N73581 001 APR 29, 1993
	AB		100MG;25MG	N73582 001 APR 29, 1993
> ADD >	AB	MYLAN	50MG;25MG	N74203 001 OCT 31, 1993
> ADD > > ADD > > ADD >	AB		100MG;25MG	N74203 002 OCT 31, 1993

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
/AZATHIOPRINE/

/AP/	/QUAD/	/EQ 100MG BASE/VIAL/	/N71056/001/ /JUN/08,/1988/
	∂ QUAD	EQ 100MG BASE/VIAL	N71056 001 JUN 08, 1988

IMURAN

/AP/	/BURROUGHS/WELLCOME/ BURROUGHS WELLCOME	/EQ 100MG BASE/VIAL/ EQ 100MG BASE/VIAL	/N17391/001/ N17391 001

AZLOCILLIN SODIUM

INJECTABLE; INJECTION
AZLIN

/MILES/	/EQ/2GM/BASE/VIAL/	/N62388/001/ /SEP/08,/1982/
∂ MILES	EQ 2GM BASE/VIAL	N62388 001 SEP 08, 1982
	/EQ/2GM/BASE/VIAL/	/N62417/001/ /OCT/12,/1982/
∂	EQ 2GM BASE/VIAL	N62417 001 OCT 12, 1982
	/EQ/4GM/BASE/VIAL/	/N62388/003/ /SEP/08,/1982/
∂	EQ 4GM BASE/VIAL	N62388 003 SEP 08, 1982
	/EQ/4GM/BASE/VIAL/	/N62417/003/ /OCT/12,/1982/
∂	EQ 4GM BASE/VIAL	N62417 003 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION
AZACTAM IN PLASTIC CONTAINER

/SQUIBB/	/10MG/ML/	/N50632/003/ /MAY/24,/1989/
∂ SQUIBB	10MG/ML	N50632 003 MAY 24, 1989

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN

/AT/	/BURROUGHS/WELLCOME/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/	/N50416/002/
	+ BURROUGHS WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002

/ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE E/
/HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/	/N62389/001/ /JUL/02,/1982/
	∂ PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62389 001 JUL 02, 1982

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

CORTISPORIN

>_DLT_>/AT/	/BURROUGHS/WELLCOME/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM;/	
>_DLT_>		/5,000 UNITS/GM/	/N50168/002/
>_DLT_>			/MAY/04,/1984/
>_ADD_>	+ BURROUGHS WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;	
>_ADD_>		5,000 UNITS/GM	N50168 002
>_ADD_>			MAY 04, 1984
>_DLT_>	/NEOMYCIN B POLYMYXIN B SULFATES & BACITRACIN ZINC &		
>_DLT_>	/HYDROCORTISONE/		
>_DLT_>/AT/	/PHARMAFAIR/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM;/	
>_DLT_>		/5,000 UNITS/GM/	/N62381/001/
>_DLT_>			/SEP/06,/1985/
>_ADD_>	∂ PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;	
>_ADD_>		5,000 UNITS/GM	N62381 001
>_ADD_>			SEP 06, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	/BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE/		
/AT/	/PHARMAFAIR/	/400 UNITS/GM;EQ 3.5MG BASE/GM;/	
		/10,000 UNITS/GM/	/N62386/001/
			/SEP/09,/1982/
	∂ PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N62386 001
			SEP 09, 1982
	BACITRACIN-NEOMYCIN-POLYMYXIN		
	/PHARMADERM/	/400/UNITS/GM;EQ/3.5MG/BASE/GM;/	
		/5,000/UNITS/GM/	/N62167/001/
	∂ PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;	
		5,000 UNITS/GM	N62167 001

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

/ADRIA/	/500MG/7.5ML/	/N18366/001/
		/DEC/29,/1983/
SAVAGE	500MG/7.5ML	N18366 001
		DEC 29, 1983

BENTONITE; SULFUR

/POWDER;/TOPICAL/		
/BENSULFOID/		
/POYTHRESS/	/66.64%;33.32%/	/N02918/001/
∂ POYTHRESS	66.64%;33.32%	N02918 001

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	PHARMACAPS	100MG	N81297 001
			JAN 29, 1993

TESSALON

AA	FOREST LABS	100MG	N11210 001

BENZTHIAZIDE

TABLET; ORAL

	/AQUATAG/		
/BP/	/SOLVAY/	/50MG/	/N16001/002/
	∂ SOLVAY	50MG	N16001 002
	EXNA		
/BP/	//ROBINS/AH/	/50MG/	/N12489/001/
	+ ROBINS AH	50MG	N12489 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

	/BEPADIN/		
/AB/	/WALLACE/	/200MG/	/N19001/001/
			/DEC/28,/1990/
/AB/		/300MG/	/N19001/002/
			/DEC/28,/1990/
/AB/		/400MG/	/N19001/003/
			/DEC/28,/1990/
	∂ WALLACE	200MG	N19001 001
			DEC 28, 1990
	∂	300MG	N19001 002
			DEC 28, 1990
	∂	400MG	N19001 003
			DEC 28, 1990

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

/AB/	/JOHNSON/RW/	/200MG/	/N19002/001/ /DEC/28,/1990/
/AB/		/300MG/	/N19002/002/ /DEC/28,/1990/
/AB//+/		/400MG/	/N19002/003/ /DEC/28,/1990/
	+ JOHNSON RW	400MG	N19002 003 DEC 28, 1990
		200MG	N19002 001 DEC 28, 1990
		300MG	N19002 002 DEC 28, 1990

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

/AB/	/PHARMADERM/	/EQ 0.05% BASE/	/N19136/001/ /JUN/26,/1984/
	@ PHARMADERM	EQ 0.05% BASE	N19136 001 JUN 26, 1984

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

/AB/	/PHARMADERM/	/EQ 0.05% BASE/	/N70274/001/ /AUG/12,/1985/
	@ PHARMADERM	EQ 0.05% BASE	N70274 001 AUG 12, 1985

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE

/AB/	/PHARMADERM/	/EQ 0.05% BASE/	/N19140/001/ /SEP/04,/1984/
	@ PHARMADERM	EQ 0.05% BASE	N19140 001 SEP 04, 1984

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

/AB/	/PHARMADERM/	/EQ 0.1% BASE/	/N18860/002/ /AUG/31,/1983/
	@ PHARMADERM	EQ 0.1% BASE	N18860 002 AUG 31, 1983

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE

/AB/	/PHARMADERM/	/EQ 0.1% BASE/	/N18870/001/ /AUG/31,/1983/
	@ PHARMADERM	EQ 0.1% BASE	N18870 001 AUG 31, 1983

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

AB	NMC	EQ 0.1% BASE	N70051 001 OCT 10, 1984

BETAMETHASONE VALERATE

/AB/	/PHARMADERM/	/EQ 0.1% BASE/	/N18864/001/ /AUG/31,/1983/
	@ PHARMADERM	EQ 0.1% BASE	N18864 001 AUG 31, 1983

/AB/	/VALHAC/ /NMC/	/EQ 0.1% BASE/	/N70051/001/ /OCT/10,/1984/

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ZIAC

+ LEDERLE	10MG;6.25MG	N20186 002 MAR 26, 1993
	2.5MG;6.25MG	N20186 003 MAR 26, 1993
	5MG;6.25MG	N20186 001 MAR 26, 1993

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

/AP/	/ASTRA/	/50MG/ML/	/N71152/001/ /AUG/10,/1987/
	@ ASTRA	50MG/ML	N71152 001 AUG 10, 1987

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL
MYBANIL

AA	PENNEX PHARMS	12.5MG/5ML;10MG/5ML	N88626 001 OCT 12, 1984

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL
MYBANIL

/AA/	/PHARM/BASICS/	/12.5MG/5ML;10MG/5ML/	/N88626/001/ /OCT/12,/1984/

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

/AA/	/ANABOLIC/	/4MG/	/N86187/001/
	@ ANABOLIC	4MG	N86187 001
/AA/	/NEWTRON/	/4MG/	/N86987/001/
	@ NEWTRON	4MG	N86987 001
AA	NYLOS TRADING	4MG	N85592 001
/AA/	/TABLICAPS/	/4MG/	/N85592/001/
/AA/	/ZENITH/	/4MG/	/N84351/001/
	@ ZENITH	4MG	N84351 001

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DC

AA	PENNEX PHARMS	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985
/AA/	/PHARM/BASICS/	/2MG/5ML;10MG/5ML;/ /12.5MG/5ML/	/N88904/001/ /FEB/21,/1985/

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DX

AA	PENNEX PHARMS	2MG/5ML;10MG/5ML; 30MG/5ML	N88811 001 JUN 07, 1985
/AA/	/PHARM/BASICS/	/2MG/5ML;10MG/5ML;/ /30MG/5ML/	/N88811/001/ /JUN/07,/1985/

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
BIPHETAP

	@ PENNEX PHARMS	4MG/5ML;25MG/5ML	N88687 001 SEP 26, 1984
	/@/PHARM/BASICS/	/4MG/5ML;25MG/5ML/	/N88687/001/ /SEP/26,/1984/

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTABARBITAL SODIUM

	@ PENNEX PHARMS	30MG/5ML	N85383 001
/AA/	/PHARM/BASICS/	/30MG/5ML/	/N85383/001/

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
STADOL

+	APOTHECON	1MG/ML	N17857 001
+		2MG/ML	N17857 002
	/BRISTOL/	/1MG/ML/	/N17857/001/
		/2MG/ML/	/N17857/002/

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL
CALDEROL

+	ORGANON	0.05MG	N18312 002
		0.02MG	N18312 001
	/+//UPJOHN/	/0.05MG/	/N18312/002/
		/0.02MG/	/N18312/001/

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR

/AP/	/RHONE/POULENC/RORER//200 IU/ML/		/N17769/001/
AP	+ RHONE POULENC RORER	200 IU/ML	N17769 001
	MIACALCIN		
	/SANDOZ/	/100/IU/ML/	/N17808/001/ /JUL/03,/1986/
	@ SANDOZ	100 IU/ML	N17808 001 JUL 03, 1986

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

ENDOSOL EXTRA

AT	ALLERGAN	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML	N20079 001 NOV 27, 1991

ENDOSOL PLUS

/AT/	/ALLERGAN/	/0.154MG/ML;0.92MG/ML;0.184MG/ML;/ /0.2MG/ML;0.38MG/ML;2.1MG/ML;/ /7.14MG/ML;0.42MG/ML/	/N20079/001/ /NOV/27,/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER		
	MCGAW	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N19864 001 JUN 10, 1993

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

/AP/	/ABBOTT/	/EQ 90MG CALCIUM/5ML/	/N80001/001/
	+ ABBOTT	EQ 90MG CALCIUM/5ML	N80001 001
/AP/	/LILLY/	/EQ 90MG CALCIUM/5ML/	/N06470/001/
	∂ LILLY	EQ 90MG CALCIUM/5ML	N06470 001
/AP/	/LYPHOMED/	/EQ 90MG CALCIUM/5ML/	/N89373/001/ /APR/30,/1987/
	∂ LYPHOMED	EQ 90MG CALCIUM/5ML	N89373 001 APR 30, 1987

CARBACHOL

INJECTABLE; INJECTION

> DLT >	/CARBACHOL/		
> DLT >/AP/	/PHARMAFAIR/	/0.01%/	/N70292/001/ /MAY/21,/1986/
> DLT >			
> ADD >	∂ PHARMAFAIR	0.01%	N70292 001 MAY 21, 1986
> ADD >			

CARBACHOL

INJECTABLE; INJECTION

MIOSTAT

> DLT >/AP/	/ALCON/	/0.01%/	/N16968/001/
> ADD >	+ ALCON	0.01%	N16968 001

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

/AP/	/ROERIG/	/EQ 1GM BASE/VIAL/	/N50306/001/
/AP/		/EQ 2GM BASE/VIAL/	/N50306/004/
/AP/		/EQ 5GM BASE/VIAL/	/N50306/002/
/AP/		/EQ 10GM BASE/VIAL/	/N50306/006/
	ROERIG	EQ 1GM BASE/VIAL	N50306 001
		EQ 2GM BASE/VIAL	N50306 004
		EQ 5GM BASE/VIAL	N50306 002
		EQ 10GM BASE/VIAL	N50306 006

PYOPEN

/AP/	/SMITHKLINE/BEECHAM/	/EQ 1GM BASE/VIAL/	/N50298/001/
/AP/		/EQ 2GM BASE/VIAL/	/N50298/002/
/AP/		/EQ 5GM BASE/VIAL/	/N50298/003/
/AP/		/EQ 10GM BASE/VIAL/	/N50298/006/
	∂ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N50298 001
	∂	EQ 2GM BASE/VIAL	N50298 002
	∂	EQ 5GM BASE/VIAL	N50298 003
	∂	EQ 10GM BASE/VIAL	N50298 006
		/EQ/20GM/BASE/VIAL/	/N50298/007/
	∂	EQ 20GM BASE/VIAL	N50298 007

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	PUREPAC	10MG;100MG	N74260 001 SEP 03, 1993
AB		25MG;100MG	N74260 002 SEP 03, 1993
AB		25MG;250MG	N74260 003 SEP 03, 1993
AB	WATSON LABS	10MG;100MG	N73381 001 SEP 28, 1993
AB		25MG;100MG	N73382 001 SEP 28, 1993
AB		25MG;250MG	N73383 001 SEP 28, 1993

CARBINOXAMINE MALEATE

/TABLET;/ORAL/
/CLISTIN/
/JOHNSON/RW/ /4MG/ /N08915/001/
@ JOHNSON RW 4MG N08915 001

CARISOPRODOL

/CAPSULE;/ORAL/
/SOMA/
/WALLACE/ /250MG/ /N11792/003/
@ WALLACE 250MG N11792 003

TABLET; ORAL
CARISOPRODOL
/AA/ /PIONEER/PHARMS/ /350MG/ /N89390/001/
@ PIONEER PHARMS 350MG /OCT/13,/1988/
N89390 001
OCT 13, 1988
/RELA/
/AA/ /SCHERING/ /350MG/ /N12155/001/
@ SCHERING 350MG N12155 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIPRESS
/BURROUGHS/WELLCOME/ /1%/ /N19972/001/
OTSUKA 1% /MAY/23,/1990/
N19972 001
MAY 23, 1990

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
DURICEF
AB + BRISTOL MYERS SQUIBB EQ 500MG BASE N50512 001
/AB//+//MEAD/JOHNSON/ /EQ 500MG BASE/ /N50512/001/

POWDER FOR RECONSTITUTION; ORAL
DURICEF
AB + BRISTOL MYERS SQUIBB EQ 125MG BASE/5ML N50527 002
AB + EQ 250MG BASE/5ML N50527 003
AB + EQ 500MG BASE/5ML N50527 001
/AB//+//MEAD/JOHNSON/ /EQ 125MG BASE/5ML/ /N50527/002/
/AB//+/ /EQ 250MG BASE/5ML/ /N50527/003/
/AB//+/ /EQ 500MG BASE/5ML/ /N50527/001/

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET; ORAL
DURICEF
AB + BRISTOL MYERS SQUIBB EQ 1GM BASE N50528 001
/AB//+//MEAD/JOHNSON/ /EQ 1GM BASE/ /N50528/001/

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL
+ LILLY EQ 10GM BASE/VIAL N50504 004

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM
/AP/ /BEN/VENUE/ /EQ 250MG BASE/VIAL/ /N62894/001/
/JUL/21,/1988/
/AP/ /EQ 500MG BASE/VIAL/ /N62894/002/
/JUL/21,/1988/
/AP/ /EQ 1GM BASE/VIAL/ /N62894/003/
/JUL/21,/1988/
/AP/ /EQ 5GM BASE/VIAL/ /N62894/004/
/JUL/21,/1988/
/AP/ /EQ 10GM BASE/VIAL/ /N62894/005/
/JUL/21,/1988/
@ BEN VENUE EQ 250MG BASE/VIAL N62894 001
JUL 21, 1988
@ EQ 500MG BASE/VIAL N62894 002
JUL 21, 1988
@ EQ 1GM BASE/VIAL N62894 003
JUL 21, 1988
@ EQ 5GM BASE/VIAL N62894 004
JUL 21, 1988
@ EQ 10GM BASE/VIAL N62894 005
JUL 21, 1988
>_ADD_> AP SMITHKLINE BEECHAM EQ 1GM BASE/VIAL N64033 001
>_ADD_> OCT 31, 1993

CEFMENOXIME HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CEFMAX/
/TAP/ /EQ/500MG/BASE/VIAL/ /N50571/001/
/DEC/30,/1987/
/EQ/1GM/BASE/VIAL/ /N50571/002/
/DEC/30,/1987/
/EQ/2GM/BASE/VIAL/ /N50571/003/
/DEC/30,/1987/

CEFMENOXIME HYDROCHLORIDE

/INJECTABLE;/INJECTION/		
/CEFMAX/		
∂ TAP	EQ 500MG BASE/VIAL	N50571 001 DEC 30, 1987
∂	EQ 1GM BASE/VIAL	N50571 002 DEC 30, 1987
∂	EQ 2GM BASE/VIAL	N50571 003 DEC 30, 1987

CEFONICID SODIUM

INJECTABLE; INJECTION		
MONOCID		
SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N63295 001 JUL 26, 1993
	/EQ/2GM/BASE/VIAL/	/N50579/003/ /MAY/23,/1984/
∂	EQ 2GM BASE/VIAL	N50579 003 MAY 23, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION		
CLAFORAN		
HOECHST ROUSSEL	EQ 500MG BASE/VIAL	N50547 001

CEFOTETAN DISODIUM

INJECTABLE; INJECTION		
CEFOTAN		
/AP/ /STUART/	/EQ 1GM BASE/VIAL/	/N50588/001/ /DEC/27,/1985/
/AP/	/EQ 2GM BASE/VIAL/	/N50588/002/ /DEC/27,/1985/
/AP/ /ZENECA/	/EQ 1GM BASE/VIAL/	/N63293/001/ /APR/29,/1993/
/AP/	/EQ 2GM BASE/VIAL/	/N63293/002/ /APR/29,/1993/
+ ZENECA	EQ 1GM BASE/VIAL	N50588 001 DEC 27, 1985
+	EQ 2GM BASE/VIAL	N50588 002 DEC 27, 1985
	EQ 1GM BASE/VIAL	N63293 001 APR 29, 1993
	EQ 2GM BASE/VIAL	N63293 002 APR 29, 1993

CEFOTETAN DISODIUM

INJECTABLE; INJECTION		
CEFOTAN IN PLASTIC CONTAINER		
+ ZENECA	EQ 20MG BASE/ML	N50694 002 JUL 30, 1993
+	EQ 40MG BASE/ML	N50694 001 JUL 30, 1993

CEFOTIAM HYDROCHLORIDE

/INJECTABLE;/INJECTION/		
/CERADON/		
/TAKEDA/	/EQ/1GM/BASE/VIAL/	/N50601/001/ /DEC/30,/1988/
∂ TAKEDA	EQ 1GM BASE/VIAL	N50601 001 DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION		
MEFOXIN IN PLASTIC CONTAINER		
MERCK	EQ 20MG BASE/ML	N63182 001 JAN 25, 1993
	EQ 40MG BASE/ML	N63182 002 JAN 25, 1993

CEFPIRAMIDE SODIUM

/INJECTABLE;/INJECTION/		
/CEFPIRAMIDE/SODIUM/		
/WYETH/AYERST/	/EQ/1GM/BASE/VIAL/	/N50633/002/ /JAN/31,/1989/
	/EQ/2GM/BASE/VIAL/	/N50633/003/ /JAN/31,/1989/
	/EQ/10GM/BASE/VIAL/	/N50633/005/ /JAN/31,/1989/
∂ WYETH AYERST	EQ 1GM BASE/VIAL	N50633 002 JAN 31, 1989
∂	EQ 2GM BASE/VIAL	N50633 003 JAN 31, 1989
∂	EQ 10GM BASE/VIAL	N50633 005 JAN 31, 1989

CEFTAZIDIME

INJECTABLE; INJECTION
TAZICEF

> ADD >	AP	SMITHKLINE BEECHAM	1GM/VIAL	N64032 001 OCT 31, 1993
> ADD >				
> ADD >	AP		2GM/VIAL	N64032 002 OCT 31, 1993
> ADD >				

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP	BAXTER	EQ 10MG BASE/ML	N63221 001 APR 29, 1993
AP		EQ 20MG BASE/ML	N63221 002 APR 29, 1993
AP		EQ 40MG BASE/ML	N63221 003 APR 29, 1993

FORTAZ IN PLASTIC CONTAINER

AP	GLAXO	EQ 10MG BASE/ML	N50634 001 APR 28, 1989
AP		EQ 20MG BASE/ML	N50634 002 APR 28, 1989
AP		EQ 40MG BASE/ML	N50634 003 APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

FUJISAWA	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
	EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

ROCHE	EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
	EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
	EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

/ROCHE/	/EQ/10MG/BASE/ML/	/N50624/001/ /FEB/11,/1987/
∂ ROCHE	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME

AP	MARSAM	EQ 750MG BASE/VIAL	N64035 001 FEB 26, 1993
AP		EQ 1.5GM BASE/VIAL	N64035 002 FEB 26, 1993
AP		EQ 7.5GM BASE/VIAL	N64036 001 FEB 26, 1993

KEFUROX

AP	LILLY	EQ 7.5GM BASE/VIAL	N62591 003 DEC 17, 1987

ZINACEF

AP	GLAXO	EQ 7.5GM BASE/VIAL	N50558 004 OCT 23, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
CALCIBIND

/+//MISSION/PHARMA/	/2.5GM/PACKET/	/N18757/002/ /DEC/28,/1982/
∂ MISSION PHARMA	2.5GM/PACKET	N18757 002 DEC 28, 1982

CEPHALEXIN

CAPSULE; ORAL
CEFANEX

AB	APOTHECON	EQ 250MG BASE	N63063 001 SEP 29, 1989
AB		EQ 500MG BASE	N63063 002 SEP 29, 1989
/AB/	/BRISTOL/MYERS/	/EQ 250MG BASE/	/N63063/001/ /SEP/29,/1989/
/AB/		/EQ 500MG BASE/	/N63063/002/ /SEP/29,/1989/

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	APOTHECON	EQ 250MG BASE	N62973 001 NOV 08, 1988
AB		EQ 500MG BASE	N62974 001 NOV 23, 1988
/AB/	/SQUIBB/MARK/	/EQ 250MG BASE/	/N62973/001/ /NOV/08,/1988/
/AB/		/EQ 500MG BASE/	/N62974/001/ /NOV/23,/1988/

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM

> DLT >/AP/	/ABBOTT/	/EQ 1GM BASE/VIAL/	/N62548/001/ /SEP/11,/1985/
> DLT >		/EQ 2GM BASE/VIAL/	/N62548/002/ /SEP/11,/1985/
> DLT >/AP/			
> DLT >			
> ADD >	a ABBOTT	EQ 1GM BASE/VIAL	N62548 001 SEP 11, 1985
> ADD >			
> ADD >	a	EQ 2GM BASE/VIAL	N62548 002 SEP 11, 1985
> ADD >			

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

	a APOTHECON	EQ 500MG BASE/VIAL	N50446 005
		EQ 500MG BASE/VIAL	N62961 001 SEP 20, 1988
	a	EQ 1GM BASE/VIAL	N50446 001
		EQ 1GM BASE/VIAL	N61769 001
		EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986
		EQ 1GM BASE/VIAL	N62961 002 SEP 20, 1988
	a	EQ 2GM BASE/VIAL	N50446 002
		EQ 2GM BASE/VIAL	N61769 002
		EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986
		EQ 2GM BASE/VIAL	N62961 003 SEP 20, 1988
	a	EQ 4GM BASE/VIAL	N50446 003
		EQ 4GM BASE/VIAL	N61769 003
		EQ 4GM BASE/VIAL	N62961 004 SEP 20, 1988
	a	EQ 20GM BASE/VIAL	N50446 004

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N50446/005/
/AP/		/EQ 1GM BASE/VIAL/	/N50446/001/
/AP/		/EQ 1GM BASE/VIAL/	/N61769/001/
/AP/		/EQ 1GM BASE/VIAL/	/N62724/001/ /DEC/23,/1986/
/AP/		/EQ 2GM BASE/VIAL/	/N50446/002/
/AP/		/EQ 2GM BASE/VIAL/	/N61769/002/
/AP/		/EQ 2GM BASE/VIAL/	/N62724/002/ /DEC/23,/1986/
/AP/		/EQ 4GM BASE/VIAL/	/N50446/003/
/AP/		/EQ 4GM BASE/VIAL/	/N61769/003/
/AP/		/EQ/20GM/BASE/VIAL/	/N50446/004/
/AP/	/BRISTOL/MYERS/	/EQ 500MG BASE/VIAL/	/N62961/001/ /SEP/20,/1988/
/AP/		/EQ 1GM BASE/VIAL/	/N62961/002/ /SEP/20,/1988/
/AP/		/EQ 2GM BASE/VIAL/	/N62961/003/ /SEP/20,/1988/
/AP/		/EQ 4GM BASE/VIAL/	/N62961/004/ /SEP/20,/1988/
/AP/	/CEPHAPIRIN SODIUM/ /LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62723/001/ /NOV/17,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N62723/002/ /NOV/17,/1986/
/AP/		/EQ 2GM BASE/VIAL/	/N62723/003/ /NOV/17,/1986/
/AP/		/EQ 4GM BASE/VIAL/	/N62723/004/ /NOV/17,/1986/
	a LYPHOMED	EQ 500MG BASE/VIAL	N62723 001 NOV 17, 1986
	a	EQ 1GM BASE/VIAL	N62723 002 NOV 17, 1986
	a	EQ 2GM BASE/VIAL	N62723 003 NOV 17, 1986
	a	EQ 4GM BASE/VIAL	N62723 004 NOV 17, 1986

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

/AP/	/MICHEL-S/ /RACHELLE/	/EQ 1GM BASE/VIAL/	/N60132/001/
	a RACHELLE	EQ 1GM BASE/VIAL	N60132 001

CHLORDIAZEPOXIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/LIBRELEASE/
/+//ROCHE/ /30MG/ /N17813/001/
/SEP/12,/1983/
@ ROCHE 30MG N17813 001
SEP 12, 1983

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /PIONEER/PHARMS/ /25MG/ /N89558/001/
/JUL/15,/1988/
@ PIONEER PHARMS 25MG N89558 001
JUL 15, 1988

LIBRIUM
/AB/ /ROCHE/ /5MG/ /N12249/002/
/AB/ /10MG/ /N12249/001/
/AB//+/ /25MG/ /N12249/003/
/AB/ /25MG/ /N85475/001/
AB + ROCHE 25MG N85475 001
@ 5MG N12249 002
@ 10MG N12249 001
@ 25MG N12249 003

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
ALDOCLOR-150
/AB/ /MSD/ /150MG;250MG/ /N16016/001/
MSD 150MG;250MG N16016 001
ALDOCLOR-250
/AB//+//MSD/ /250MG;250MG/ /N16016/002/
+ MSD 250MG;250MG N16016 002
/METHYLDOPA AND CHLOROTHIAZIDE/
/AB/ /PAR/ /150MG;250MG/ /N70783/001/
/NOV/06,/1987/
/AB/ /250MG;250MG/ /N70654/001/
/NOV/06,/1987/
@ PAR 150MG;250MG N70783 001
NOV 06, 1987
@ 250MG;250MG N70654 001
NOV 06, 1987

CHLOROTRIANISENE

CAPSULE; ORAL
TACE
/MERRELL/DOW/ /72MG/ /N16235/001/
@ MERRELL DOW 72MG N16235 001

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE
/AP/ /BEL/MAR/ /10MG/ML/ /N80821/001/
@ BEL MAR 10MG/ML N80821 001
/AP/ /STERIS/ /100MG/ML/ /N86095/001/
STERIS 100MG/ML N86095 001
/PYRIDAMAL 100/
/AP/ /BEL/MAR/ /100MG/ML/ /N83733/001/
@ BEL MAR 100MG/ML N83733 001

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
/AA/ /NEWTRON/ /4MG/ /N86519/001/
@ NEWTRON 4MG N86519 001

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
CHLORPROMAZINE HCL
@ PENNEX PHARMS 30MG/ML N87032 001
JUL 08, 1982
@ 100MG/ML N87053 001
/AA/ /PHARM/BASICS/ /30MG/ML/ /N87032/001/
/JUL/08,/1982/
/AA/ /100MG/ML/ /N87053/001/

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
/AP/ /LYPHOMED/ /25MG/ML/ /N84911/001/
@ LYPHOMED 25MG/ML N84911 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
>DLT >/AB/ /ABBOTT/ /50MG/ /N87384/001/
>ADD > @ ABBOTT 50MG N87384 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
/AB/ /PHARM/BASICS/ /50MG/ /N89052/001/ /JUN/01,/1987/
∂ PHARM BASICS 50MG N89052 001 JUN 01, 1987

CHLORTHALIDONE; METOPROLOL TARTRATE

/CAPSULE;/ORAL/
/LOPRESSIDONE/
/+//CIBA/ /25MG;200MG/ /N19451/002/ /DEC/31,/1987/
/25MG;100MG/ /N19451/001/ /DEC/31,/1987/
∂ CIBA 25MG;100MG N19451 001 DEC 31, 1987
∂ 25MG;200MG N19451 002 DEC 31, 1987

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
/AA/ /PIONEER/PHARMS/ /250MG/ /N89592/001/ /JAN/06,/1989/
/AA/ /500MG/ /N89948/001/ /JAN/06,/1989/
∂ PIONEER PHARMS 250MG N89592 001 JAN 06, 1989
∂ 500MG N89948 001 JAN 06, 1989

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN
> DLT > /BOOTS/ /10,000/UNITS/VIAL/ /N18663/001/ /NOV/10,/1982/
> DLT >
> ADD > ∂ BOOTS 10,000 UNITS/VIAL N18663 001 NOV 10, 1982
> ADD >

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC
CATARASE
+ IOLAB 300 UNITS/VIAL /150/UNITS/VIAL/ N16938 001 /N18121/001/
∂ 150 UNITS/VIAL /300/UNITS/VIAL/ N18121 001 /N16938/001/

CISAPRIDE MONOHYDRATE

TABLET; ORAL
PROPULSID
> DLT > /+//JANSSEN/ /EQ/20MG/BASE/ /N20210/002/ /JUL/29,/1993/
> DLT > JANSSEN EQ 10MG BASE N20210 001 JUL 29, 1993
> ADD > ∂ EQ 20MG BASE N20210 002 JUL 29, 1993
> ADD >

CLADRIBINE

INJECTABLE; INJECTION
LEUSTATIN
+ JOHNSON RW 1MG/ML N20229 001 FEB 26, 1993

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE
> ADD > AA BARRE EQ 0.5MG BASE/5ML N74075 001 OCT 31, 1993
> ADD >

TABLET; ORAL
CLEMASTINE FUMARATE
> ADD > AB GENEVA 2.68MG N73459 001 OCT 31, 1993
> ADD >

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

AB	+ UPJOHN	EQ 75MG BASE	N50162 001
/AB/	/+/	/EQ 75MG BASE/	/N50162/001/
AB	+	EQ 150MG BASE	N50162 002
/AB/	/+/	/EQ 150MG BASE/	/N50162/002/
	@	EQ 75MG BASE	N61809 001
	@	EQ 150MG BASE	N61809 002

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP	+ UPJOHN	EQ 150MG BASE/ML	N50441 001

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

/AP/	/LYPHOMED/	/EQ 12MG BASE/ML/	/N50636/001/ /DEC/22,/1989/
	@ LYPHOMED	EQ 12MG BASE/ML	N50636 001 DEC 22, 1989

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL

/AB/	/BIOCRAFT/	/0.1MG/	/N70747/001/ /MAR/20,/1986/
/AB/		/0.2MG/	/N70702/001/ /MAR/20,/1986/
/AB/		/0.3MG/	/N70659/001/ /MAR/20,/1986/
	@ BIOCRAFT	0.1MG	N70747 001 JUL 08, 1986
	@	0.2MG	N70702 001 JUL 08, 1986
	@	0.3MG	N70659 001 JUL 08, 1986
/AB/	/PAR/	/0.1MG/	/N70461/001/ /NOV/22,/1985/
/AB/		/0.2MG/	/N70460/001/ /NOV/22,/1985/
/AB/		/0.3MG/	/N70459/001/ /NOV/22,/1985/
	@ PAR	0.1MG	N70461 001 JUL 08, 1986
	@	0.2MG	N70460 001 JUL 08, 1986
	@	0.3MG	N70459 001 JUL 08, 1986

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB	TARO	1%	N72640 001 AUG 31, 1993

LOTRIMIN

AB	+ SCHERING	1%	N17619 001
/BT/	/+/	/1%/	/N17619/001/
	/CREAM;/VAGINAL/ /GYNE-LOTRIMIN/		
/BT/	/SCHERING/	/1%/	/N18052/001/
	/MYCELEX-G/		
/BT/	/MILES/	/1%/	/N18230/001/
	/TABLET;/VAGINAL/ /GYNE-LOTRIMIN/		
/BT/	/SCHERING/	/100MG/	/N17717/001/
	/MYCELEX-G/		
/BT/	/MILES/	/100MG/	/N18182/001/

CLOXACILLIN SODIUM

CAPSULE; ORAL

TEGOPEN

AB	+ APOTHECON	EQ 250MG BASE	N61452 001
AB	+	EQ 500MG BASE	N61452 002
/AB/	//BRISTOL/	/EQ 250MG BASE/	/N61452/001/
/AB/	/+/	/EQ 500MG BASE/	/N61452/002/

POWDER FOR RECONSTITUTION; ORAL

TEGOPEN

AA	APOTHECON	EQ 125MG BASE/5ML	N61453 001
/AA/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N61453/001/

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC W/ CODEINE

	@ PENNEX PHARMS	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88896 001 JAN 04, 1985
/AA/	/PHARM/BASICS/	/10MG/5ML;5MG/5ML;/ /6.25MG/5ML/	/N88896/001/ /JAN/04,/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ CODEINE

/AA/	/PENNEX/PHARMS/	/10MG/5ML;6.25MG/5ML/	/N088875/001/ /DEC/17,/1984/
	∂ PENNEX PHARMS	10MG/5ML;6.25MG/5ML	N88875 001 DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA	PENNEX PHARMS	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001 NOV 16, 1984
/AA/	/PHARM/BASICS/	/10MG/5ML;30MG/5ML;/ /1.25MG/5ML/	/N088833/001/ /NOV/16,/1984/

CORTICOTROPIN

INJECTABLE; INJECTION
ACTHAR

/AP/	/ARMOUR/	/25 UNITS/VIAL/	/N07504/002/
/AP/		/40 UNITS/VIAL/	/N07504/003/
AP	RHONE POULENC RORER	25 UNITS/VIAL	N07504 002
AP		40 UNITS/VIAL	N07504 003
	H.P. ACTHAR GEL		
/BC/	/ARMOUR/	/40/UNITS/ML/	/N08372/006/
/BC/+/		/80/UNITS/ML/	/N08372/008/
BC	RHONE POULENC RORER	40 UNITS/ML	N08372 006
BC +		80 UNITS/ML	N08372 008
	/PURIFIED/CORTROPHIN/GEL/		
/BC/	/ORGANON/	/40/UNITS/ML/	/N08975/001/
/BC/		/80/UNITS/ML/	/N08975/002/
	∂ ORGANON	40 UNITS/ML	N08975 001
	∂	80 UNITS/ML	N08975 002

CORTICOTROPIN-ZINC HYDROXIDE

	/INJECTABLE;/INJECTION/ /CORTROPHIN-ZINC/		
	/+//ORGANON/	/40/UNITS/ML/	/N09854/001/
	∂ ORGANON	40 UNITS/ML	N09854 001

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

/BP/	/HEATHER/	/25MG/	/N85736/001/
	∂ HEATHER	25MG	N85736 001

CROMOLYN SODIUM

	/SOLUTION;/NASAL/ /NASALCROM/ /FISONS/	/4%/	/N18306/001/ /MAR/18,/1983/

SPRAY, METERED; NASAL
NASALCROM

+	FISONS	5.2MG/INH	N18306 001 MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

/AP/	/DELL/	/0.03MG/ML/	/N080689/001/
	DELL	0.03MG/ML	N80689 001
/AP/	/FUJISAWA/	/1MG/ML/	/N083075/001/
	∂ FUJISAWA	1MG/ML	N83075 001
	/RUBIVITE/		
/AP/	/BEL/MAR/	/0.03MG/ML/	/N10791/004/
/AP/		/0.1MG/ML/	/N10791/002/
/AP/		/1MG/ML/	/N10791/003/
		/0.05MG/ML/	/N10791/001/
		/0.12MG/ML/	/N10791/005/
	∂ BEL MAR	0.03MG/ML	N10791 004
	∂	0.05MG/ML	N10791 001
	∂	0.1MG/ML	N10791 002
	∂	0.12MG/ML	N10791 005
	∂	1MG/ML	N10791 003

CYCLACILLIN

	/POWDER/FOR/RECONSTITUTION;/ORAL/ /CYCLAPEN-W/		
	/+//WYETH/AYERST/	/500MG/5ML/	/N050508/003/
		/125MG/5ML/	/N050508/001/
		/250MG/5ML/	/N050508/002/
	∂ WYETH AYERST	125MG/5ML	N50508 001
	∂	250MG/5ML	N50508 002
	∂	500MG/5ML	N50508 003

CYCLIZINE LACTATE

/INJECTABLE;/INJECTION/
/MAREZINE/
/BURROUGHS/WELLCOME/ /50MG/ML/ /N09495/001/
@ BURROUGHS WELLCOME 50MG/ML N09495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL
AB INVAMED 10MG N73683 001
FEB 26, 1993

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
NEOSAR
AP ADRIA 100MG/VIAL N40015 001
APR 29, 1993
AP 200MG/VIAL N40015 002
APR 29, 1993
AP 500MG/VIAL N40015 003
APR 29, 1993
AP 1GM/VIAL N40015 004
APR 29, 1993
AP 2GM/VIAL N40015 005
APR 29, 1993

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL
@ PENNEX PHARMS 2MG/5ML N87001 001
NOV 04, 1982
/AA/ /PHARM/BASICS/ /2MG/5ML/ /N87001/001/
/NOV/04,/1982/

TABLET; ORAL
CYPROHEPTADINE HCL
/AA/ /MYLAN/ /4MG/ /N86678/001/
@ MYLAN 4MG N86678 001

DESIPRAMINE HYDROCHLORIDE

/CAPSULE;/ORAL/
/PERTOFRANE/
/+//RHONE/POULENC/RORER//50MG/ /N13621/002/
/25MG/ /N13621/001/
@ RHONE POULENC RORER 25MG N13621 001
@ 50MG N13621 002

DESLANOSIDE

/INJECTABLE;/INJECTION/
/CEDILANID-D/
/SANDOZ/ /0.2MG/ML/ /N09282/002/
@ SANDOZ 0.2MG/ML N09282 002

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP
RHONE POULENC RORER 0.01MG/INH N17922 002
FEB 06, 1989

DESOXYCORTICOSTERONE PIVALATE

/INJECTABLE;/INJECTION/
/PERCORTEN/
/CIBA/ /25MG/ML/ /N08822/001/
@ CIBA 25MG/ML N08822 001

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE
AA BARRE 0.5MG/5ML N88997 001
OCT 10, 1986
/AA/ /NASKA/ /0.5MG/5ML/ /N88997/001/
/OCT/10,/1986/

MYMETHASONE
AA PENNEX PHARMS 0.5MG/5ML N88254 001
JUL 27, 1983
/AA/ /PHARM/BASICS/ /0.5MG/5ML/ /N88254/001/
/JUL/27,/1983/

DEXAMETHASONE

SOLUTION; ORAL

	DEXAMETHASONE		
	/3/ROXANE/	/0.5MG/5ML/	/N88248/001/ /SEP/01,/1983/
	ROXANE	0.5MG/5ML	N88248 001 SEP 01, 1983

TABLET; ORAL

	DECADRON		
AB	MSD	0.5MG	N11664 001
AB	+	0.75MG	N11664 002
AB		1.5MG	N11664 003
AB		4MG	N11664 005
/BP/		/0.5MG/	/N11664/001/
/BP/+/		/0.75MG/	/N11664/002/
/BP/		/1.5MG/	/N11664/003/
/BP/		/4MG/	/N11664/005/
	DEXAMETHASONE		
AB	ROXANE	0.5MG	N84611 001
AB		0.75MG	N84613 001
AB		1.5MG	N84610 001
AB		4MG	N84612 001
/BP/		/0.5MG/	/N84611/001/
/BP/		/0.75MG/	/N84613/001/
/BP/		/1.5MG/	/N84610/001/
/BP/		/4MG/	/N84612/001/

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	/DEXASPORIN/		
/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/GM;/ /10,000 UNITS/GM/	/N62411/001/ /MAY/16,/1983/
	@ PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62411 001 MAY 16, 1983

SUSPENSION/DROPS; OPHTHALMIC

	/DEXASPORIN/		
/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/ML;/ /10,000 UNITS/ML/	/N62428/001/ /MAY/18,/1983/
	@ PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62428 001 MAY 18, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	DEXAMETHASONE SODIUM PHOSPHATE		
/AP/	/BEL/MAR/	/EQ 4MG PHOSPHATE/ML/	/N84752/001/
	@ BEL MAR	EQ 4MG PHOSPHATE/ML	N84752 001
/AP/	/BRISTOL/	/EQ 4MG PHOSPHATE/ML/	/N87065/001/
	@ FUJISAWA	EQ 4MG PHOSPHATE/ML	N87065 001
/AP/	/WYETH/AYERST/	/EQ 4MG PHOSPHATE/ML/	/N85641/001/
	@ WYETH AYERST	EQ 4MG PHOSPHATE/ML	N85641 001
	HEXADROL		
	/ORGANON/	/EQ/20MG/PHOSPHATE/ML/	/N14694/004/
	@ ORGANON	EQ 20MG PHOSPHATE/ML	N14694 004

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

	MYLARAMINE		
AA	PENNEX PHARMS	2MG/5ML	N88251 001 MAR 23, 1984
/AA/	/PHARM/BASICS/	/2MG/5ML/	/N88251/001/ /MAR/23,/1984/

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	/DEXAMPEX/		
/AA/	/LEMMON/	/5MG/	/N83735/001/
/AA/		/10MG/	/N83735/002/
	@ LEMMON	5MG	N83735 001
	@	10MG	N83735 002
	/FERNDEX/		
/AA/	/FERNDALE/	/5MG/	/N84001/001/
	@ FERNDALE	5MG	N84001 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	/PROMETHAZINE W/ DEXTROMETHORPHAN/		
/AA/	/PHARM/BASICS/	/15MG/5ML;6.25MG/5ML/	/N88864/001/ /JAN/04,/1985/
	@ PENNEX PHARMS	15MG/5ML;6.25MG/5ML	N88864 001 JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/500MG/ML/	/N19445/001/ /JUN/03,/1986/
	∂ ABBOTT	500MG/ML	N19445 001 JUN 03, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML	N19844 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001 AUG 09, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

/HYPAQUE-M;75%/ /STERLING/	/50%;25%/	/N10220/003/
∂ STERLING	50%;25%	N10220 003
/HYPAQUE-M;90%/ /STERLING/	/60%;30%/	/N10220/002/
∂ STERLING	60%;30%	N10220 002

DIATRIZOATE SODIUM

/SOLUTION;/URETERAL/ /HYPAQUE/SODIUM/20%/ /STERLING/	/20%/	/N09561/002/
∂ STERLING	20%	N09561 002

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP	MARSAM	5MG/ML	N72370 001 JAN 29, 1993
AP		5MG/ML	N72371 001 JAN 29, 1993
AP		5MG/ML	N72397 001 JAN 29, 1993

VALIUM

/AP/	/ROCHE/	/5MG/ML/	/N16087/001/
AP	+ ROCHE	5MG/ML	N16087 001

INJECTABLE; INTRAVENOUS

DIZAC

+ KABI	5MG/ML	N19287 001 JUN 18, 1993

TABLET; ORAL

DIAZEPAM

∂ FERNDALE	2MG	N70903 001 APR 01, 1987
∂	5MG	N70904 001 APR 01, 1987
∂	10MG	N70905 001 APR 01, 1987

DIAZEPAM

TABLET; ORAL

	DIAZEPAM		
/AB/	/PHARM/BASICS/	/2MG/	/N70903/001/ /APR/01,/1987/
/AB/		/5MG/	/N70904/001/ /APR/01,/1987/
/AB/		/10MG/	/N70905/001/ /APR/01,/1987/
/AB/	/ZENITH/	/2MG/	/N70360/001/ /SEP/04,/1985/
/AB/		/5MG/	/N70361/001/ /SEP/04,/1985/
	∂ ZENITH	2MG	N70360 001 SEP 04, 1985
	∂	5MG	N70361 001 SEP 04, 1985

DIAZOXIDE

CAPSULE; ORAL

	PROGLYCEM		
	+ BAKER NORTON	50MG	N17425 001
	/+//MEDCL/MKTG/	/50MG/	/N17425/001/

INJECTABLE; INJECTION

	/DIAZOXIDE/		
/AP/	/QUAD/	/15MG/ML/	/N71908/001/ /JAN/26,/1988/
	∂ QUAD	15MG/ML	N71908 001 JAN 26, 1988
	MYPERSTAT		
/AP/	/SCHERING/	/15MG/ML/	/N16996/001/
	SCHERING	15MG/ML	N16996 001

SUSPENSION; ORAL

	PROGLYCEM		
> ADD >	+ BAKER NORTON	50MG/ML	N17453 001
> DLT >	/+//MEDCL/MKTG/	/50MG/ML/	/N17453/001/

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	VOLTAREN		
	/CIBA/	/0.1%/	/N20037/001/ /MAR/28,/1991/
	CIBA VISION	0.1%	N20037 001 MAR 28, 1991

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DYCILL		
/AB/	/SMITHKLINE/BEECHAM/	/EQ 250MG BASE/	/N60254/002/
/AB/		/EQ 500MG BASE/	/N60254/003/
	∂ SMITHKLINE BEECHAM	EQ 250MG BASE	N60254 002
	∂	EQ 500MG BASE	N60254 003
	DYNAPEN		
AB	APOTHECON	EQ 125MG BASE	N61454 002
AB		EQ 250MG BASE	N61454 001
/AB/	/BRISTOL/	/EQ 125MG BASE/	/N61454/002/
/AB/		/EQ 250MG BASE/	/N61454/001/

POWDER FOR RECONSTITUTION; ORAL

	DYNAPEN		
AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001
/AB/	/BRISTOL/	/EQ 62.5MG BASE/5ML/	/N61455/001/

DICUMAROL

TABLET; ORAL

	DICUMAROL		
	/+//ABBOTT/	/50MG/	/N05545/004/
	∂ ABBOTT	50MG	N05545 004

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL		
/AB/	/PIONEER/PHARMS/	/10MG/	/N89361/001/ /JAN/10,/1989/
	∂ PIONEER PHARMS	10MG	N89361 001 JAN 10, 1989

TABLET; ORAL

	DICYCLOMINE HCL		
/AB/	/PIONEER/PHARMS/	/20MG/	/N88585/001/ /AUG/20,/1986/
	∂ PIONEER PHARMS	20MG	N88585 001 AUG 20, 1986

DIETHYLSTILBESTROL

/INJECTABLE;/INJECTION/
/STILBESTROL/
/SQUIBB/

	/0.2MG/ML/	/N04056/003/
	/0.5MG/ML/	/N04056/004/
	/1MG/ML/	/N04056/005/
	/5MG/ML/	/N04056/006/
@ SQUIBB	0.2MG/ML	N04056 003
@	0.5MG/ML	N04056 004
@	1MG/ML	N04056 005
@	5MG/ML	N04056 006

/SUPPOSITORY;/VAGINAL/
/STILBESTROL/

/+//SQUIBB/	/0.1MG/	/N04056/001/
/+/	/0.5MG/	/N04056/002/
@ SQUIBB	0.1MG	N04056 001
@	0.5MG	N04056 002

TABLET, DELAYED RELEASE; ORAL
STILBETIN

/BE/ /SQUIBB/	/0.1MG/	/N04056/011/
@ SQUIBB	0.1MG	N04056 011

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD

BC + CARDERM	180MG	N20062 002 DEC 27, 1991
BC +	240MG	N20062 003 DEC 27, 1991
+	120MG	N20062 001 AUG 10, 1992
+	300MG	N20062 004 DEC 27, 1991
/BC/+//MARION/MERRELL/DOW/	/180MG/	/N20062/002/ /DEC/27,/1991/
/BC/+/	/240MG/	/N20062/003/ /DEC/27,/1991/
/+/	/120MG/	/N20062/001/ /AUG/10,/1992/
/+/	/300MG/	/N20062/004/ /DEC/27,/1991/

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	APOTHECON	30MG	N74051 001 MAR 31, 1993
AB		60MG	N74051 002 MAR 31, 1993
AB		90MG	N74051 003 MAR 31, 1993
AB		120MG	N74051 004 MAR 31, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

/AA/	/LEMMON/	/25MG/	/N85874/001/
/AA/		/50MG/	/N85874/002/
	@ LEMMON	25MG	N85874 001
	@	50MG	N85874 002

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

/AP/	/BEL/MAR/	/10MG/ML/	/N80822/001/
	@ BEL MAR	10MG/ML	N80822 001
/AP/	/BRISTOL/	/10MG/ML/	/N87066/001/
	@ FUJISAWA	10MG/ML	N87066 001

DIPHENYLPYRALINE HYDROCHLORIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/HISPRIL/

/+//SMITHKLINE/BEECHAM/ /5MG/		/N11945/001/
@ SMITHKLINE BEECHAM	5MG	N11945 001

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

/AB/	/KV/	/EQ 100MG BASE/	/N71929/001/ /AUG/19,/1988/
B*	KV	EQ 100MG BASE	N71929 001 AUG 19, 1988

DIVALPROEX SODIUM

/TABLET;/DELAYED/RELEASE;/ORAL/
/DEPAKOTE/CP/
/ABBOTT/ /EQ/250MG/BASE/ /N19794/001/ /JUL/11,/1990/
/EQ/500MG/BASE/ /N19794/002/ /JUL/11,/1990/

∂ ABBOTT	EQ 250MG BASE	N19794 001 JUL 11, 1990
∂	EQ 500MG BASE	N19794 002 JUL 11, 1990

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

> ADD >		**DOBUTAMINE HCL**	
> ADD >	AP	GENSIA	EQ 12.5MG BASE/ML — N74206 001 OCT 19, 1993
> ADD >		**DOBUTAMINE HCL IN DEXTROSE 5%**	
> ADD >	AP +	ABBOTT	EQ 50MG BASE/100ML — N20269 001 OCT 19, 1993
> ADD >	AP +		EQ 100MG BASE/100ML — N20269 002 OCT 19, 1993
> ADD >	AP +		EQ 200MG BASE/100ML — N20269 003 OCT 19, 1993
> ADD >		**DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER**	
> ADD >	AP	ABBOTT	EQ 50MG BASE/100ML — N20201 003 OCT 19, 1993
> ADD >	AP		EQ 100MG BASE/100ML — N20201 002 OCT 19, 1993
> ADD >	AP		EQ 200MG BASE/100ML — N20201 001 OCT 19, 1993
> ADD >	AP +	BAXTER	EQ 50MG BASE/100ML — N20255 001 OCT 19, 1993
> ADD >	AP +		EQ 100MG BASE/100ML — N20255 003 OCT 19, 1993
> ADD >	AP +		EQ 200MG BASE/100ML — N20255 004 OCT 19, 1993
> ADD >	+		EQ 400MG BASE/100ML — N20255 005 OCT 19, 1993
> ADD >		**DOBUTREX**	
> ADD >	AP +	LILLY	EQ 12.5MG BASE/ML — N17820 002

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

/AP/ /ASTRA/	/40MG/ML/	/N70087/001/ /OCT/23,/1985/
/AP/	/80MG/ML/	/N70089/001/ /OCT/23,/1985/
/AP/	/80MG/ML/	/N70090/001/ /OCT/23,/1985/
/AP/	/160MG/ML/	/N70093/001/ /OCT/23,/1985/
/AP/	/160MG/ML/	/N70094/001/ /OCT/23,/1985/
∂ ASTRA	40MG/ML	N70087 001 OCT 23, 1985
∂	80MG/ML	N70089 001 OCT 23, 1985
∂	80MG/ML	N70090 001 OCT 23, 1985
∂	160MG/ML	N70093 001 OCT 23, 1985
∂	160MG/ML	N70094 001 OCT 23, 1985
/AP/ /BRISTOL/	/40MG/ML/	/N18549/001/ /MAR/11,/1983/
∂ FUJISAWA	40MG/ML	N18549 001 MAR 11, 1983
/AP/ /LYPHOMED/	/40MG/ML/	/N70012/001/ /JUN/12,/1985/
∂ LYPHOMED	40MG/ML	N70012 001 JUN 12, 1985

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HCL

AA	PENNEX PHARMS	EQ 10MG BASE/ML	N71918 001 JUL 20, 1988
/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N71918/001/ /JUL/20,/1988/

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE MONOHYDRATE

/*//MEDICOPHARMA/	/EQ/100MG/BASE/	/N50641/001/ /DEC/29,/1989/
+ VINTAGE	EQ 100MG BASE	N50641 001 DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

/AB/	/PAR/	/EQ 50MG BASE/	/N62434/001/ /OCT/19,/1984/
/AB/		/EQ 100MG BASE/	/N62442/001/ /DEC/22,/1983/
	∂ PAR	EQ 50MG BASE	N62434 001 OCT 19, 1984
	∂	EQ 100MG BASE	N62442 001 DEC 22, 1983

TABLET; ORAL
DOXY-TABS

	∂ RACHELLE	EQ 50MG BASE	N62269 003

DOXYCYCLINE HYCLATE

/AB/	/HEATHER/	/EQ 100MG BASE/	/N62462/001/ /MAY/11,/1983/
	∂ HEATHER	EQ 100MG BASE	N62462 001 MAY 11, 1983

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/QUAD/	/2.5MG/ML/	/N71941/001/ /AUG/17,/1988/
	∂ QUAD	2.5MG/ML	N71941 001 AUG 17, 1988
/AP/	/SMITH/NEPHEW/SOLOPAK/	/2.5MG/ML/	/N71754/001/ /SEP/06,/1988/
/AP/		/2.5MG/ML/	/N71755/001/ /SEP/06,/1988/
AP	SOLOPAK	2.5MG/ML	N71754 001 SEP 06, 1988
AP		2.5MG/ML	N71755 001 SEP 06, 1988

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

/AP/	/ASTRA/	/2.5MG/ML;/ /EQ 0.05MG BASE/ML/	/N72028/001/ /APR/13,/1989/
	∂ ASTRA	2.5MG/ML; EQ 0.05MG BASE/ML	N72028 001 APR 13, 1989

EDETATE DISODIUM

INJECTABLE; INJECTION
DISODIUM EDETATE

/AP/	/STERIS/	/150MG/ML/	/N84356/001/
	∂ STERIS	150MG/ML	N84356 001

EFLORNITHINE HYDROCHLORIDE

	/INJECTABLE;/INJECTION/ /ORNIDYL/ /MERRELL/DOW/	/200MG/ML/	/N19879/002/ /NOV/28,/1990/
	∂ MERRELL DOW	200MG/ML	N19879 002 NOV 28, 1990

ENCAINIDE HYDROCHLORIDE

	/CAPSULE;/ORAL/ /ENKAID/ /+//BRISTOL/	/50MG/	/N18981/004/ /DEC/24,/1986/
		/25MG/	/N18981/002/ /DEC/24,/1986/
		/35MG/	/N18981/003/ /DEC/24,/1986/
	∂ BRISTOL	25MG	N18981 002 DEC 24, 1986
	∂	35MG	N18981 003 DEC 24, 1986
	∂	50MG	N18981 004 DEC 24, 1986

ENOXACIN

TABLET; ORAL
PENETREX

	/+//PARKE/DAVIS/	/400MG/	/N19616/005/ /DEC/31,/1991/
		/200MG/	/N19616/004/ /DEC/31,/1991/
	+ RHONE POULENC RORER	400MG	N19616 005 DEC 31, 1991
		200MG	N19616 004 DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX
RHONE POULENC RORER 30MG/0.3ML N20164 001
MAR 29, 1993

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE
AP STERLING WINTHROP 0.01MG/ML;2% N40057 002
FEB 26, 1993
AP 0.02MG/ML;2% N40057 001
FEB 26, 1993

LIDOCAINE HCL W/ EPINEPHRINE
/AP/ /BEL/MAR/ /0.01MG/ML;1%/ /N80820/001/
/AP/ /0.01MG/ML;2%/ /N80757/001/
@ BEL MAR 0.01MG/ML;1% N80820 001
@ 0.01MG/ML;2% N80757 001

EPINEPHRINE; PROCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/PROCAINE/HCL/W/EPINEPHRINE/
/BEL/MAR/ /0.02MG/ML;1%/ /N80758/001/
/0.02MG/ML;2%/ /N80759/001/
@ BEL MAR 0.02MG/ML;1% N80758 001
@ 0.02MG/ML;2% N80759 001

ERGOLOID MESYLATES

TABLET; ORAL
HYDERGINE
/SANDOZ/ /0.5MG/ /N17993/003/
@ SANDOZ 0.5MG N17993 003

TABLET; SUBLINGUAL
HYDROGENATED ERGOT ALKALOIDS
/AA/ /ZENITH/ /0.5MG/ /N87186/001/
@ ZENITH 0.5MG N87186 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR
/AA/ /FISONS/ /2MG/ /N87693/001/
/FEB/24,/1983/

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR
AA LOTUS 2MG N87693 001
FEB 24, 1983

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
/ERYC/SPRINKLES/
/+//FAULDING/ /125MG/ /N50593/001/
/JUL/22,/1985/
@ FAULDING 125MG N50593 001
JUL 22, 1985

GEL; TOPICAL
ERYGEL
/AT/ /HERBERT/ /2%/ /N50617/001/
/OCT/21,/1987/
AT + HERBERT 2% N50617 001
OCT 21, 1987

ERYTHROMYCIN
AT STIEFEL 2% N63211 001
JAN 29, 1993

OINTMENT; OPHTHALMIC
ERYTHROMYCIN
/AT/ /PHARMADERM/ /5MG/GM/ /N62446/001/
/SEP/26,/1983/
@ PHARMADERM 5MG/GM N62446 001
SEP 26, 1983
/AT/ /PHARMAFAIR/ /5MG/GM/ /N62481/001/
/APR/05,/1984/
@ PHARMAFAIR 5MG/GM N62481 001
APR 05, 1984

/POWDER;/FOR/RX/COMPOUNDING/
/ERYTHROMYCIN/
/PADDOCK/ /100%/ /N50610/001/
/NOV/07,/1986/
@ PADDOCK 100% N50610 001
NOV 07, 1986

SOLUTION; TOPICAL
ERYTHRA-DERM
AT PADDOCK 2% N62687 001
FEB 05, 1988

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	BARRE	2%	N62957 001 JUL 21, 1988
/AT/	/NASKA/	/2%/	/N62957/001/ /JUL/21,/1988/
AT	PENNEX PHARMS	2%	N62825 001 OCT 23, 1987
/AT/	/PHARM/BASICS/	/2%/	/N62825/001/ /OCT/23,/1987/
>DLT >/AT/	/PHARMAFAIR/	/1.5%/	/N62485/001/ /JUL/11,/1984/
>DLT > >ADD > >ADD >	∂ PHARMAFAIR	1.5%	N62485 001 JUL 11, 1984
/AT/	/ETS-2%/ /PADDOCK/	/2%/	/N62687/001/ /FEB/05,/1988/

SWAB; TOPICAL
C-SOLVE-2

AT	SYOSSET	2%	N62751 001 JUL 30, 1993

TABLET, COATED PARTICLES; ORAL
PCE

/+//ABBOTT/	/333MG/	/N50611/001/ /SEP/09,/1986/
+ ABBOTT	500MG	N50611 002 AUG 22, 1990
	333MG	N50611 001 SEP 09, 1986
	/500MG/	/N50611/002/ /AUG/22,/1990/

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE

∂ LIFE LABS	EQ 250MG BASE/5ML	N62362 001 DEC 17, 1982

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE

AP	GENSIA	EQ 500MG BASE/VIAL	N63253 001 JUL 30, 1993
AP		EQ 1GM BASE/VIAL	N63253 002 JUL 30, 1993
/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62604/001/ /NOV/24,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N62604/002/ /NOV/24,/1986/
	∂ LYPHOMED	EQ 500MG BASE/VIAL	N62604 001 NOV 24, 1986
	∂	EQ 1GM BASE/VIAL	N62604 002 NOV 24, 1986

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

+ ANAQUEST	10MG/ML	N19386 001 AUG 15, 1988
+	250MG/ML	N19386 002 DEC 31, 1986
/DUPONT/	/10MG/ML/	/N19386/001/ /AUG/15,/1988/
	/250MG/ML/	/N19386/002/ /DEC/31,/1986/

ESTRADIOL

TABLET; ORAL
ESTRACE

BRISTOL MYERS SQUIBB	0.5MG	N81295 001 JUN 30, 1993

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN

+ AYERST	0.625MG/GM	N20216 001
/+//WYETH/AYERST/	/0.625MG/GM/	/N83273/001/

ESTROGENS, CONJUGATED

TABLET; ORAL
CONJUGATED ESTROGENS

> DLT >	/*/ZENITH/	/0.3MG/	/N88569/001/ /NOV/29,/1984/
> DLT >			
> DLT >	/*/	/0.625MG/	/N83373/001/
> DLT >	/*/	/1.25MG/	/N83601/001/
> DLT >	/*/	/2.5MG/	/N83602/001/
	PREMARIN		
	+ WYETH AYERST	1.25MG	N04782 001
	/*/	/2.5MG/	/N04782/002/
		/1.25MG/	/N04782/001/
		2.5MG	N04782 002

ESTROPIPATE

TABLET; ORAL

	ESTROPIPATE		
AB	WATSON LABS	0.75MG	N81213 001 SEP 23, 1993
AB		1.5MG	N81214 001 SEP 23, 1993
AB		3MG	N81215 001 SEP 23, 1993
AB		6MG	N81216 001 SEP 23, 1993
	OGEN 1.25		
/AB/	/*/ABBOTT/	/1.5MG/	/N83220/002/
AB	ABBOTT	1.5MG	N83220 002
	OGEN 2.5		
AB	+ ABBOTT	3MG	N83220 003
	/*/	/3MG/	/N83220/003/
	OGEN 5		
AB	ABBOTT	6MG	N83220 004

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORETHIN 1/35E-21		
AB	ROBERTS	0.035MG;1MG	N71480 001 APR 12, 1988
/AB/	/SCHIAPPARELLI/SEARLE/	0.035MG;1MG/	/N71480/001/ /APR/12,/1988/

TABLET; ORAL-28

	NORETHIN 1/35E-28		
AB	ROBERTS	0.035MG;1MG	N71481 001 APR 12, 1988

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	NORETHIN 1/35E-28		
/AB/	/SCHIAPPARELLI/SEARLE/	0.035MG;1MG/	/N71481/001/ /APR/12,/1988/

ETHOSUXIMIDE

SYRUP; ORAL

	ETHOSUXIMIDE		
AA	COPLEY	250MG/5ML	N81306 001 JUL 30, 1993
	ZARONTIN		
AA	PARKE DAVIS	250MG/5ML	N80258 001

ETHYNODIOL DIACETATE; MESTRANOL

	/TABLET;ORAL-21/		
	/OVULEN-21/		
	/*//SEARLE/	/1MG;0.1MG/	/N16029/003/
	@ SEARLE	1MG;0.1MG	N16029 003
	/TABLET;ORAL-28/		
	/OVULEN-28/		
	/SEARLE/	/1MG;0.1MG/	/N16705/001/
	@ SEARLE	1MG;0.1MG	N16705 001

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

	DIDRONEL		
	+ MGI	50MG/ML	N19545 001 APR 20, 1987
	/P/AND/S/	/50MG/ML/	/N19545/001/ /APR/20,/1987/

FELBAMATE

SUSPENSION; ORAL

	FELBATOL		
	+ WALLACE	600MG/5ML	N20189 003 JUL 29, 1993

TABLET; ORAL-28
NORETHIN 1/35E-28
AB ROBERTS 0.035MG;1MG N71481 001
APR 12, 1988

FELBAMATE

TABLET; ORAL
FELBATOL
+ WALLACE 600MG N20189 002
JUL 29, 1993
400MG N20189 001
JUL 29, 1993

FENTANYL CITRATE

> ADD > TROCHE/LOZENGE; ORAL
> ADD > FENTANYL
> ADD > + ANESTA EQ 0.4MG BASE N20195 003
> ADD > OCT 04, 1993
> ADD > EQ 0.2MG BASE N20195 001
> ADD > OCT 04, 1993
> ADD > EQ 0.3MG BASE N20195 002
> ADD > OCT 04, 1993

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ /0.01%/ /N88047/001/
/DEC/16,/1982/
/AT/ /0.025%/ /N88045/001/
/DEC/16,/1982/
@ PHARMADERM 0.01% N88047 001
DEC 16, 1982
@ 0.025% N88045 001
DEC 16, 1982
/AT/ /PHARMAFAIR/ /0.01%/ /N88499/001/
/AUG/02,/1984/
/AT/ /0.025%/ /N88506/001/
/AUG/02,/1984/
@ PHARMAFAIR 0.01% N88499 001
AUG 02, 1984
@ 0.025% N88506 001
AUG 02, 1984

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ /0.025%/ /N88046/001/
/DEC/16,/1982/
@ PHARMADERM 0.025% N88046 001
DEC 16, 1982

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMAFAIR/ /0.025%/ /N88507/001/
/FEB/27,/1984/
@ PHARMAFAIR 0.025% N88507 001
FEB 27, 1984

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
@ PENNEX PHARMS 0.01% N88312 001
JAN 27, 1984
/AT/ /PHARM/BASICS/ /0.01%/ /N88312/001/
/JAN/27,/1984/

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
/AP/ /MARCHAR/ /50MG/ML/ /N87791/001/
/JAN/18,/1983/
@ MARCHAR 50MG/ML N87791 001
JAN 18, 1983

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC
LILLY EQ 10MG BASE N18936 006
DEC 23, 1992

FLUOXYMESTERONE

TABLET; ORAL
> DLT > /ANDROID-F/
> DLT > /BP/ /ICN/ /10MG/ /N87196/001/
> ADD > @ ICN 10MG N87196 001

FLUOXYMESTERONE
> DLT > /BP/ /ICN/ /10MG/ /N88221/001/
> DLT > /MAY/05,/1983/
> ADD > @ ICN 10MG N88221 001
> ADD > MAY 05, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
PROLIXIN DECANOATE

AO	+ APOTHECON	25MG/ML	N16727 001
/AO/	/SQUIBB/	/25MG/ML/	/N16727/001/

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION
PROLIXIN ENANTHATE

+ APOTHECON	25MG/ML	N16110 001
/SQUIBB/	/25MG/ML/	/N16110/001/

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
PROLIXIN

AA	APOTHECON	5MG/ML	N70533 001 NOV 07, 1985
/AA/	/SQUIBB/	/5MG/ML/	/N70533/001/ /NOV/07,/1985/

ELIXIR; ORAL
FLUPHENAZINE HCL

AA	COPLEY	2.5MG/5ML	N81310 001 APR 29, 1993

PROLIXIN

AA	APOTHECON	2.5MG/5ML	N12145 003
	/SQUIBB/	/2.5MG/5ML/	/N12145/003/

INJECTABLE; INJECTION
PROLIXIN

AP	+ APOTHECON	2.5MG/ML	N11751 005
/AP/	/SQUIBB/	/2.5MG/ML/	/N11751/005/

TABLET; ORAL
PROLIXIN

AB	APOTHECON	1MG	N11751 004
AB		2.5MG	N11751 001
AB		5MG	N11751 003
AB	+	10MG	N11751 002
/AB/	/SQUIBB/	/1MG/	/N11751/004/
/AB/		/2.5MG/	/N11751/001/
/AB/		/5MG/	/N11751/003/
/AB//+/		/10MG/	/N11751/002/

FLUPHENAZINE HYDROCHLORIDE

/TABLET;/EXTENDED/RELEASE;/ORAL/
/PERMITTIL/

/+//SCHERING/		/1MG/	/N12419/004/
	∂ SCHERING	1MG	N12419 004

FOLIC ACID

TABLET; ORAL
FOLIC ACID

/AA/	/PIONEER/PHARMS/	/1MG/	/N88949/001/ /SEP/13,/1985/
	∂ PIONEER PHARMS	1MG	N88949 001 SEP 13, 1985

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/ASTRA/	/10MG/ML/	/N70014/001/ /SEP/09,/1985/
	∂ ASTRA	10MG/ML	N70014 001 SEP 09, 1985

SOLUTION; ORAL
FUROSEMIDE

AA	PENNEX PHARMS	10MG/ML	N70655 001 OCT 02, 1987
/AA/	/PHARM/BASICS/	/10MG/ML/	/N70655/001/ /OCT/02,/1987/

TABLET; ORAL
FUROSEMIDE

/AB/	/PARKE/DAVIS/	/20MG/	/N18419/001/ /JAN/31,/1983/
/AB/		/40MG/	/N18419/002/ /JAN/31,/1983/
/AB/		/80MG/	/N18419/003/ /NOV/13,/1984/
	∂ WARNER CHILCOTT	20MG	N18419 001 JAN 31, 1983
	∂	40MG	N18419 002 JAN 31, 1983
	∂	80MG	N18419 003 NOV 13, 1984

GADODIAMIDE

INJECTABLE; INJECTION
OMNISCAN
STERLING WINTHROP 287MG/ML N20123 001 JAN 08, 1993

GEMFIBROZIL

CAPSULE; ORAL
GEMFIBROZIL
AB MYLAN 300MG N73466 001 JAN 25, 1993
AB PUREPAC 300MG N72929 001 JAN 29, 1993

LOPID
AB + PARKE DAVIS 300MG N18422 002

TABLET; ORAL
GEMFIBROZIL
AB LEDERLE 600MG N74270 001 SEP 27, 1993
>_ADD_> >_ADD_> AB LEMMON 600MG N74256 001 OCT 31, 1993

LOPID
AB + PARKE DAVIS 600MG N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE
/AT/ /PHARMADERM/ /EQ 1MG BASE/GM/ /N62530/001/ /JUL/05,/1984/
∂ PHARMADERM EQ 1MG BASE/GM N62530 001 JUL 05, 1984

INJECTABLE; INJECTION
GENTAMICIN SULFATE
/AP/ /WYETH/AYERST/ /EQ 10MG BASE/ML/ /N62264/001/
/AP/ /EQ 40MG BASE/ML/ /N62264/002/
∂ WYETH AYERST EQ 10MG BASE/ML N62264 001
∂ EQ 40MG BASE/ML N62264 002

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
>_DLT_>/AP/ /ABBOTT/ /EQ 60MG BASE/100ML/ /N62588/006/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 70MG BASE/100ML/ /N62588/007/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 80MG BASE/100ML/ /N62588/008/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 90MG BASE/100ML/ /N62588/009/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 100MG BASE/100ML/ /N62588/010/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 1.2MG BASE/ML/ /N62588/001/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 1.4MG BASE/ML/ /N62588/002/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 1.6MG BASE/ML/ /N62588/003/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 1.8MG BASE/ML/ /N62588/004/ /JAN/06,/1986/
>_DLT_>/AP/ /EQ 2MG BASE/ML/ /N62588/005/ /JAN/06,/1986/

>_ADD_> ∂ ABBOTT EQ 60MG BASE/100ML N62588 006 JAN 06, 1986
>_ADD_> ∂ EQ 70MG BASE/100ML N62588 007 JAN 06, 1986
>_ADD_> ∂ EQ 80MG BASE/100ML N62588 008 JAN 06, 1986
>_ADD_> ∂ EQ 90MG BASE/100ML N62588 009 JAN 06, 1986
>_ADD_> ∂ EQ 100MG BASE/100ML N62588 010 JAN 06, 1986
>_ADD_> ∂ EQ 1.2MG BASE/ML N62588 001 JAN 06, 1986
>_ADD_> ∂ EQ 1.4MG BASE/ML N62588 002 JAN 06, 1986
>_ADD_> ∂ EQ 1.6MG BASE/ML N62588 003 JAN 06, 1986
>_ADD_> ∂ EQ 1.8MG BASE/ML N62588 004 JAN 06, 1986
>_ADD_> ∂ EQ 2MG BASE/ML N62588 005 JAN 06, 1986

OINTMENT; OPHTHALMIC
GENTAFAIR
/AT/ /PHARMAFAIR/ /EQ 3MG BASE/GM/ /N62443/001/ /MAY/26,/1983/
∂ PHARMAFAIR EQ 3MG BASE/GM N62443 001 MAY 26, 1983

GLIPIZIDE

TABLET; ORAL
GLUCOTROL

+ PFIZER	10MG	N17783 002 MAY 08, 1984
	2.5MG	N17783 003 MAY 11, 1993
	5MG	N17783 001 MAY 08, 1984
/+//ROERIG/	/10MG/	/N17783/002/ /MAY/08,/1984/
	/5MG/	/N17783/001/ /MAY/08,/1984/

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON

/AP/ /LILLY/	/EQ 1MG BASE/VIAL/	/N12122/001/
LILLY	EQ 1MG BASE/VIAL	N12122 001
/AP/ /QUAD/	/EQ 1MG BASE/VIAL/	/N71022/001/ /MAR/04,/1987/
@ QUAD	EQ 1MG BASE/VIAL	N71022 001 MAR 04, 1987

GLUTETHIMIDE

CAPSULE; ORAL
DORIDEN

/S/RHONE/POULENC/RORER//500MG/		/N09519/008/

GLYBURIDE

TABLET; ORAL
/GLUBATE/

/BX/ /HOECHST/ROUSSEL/	/1.5MG/	/N20055/001/ /APR/17,/1992/
/BX/	/3MG/	/N20055/002/ /APR/17,/1992/
@ HOECHST ROUSSEL	1.5MG	N20055 001 APR 17, 1992
@	3MG	N20055 002 APR 17, 1992

GLYBURIDE

TABLET; ORAL
GLYNASE

/BX/ /UPJOHN/	/1.5MG/	/N20051/001/ /MAR/04,/1992/
/+/	/3MG/	/N20051/002/ /MAR/04,/1992/
UPJOHN	3MG	N20051 002 MAR 04, 1992
+	6MG	N20051 004 SEP 24, 1993
	1.5MG	N20051 001 MAR 04, 1992
	4.5MG	N20051 003 SEP 24, 1993

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT

+ FERRING	0.8MG/VIAL	N19687 001 OCT 10, 1989
+	3.2MG/VIAL	N19687 002 OCT 10, 1989
/LUTREPULSE/PUMP/KIT/ /FERRING/	/0.8MG/VIAL/	/N19687/001/ /OCT/10,/1989/
	/3.2MG/VIAL/	/N19687/002/ /OCT/10,/1989/

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

/AP/ /BEL/MAR/	/5,000 UNITS/VIAL/	/N17054/001/
AP @ BEL MAR	5,000 UNITS/VIAL	N17054 001
/AP/	/10,000 UNITS/VIAL/	/N17054/002/
AP @	10,000 UNITS/VIAL	N17054 002

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
ZOLADEX

/+//IMPERIAL/CHEM/	/EQ/3.6MG/BASE/	/N19726/001/ /DEC/29,/1989/
+ ZENECA	EQ 3.6MG BASE	N19726 001 DEC 29, 1989

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
/NEO-POLYCIN/
/AT/ /DOW/ /0.025MG/ML;EQ 1.75MG BASE/ML;/ /10,000 UNITS/ML/ /N60427/001/
∂ DOW 0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML N60427 001

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL
GRISACTIN
/WYETH/AYERST/ /125MG/ /N50051/002/
∂ WYETH AYERST 125MG N50051 002

HALOFANTRINE HYDROCHLORIDE

/TABLET;/ORAL/
/HALFAN/
/*//SMITHKLINE/BEECHAM/ /250MG/ /N20250/001/ /JUL/24,/1992/
∂ SMITHKLINE BEECHAM 250MG N20250 001 JUL 24, 1992

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

>_DLT_>/AB/	/LEDERLE/	/0.5MG/	/N72727/001/ /SEP/19,/1989/
>_DLT_>/AB/		/1MG/	/N72728/001/ /SEP/19,/1989/
>_DLT_>/AB/		/2MG/	/N72729/001/ /SEP/19,/1989/
>_DLT_>/AB/		/5MG/	/N72730/001/ /SEP/19,/1989/
>_DLT_>/AB/		/10MG/	/N72731/001/ /SEP/19,/1989/
>_DLT_>/AB/		/20MG/	/N72732/001/ /SEP/19,/1989/
>_ADD_>	∂ LEDERLE	0.5MG	N72727 001 SEP 19, 1989
>_ADD_>	∂	1MG	N72728 001 SEP 19, 1989
>_ADD_>	∂	2MG	N72729 001 SEP 19, 1989
>_ADD_>	∂	5MG	N72730 001 SEP 19, 1989
>_ADD_>	∂	10MG	N72731 001 SEP 19, 1989
>_ADD_>	∂	20MG	N72732 001 SEP 19, 1989

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

	∂ PENNEX PHARMS	EQ 2MG BASE/ML	N70710 001 MAR 07, 1986
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001 FEB 26, 1993
/AA/	/PHARM/BASICS/	/EQ 2MG BASE/ML/	/N70710/001/ /MAR/07,/1986/
AA	SILARX	EQ 2MG BASE/ML	N73364 001 SEP 28, 1993

INJECTABLE; INJECTION
HALOPERIDOL

AP	MARSAM	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
AP		EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

/AP/	/SMITH/NEPHEW/SOLOPAK/	/EQ 5MG BASE/ML/	/N70801/001/ /DEC/14,/1987/
/AP/		/EQ 5MG BASE/ML/	/N70864/001/ /DEC/14,/1987/
AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION

LIQUAEMIN SODIUM

/AP/	/ORGANON/	/20,000 UNITS/ML/	/N00552/001/
/AP/		/40,000 UNITS/ML/	/N00552/002/
	@ ORGANON	20,000 UNITS/ML	N00552 001
	@	40,000 UNITS/ML	N00552 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

/TURGEX/

/XTTRIUM/	/3%/	/N18375/001/
@ XTTRIUM	3%	N18375 001

EMULSION; TOPICAL

/HEXA-GERM/

/AT/	/HUNTINGTON/	/3%/	/N17411/001/
	@ HUNTINGTON	3%	N17411 001

PHISOHEX

/AT/	/STERLING/	/3%/	/N08402/001/
	@ STERLING	3%	N08402 001

/TURGEX/

/AT/	/XTTRIUM/	/3%/	/N19055/001/ /NOV/30,/1984/
	@ XTTRIUM	3%	N19055 001 NOV 30, 1984

SOLUTION; TOPICAL

/DIAL/

/AT/	/ARMOUR/DIAL/	/0.25%/	/N17421/002/
	@ DIAL	0.25%	N17421 002

/GERMA-MEDICA/

	/HUNTINGTON/	/1%/	/N17412/001/
	@ HUNTINGTON	1%	N17412 001

HEXACHLOROPHENE

SOLUTION; TOPICAL

/GERMA-MEDICA/ /MG/

	/HUNTINGTON/	/0.25%/	/N17412/002/
	@ HUNTINGTON	0.25%	N17412 002

SPONGE; TOPICAL

/HEXASCRUB/

/AT/	/PROF/DSPLS/	/3%/	/N18363/001/
	@ PROF DSPLS	3%	N18363 001

/PHISO-SCRUB/

/AT/	/STERLING/	/3%/	/N17446/001/
	@ STERLING	3%	N17446 001

/SCRUBTEAM/SURGICAL/SPONGEBRUSH/

	/3M/	/330MG/	/N17413/001/
	@ 3M	330MG	N17413 001

HEXAFLUORENIUM BROMIDE

/INJECTABLE;/INJECTION/

/MYLAXEN/

	/WALLACE/	/20MG/ML/	/N09789/003/
	@ WALLACE	20MG/ML	N09789 003

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

	/LILLY/	/EQ/0.1MG/BASE/ML/	/N00734/003/
	@ LILLY	EQ 0.1MG BASE/ML	N00734 003
	@	/EQ/0.2MG/BASE/ML/ EQ 0.2MG BASE/ML	/N00734/002/ N00734 002
	@	/EQ/1MG/BASE/ML/ EQ 1MG BASE/ML	/N00734/001/ N00734 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

MYCODONE

AA	PENNEX PHARMS	1.5MG/5ML;5MG/5ML	N88008 001 MAR 03, 1983
/AA/	/PHARM/BASICS/	/1.5MG/5ML;5MG/5ML/	/N88008/001/ /MAR/03,/1983/

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

>_ADD_> AP	+ CIBA	20MG/ML	N08303 003
>_DLT_>		/20MG/ML/	/N08303/003/

HYDRALAZINE HCL

>_ADD_>	/a/SMITH/NEPHEW/SOLOPAK/	/20MG/ML/	/N88517/001/
>_DLT_>			/AUG/22,/1985/
>_DLT_>			
>_ADD_> AP	SOLOPAK	20MG/ML	N88517 001
>_ADD_>			AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; RESERPINE

/TABLET;/ORAL/

/SERPASIL-APRESOLINE/

/+//CIBA/		/50MG;0.2MG/	/N09296/002/
		/25MG;0.1MG/	/N09296/004/
	a CIBA	25MG;0.1MG	N09296 004
	a	50MG;0.2MG	N09296 002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

	a PENNEX PHARMS	50MG/5ML	N89661 001
			JUN 20, 1988
/AA/	/PHARM/BASICS/	/50MG/5ML/	/N89661/001/
			/JUN/20,/1988/
/AA/	/ROXANE/	/50MG/5ML/	/N88587/001/
			/JUL/02,/1984/
	ROXANE	50MG/5ML	N88587 001
			JUL 02, 1984

TABLET; ORAL

HYDROCHLOROTHIAZIDE

/AB/	/INWOOD/	/25MG/	/N84776/001/
/AB/		/50MG/	/N84776/002/
	a INWOOD	25MG	N84776 001
	a	50MG	N84776 002
>_DLT_>/AB/	/LEMMON/	/25MG/	/N88924/001/
>_DLT_>			/FEB/07,/1985/
/AB/		/50MG/	/N88923/001/
			/FEB/07,/1985/
>_ADD_>	a LEMMON	25MG	N88924 001
>_ADD_>			FEB 07, 1985
	a	50MG	N88923 001
			FEB 07, 1985

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

/AB/	/SCHERING/	/25MG;100MG/	/N19046/001/
			/APR/06,/1987/
/AB/		/25MG;200MG/	/N19046/002/
			/APR/06,/1987/
/AB//+/		/25MG;300MG/	/N19046/003/
			/APR/06,/1987/
	+ SCHERING	25MG;300MG	N19046 003
			APR 06, 1987
		25MG;100MG	N19046 001
			APR 06, 1987
		25MG;200MG	N19046 002
			APR 06, 1987

/TRANDATE HCT/

/AB/	/GLAXO/	/25MG;100MG/	/N19174/001/
			/APR/10,/1987/
/AB/		/25MG;200MG/	/N19174/002/
			/APR/10,/1987/
/AB/		/25MG;300MG/	/N19174/003/
			/APR/10,/1987/
	a GLAXO	25MG;100MG	N19174 001
			APR 10, 1987
	a	25MG;200MG	N19174 002
			APR 10, 1987
	a	25MG;300MG	N19174 003
			APR 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC 20/12.5

/AB/	/IMPERIAL/CHEM/	/12.5MG;20MG/	/N19888/001/
			/SEP/20,/1990/
AB	ZENECA	12.5MG;20MG	N19888 001
			SEP 20, 1990

ZESTORETIC 20/25

/AB/	/IMPERIAL/CHEM/	/25MG;20MG/	/N19888/002/
			/JUL/20,/1989/
AB	ZENECA	25MG;20MG	N19888 002
			JUL 20, 1989

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AB/	/UPSHER/SMITH/	/25MG;25MG/	/N87553/001/
	a UPSHER SMITH	25MG;25MG	N87553 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	25MG;37.5MG	N73449 001 SEP 23, 1993

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT	BARRE	2.5%	N89682 001 MAR 10, 1988
/AT/	/BIOCRAFT/	/0.5%/	/N80400/002/
/AT/		/1%/	/N80400/003/
/AT/		/2.5%/	/N80400/004/
	∂ BIOCRAFT	0.5%	N80400 002
	∂	1%	N80400 003
	∂	2.5%	N80400 004
/AT/	/NASKA/	/2.5%/	/N89682/001/ /MAR/10,/1988/
/AT/	/PHARMADERM/	/1%/	/N88845/001/ /FEB/27,/1986/
	∂ PHARMADERM	1%	N88845 001 FEB 27, 1986

LOTION; TOPICAL
ACTICORT

AT	BAKER NORTON	1%	N86535 001
/AT/	/KEY/PHARMS/	/1%/	/N86535/001/
	/BALNEOL-HC/		
/AT/	/SOLVAY/	/1%/	/N88041/001/ /DEC/03,/1982/
	∂ SOLVAY	1%	N88041 001 DEC 03, 1982

OINTMENT; TOPICAL
HYDROCORTISONE

AT	FOUGERA	2.5%	N81203 001 MAY 28, 1993
/AT/	/PHARMADERM/	/1%/	/N88842/001/ /FEB/09,/1987/
	∂ PHARMADERM	1%	N88842 001 FEB 09, 1987

TABLET; ORAL
HYDROCORTISONE

> ADD >	∂ FERRANTE	10MG	N80568 001
> ADD >	∂	20MG	N80568 002

HYDROCORTISONE

TABLET; ORAL
HYDROCORTISONE

> DLT >	/BP/	/MK/	/10MG/	/N80568/001/
> DLT >	/BP/		/20MG/	/N80568/002/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC
/NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; /10,000 UNITS/ML/	/N62617/001/ /SEP/18,/1985/
	∂ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62617 001 SEP 18, 1985

SUSPENSION/DROPS; OPHTHALMIC
/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; /10,000 UNITS/ML/	/N62623/001/ /SEP/24,/1985/
	∂ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62623 001 SEP 24, 1985

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

/BP/	/BEL/MAR/	/25MG/ML/	/N83739/001/
/BP/		/50MG/ML/	/N83739/002/
	∂ BEL MAR	25MG/ML	N83739 001
	∂	50MG/ML	N83739 002

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL
PRAMOSONE

/FERNDALE/	/0.5%;1%/	/N83213/002/
∂ FERNDALE	0.5%;1%	N83213 002

HYDROCORTISONE BUTYRATE

> DLT >	/OINTMENT;/TOPICAL/		
> DLT >	/LOCOID/		
> DLT >	/ALLERGAN/	/0.1%/	/N19106/001/
> DLT >			/JUL/03,/1984/

HYDROCORTISONE BUTYRATE

> DLT >	/OINTMENT;/TOPICAL/		
> DLT >	/LOCOID/		
> ADD >	∂ GALDERMA	0.1%	N19106 001
> ADD >			JUL 03, 1984

HYDROFLUMETHIAZIDE

TABLET; ORAL

	SALURON		
/AB/	/+//BRISTOL/	/50MG/	/N11949/001/
AB +	ROBERTS	50MG	N11949 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	SALUTENSIN		
/BP/	+//BRISTOL/	/50MG;0.125MG/	/N12359/003/
BP +	ROBERTS	50MG;0.125MG	N12359 003
	SALUTENSIN-DEMI		
	/BRISTOL/	/25MG;0.125MG/	/N12359/004/
	ROBERTS	25MG;0.125MG	N12359 004

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

	HYDROXOMIN		
/AP/	/BEL/MAR/	/1MG/ML/	/N84629/001/
	∂ BEL MAR	1MG/ML	N84629 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL		
AP	FUJISAWA	25MG/ML	N88184 001
			MAR 31, 1983
AP		50MG/ML	N88185 001
			MAR 31, 1983
/AP/	/LYPHOMED/	/25MG/ML/	/N88184/001/
			/MAR/31,/1983/
/AP/		/50MG/ML/	/N88185/001/
			/MAR/31,/1983/
/AP/	/WYETH/AYERST/	/25MG/ML/	/N86258/001/
/AP/		/50MG/ML/	/N86258/002/
	∂ WYETH AYERST	25MG/ML	N86258 001
	∂	50MG/ML	N86258 002

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

	HYDROXYZINE HCL		
AA	BARRE	10MG/5ML	N88785 001
			FEB 03, 1988
/AA/	/NASKA/	/10MG/5ML/	/N88785/001/
			/FEB/03,/1988/
AA	PENNEX PHARMS	10MG/5ML	N87294 001
			APR 12, 1982
/AA/	/PHARM/BASICS/	/10MG/5ML/	/N87294/001/
			/APR/12,/1982/

TABLET; ORAL

	HYDROXYZINE HCL		
/AB/	/CHELSEA/	/10MG/	/N86827/001/
/AB/		/25MG/	/N86829/001/
/AB/		/50MG/	/N86836/001/
	∂ CHELSEA	10MG	N86827 001
	∂	25MG	N86829 001
	∂	50MG	N86836 001

IBUPROFEN

TABLET; ORAL

	IBUPROFEN		
AB	NORTON HN	400MG	N71145 001
			SEP 23, 1986
AB		600MG	N71146 001
			SEP 23, 1986
AB		800MG	N71769 001
			MAY 08, 1987
	IBUPROFEN		
/AB/	/PAR/	/300MG/	/N70328/001/
			/AUG/06,/1985/
	∂ PAR	300MG	N70328 001
			AUG 06, 1985
	/IFEN/		
/AB/	/LUCHEM/	/400MG/	/N71145/001/
			/SEP/23,/1986/
/AB/		/600MG/	/N71146/001/
			/SEP/23,/1986/
/AB/		/800MG/	/N71769/001/
			/MAY/08,/1987/

IDOXURIDINE

/OINTMENT;/OPHTHALMIC/
/STOXIL/
/+//SMITHKLINE/BEECHAM/ /0.5%/ /N15868/001/
∂ SMITHKLINE BEECHAM 0.5% N15868 001

SOLUTION/DROPS; OPHTHALMIC
/STOXIL/
/AT/ /SMITHKLINE/BEECHAM/ /0.1%/ /N13934/001/
∂ SMITHKLINE BEECHAM 0.1% N13934 001

INDAPAMIDE

TABLET; ORAL
LOZOL
RHONE POULENC RORER 1.25MG N18538 002
APR 29, 1993

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
IODOHIPPURATE SODIUM I 131
/AP/ /CIS/ /0.2MCI/ML/ /N17313/001/
AP SORIN 0.2MCI/ML N17313 001

IOHEXOL

/INJECTABLE;/INJECTION/
/OMNIPAQUE/180/
/STERLING/ /38.8%/ /N18956/001/
/DEC/26,/1985/

/SOLUTION;/INJECTION;/ORAL/
/OMNIPAQUE/240/
/STERLING/ /51.8%/ /N18956/002/
/DEC/26,/1985/

/OMNIPAQUE/300/
/STERLING/ /64.7%/ /N18956/003/
/DEC/26,/1985/

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 180
+ STERLING 38.8% N18956 001
DEC 26, 1985

OMNIPAQUE 240
+ STERLING 51.8% N18956 002
DEC 26, 1985

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 300
+ STERLING 64.7% N18956 003
DEC 26, 1985

IOTROLAN

/INJECTABLE;/INTRATHECAL/
/OSMOVIST/
/BERLEX/ /EQ/190MG/IODINE/ML/ /N19580/001/
/DEC/07,/1989/
/EQ/240MG/IODINE/ML/ /N19580/002/
/DEC/07,/1989/
∂ BERLEX EQ 190MG IODINE/ML N19580 001
DEC 07, 1989
∂ EQ 240MG IODINE/ML N19580 002
DEC 07, 1989

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ATROVENT
+ BOEHRINGER INGELHEIM 0.02% N20228 001
SEP 29, 1993

IRON DEXTRAN

INJECTABLE; INJECTION
INFED
BP + SCHEIN PHARM EQ 50MG IRON/ML N17441 001
/IRON/DEXTRAN/
/BP/ /STERIS/ /EQ/50MG/IRON/ML/ /N17441/001/

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
/AN/ /ASTRA/ /0.125%/ /N87938/001/
/NOV/15,/1982/
/0.062%/ /N87937/001/
/NOV/15,/1982/
∂ ASTRA 0.062% N87937 001
NOV 15, 1982
∂ 0.125% N87938 001
NOV 15, 1982

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	ISOETHARINE HCL		
/AN/	/PARKE/DAVIS/	/1%/	/N85889/001/
		/0.5%/	/N85997/001/
	@ PARKE DAVIS	0.5%	N85997 001
	@	1%	N85889 001

ISOFLURANE

LIQUID; INHALATION

	FORANE		
AN	+ ANAQUEST	99.9%	N17624 001
	ISOFLURANE		
AN	ABBOTT	99.9%	N74097 001 JAN 25, 1993

ISONIAZID

INJECTABLE; INJECTION

	NYDRAZID		
	+ APOTHECON	100MG/ML	N08662 001
	/SQUIBB/	/100MG/ML/	/N08662/001/

TABLET; ORAL

	ISONIAZID		
/AA/	/EON/LABS/	/100MG/	/N08678/002/
AA	+ EON LABS	100MG	N08678 002
/AA/		/300MG/	/N08678/003/
AA	+	300MG	N08678 003
	/STANOZIDE/		
/AA/	/EVERYLIFE/	/300MG/	/N80126/002/
	@ EVERYLIFE	300MG	N80126 002

ISOPROPAMIDE IODIDE

	/TABLET;/ORAL/		
	/DARBID/		
	/SMITHKLINE/BEECHAM/	/EQ/5MG/BASE/	/N10744/001/
	@ SMITHKLINE BEECHAM	EQ 5MG BASE	N10744 001

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

	AEROLONE		
/AN/	/LILLY/	/0.25%/	/N07245/001/
	+ LILLY	0.25%	N07245 001

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

	/ISOPROTERENOL HCL/		
/AN/	/PARKE/DAVIS/	/0.25%/	/N85994/001/
/AN/		/0.5%/	/N85540/001/
	@ PARKE DAVIS	0.25%	N85994 001
	@	0.5%	N85540 001
	ISUPREL		
/AN/	/STERLING/	/0.5%/	/N06327/002/
	+ STERLING WINTHROP	0.5%	N06327 002
	/VAPO-ISO/		
/AN/	/FISONS/	/0.5%/	/N16813/001/
	@ FISONS	0.5%	N16813 001

TABLET; RECTAL, SUBLINGUAL

	ISUPREL		
	/STERLING/	/15MG/	/N06328/002/
	@ STERLING	15MG	N06328 002

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE		
/AB/	/ICI/	/20MG/	/N86405/002/ /AUG/21,/1990/
/AB/		/30MG/	/N88124/001/ /AUG/21,/1990/
/AB/		/40MG/	/N88125/001/ /AUG/21,/1990/
AB	ZENECA	20MG	N86405 002 AUG 21, 1990
AB		30MG	N88124 001 AUG 21, 1990
AB		40MG	N88125 001 AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO		
/AB//+//WYETH/		/20MG/	/N19091/001/ /DEC/30,/1991/
BX	+ WYETH	20MG	N19091 001 DEC 30, 1991

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET

BX	SCHWARZ PHARMA	20MG	N20215 001 JUN 30, 1993
		10MG	N20215 002 JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL
IMDUR

	@ SCHERING PLOUGH	30MG	N20225 001 AUG 12, 1993
		60MG	N20225 002 AUG 12, 1993

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX

	APOTHECON	EQ 500MG BASE	N62726 001 MAR 06, 1987
	/BRISTOL/	/EQ/500MG/BASE/	/N62726/001/ /MAR/06,/1987/

INJECTABLE; INJECTION
KANTREX

AP	APOTHECON	EQ 75MG BASE/2ML	N61901 003
AP		EQ 500MG BASE/2ML	N61901 001
AP		EQ 1GM BASE/3ML	N61901 002
/AP/	/BRISTOL/	/EQ 75MG BASE/2ML/	/N61901/003/
/AP/		/EQ 500MG BASE/2ML/	/N61901/001/
/AP/		/EQ 1GM BASE/3ML/	/N61901/002/
	/KLEBOIL/		
/AP/	/SMITHKLINE/BEECHAM/	/EQ 75MG BASE/2ML/	/N62170/001/
/AP/		/EQ 500MG BASE/2ML/	/N62170/002/
/AP/		/EQ 1GM BASE/3ML/	/N62170/003/
	@ SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001
	@	EQ 500MG BASE/2ML	N62170 002
	@	EQ 1GM BASE/3ML	N62170 003

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

AB	LEDERLE	25MG	N74014 001 JAN 29, 1993
AB		50MG	N74014 002 JAN 29, 1993
AB		75MG	N74014 003 JAN 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

+	WYETH AYERST	200MG	N19816 001 SEP 24, 1993

LACTULOSE

SOLUTION; ORAL

	/CEPHULAC/		
/AA/	/MERRELL/DOW/	/10GM/15ML/	/N17657/001/
	/ENULOSE/		
/AA/	/BARRE/	/10GM/15ML/	/N71548/001/ /AUG/15,/1988/
	EVALOSE		
AA	COPLEY	10GM/15ML	N73497 001 MAY 28, 1993
	LACTULOSE		
	@ PENNEX PHARMS	10GM/15ML	N71841 001 SEP 22, 1988
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71841/001/ /SEP/22,/1988/
	/LACTULOSE/		
	/SOLVAY/	/10GM/15ML/	/N17906/001/
	LAXILOSE		
AA	TECHNILAB	10GM/15ML	N73686 001 MAY 28, 1993

SOLUTION; ORAL, RECTAL

	ACILAC		
AA	TECHNILAB	10GM/15ML	N73685 001 MAY 28, 1993
	CEPHULAC		
AA	MERRELL DOW	10GM/15ML	N17657 001
	ENULOSE		
AA	BARRE	10GM/15ML	N71548 001 AUG 15, 1988

LACTULOSE

SOLUTION; ORAL, RECTAL

	GENERLAC		
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71842/001/ /SEP/27,/1988/
	@ PENNEX PHARMS	10GM/15ML	N71842 001 SEP 27, 1988
	HEPTALAC		
AA	COPLEY	10GM/15ML	N73504 001 MAY 28, 1993
	LACTULOSE		
	@ SOLVAY	10GM/15ML	N17906 001
	/PORTALAC/		
/AA/	/SOLVAY/	/10GM/15ML/	/N72374/001/ /MAR/22,/1989/
	@ SOLVAY	10GM/15ML	N72374 001 MAR 22, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM		
AP	GENSIA	EQ 50MG BASE/VIAL	N81278 001 SEP 28, 1993
AP		EQ 100MG BASE/VIAL	N81277 001 SEP 28, 1993

TABLET; ORAL

	LEUCOVORIN CALCIUM		
>_ADD_> AB	IMMUNEX	EQ 10MG BASE	N71962 001 NOV 19, 1987
>_ADD_>			
>_ADD_> AB +		EQ 15MG BASE	N71104 001 MAR 04, 1987
>_ADD_>			
>_ADD_> BX		EQ 5MG BASE	N18459 001 JAN 30, 1986
>_ADD_>			
>_DLT_>/AB/	/LEDERLE/	/EQ 10MG BASE/	/N71962/001/ /NOV/19,/1987/
>_DLT_>			
>_DLT_>/AB//+/		/EQ 15MG BASE/	/N71104/001/ /MAR/04,/1987/
>_DLT_>			
>_DLT_> /BX/		/EQ/5MG/BASE/	/N18459/001/ /JAN/30,/1986/
>_DLT_>			
AB	ROXANE	EQ 5MG BASE	N72733 001 FEB 22, 1993
AB		EQ 10MG BASE	N72734 001 FEB 22, 1993
AB		EQ 15MG BASE	N72735 001 FEB 22, 1993
AB		EQ 25MG BASE	N72736 001 FEB 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON		
/+//TAP/		/1MG/0.2ML/	/N19010/001/ /APR/09,/1985/
+ TAP		5MG/ML	N19010 001 APR 09, 1985
		5MG/ML	N20263 001 APR 16, 1993
	LUPRON DEPOT		
+ TAP		3.75MG/VIAL	N20011 001 OCT 22, 1990
+		7.5MG/VIAL	N19732 001 JAN 26, 1989
		/3.75MG/VIAL/	/N20011/001/ /OCT/22,/1990/
		/7.5MG/VIAL/	/N19732/001/ /JAN/26,/1989/
	LUPRON DEPOT-PED		
+ TAP		3.75MG/VIAL&7.5MG/VIAL	N20263 003 APR 16, 1993
+		7.5MG/VIAL&7.5MG/VIAL	N20263 004 APR 16, 1993
+		7.5MG/VIAL	N20263 002 APR 16, 1993

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM		
BIODEVELOPMENT	10MG/ML	N20315 001 JUL 09, 1993
/BIOMETRICS/RES/	/10MG/ML/	/N20315/001/ /JUL/09,/1993/

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/		
/RAVOCAINE/AND/NOVOCAIN/W/NEO-COBEFRIN/		
/COOK/WAITE/	/0.05MG/ML;2%;0.4%/	/N08592/007/
@ STERLING WINTHROP	0.05MG/ML;2%;0.4%	N08592 007

LIDOCAINE

/SUPPOSITORY;/RECTAL/		
/XYLOCAINE/		
/ASTRA/	/100MG/	/N13077/001/
@ ASTRA	100MG	N13077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

> DLT >	/AP/ /ABBOTT/	/10%/	/N87980/001/ /FEB/02,/1983/
> DLT >			
> ADD >	∂ ABBOTT	10%	N87980 001 FEB 02, 1983
> ADD >			
	/AP/ /BEL/MAR/	/1%/	/N80710/001/
	/AP/	/2%/	/N80760/001/
	∂ BEL MAR	1%	N80710 001
	∂	2%	N80760 001
	/AP/ /BRISTOL/	/1%/	/N80390/001/
	/AP/	/2%/	/N80390/002/
	AP FUJISAWA	1%	N80404 002
	AP	2%	N80404 003
	∂	1%	N80390 001
	∂	2%	N80390 002
	/AP/ /LYPHOMED/	/1%/	/N80404/002/
	/AP/	/1%/	/N86761/001/
	/AP/	/2%/	/N80404/003/
	/AP/	/2%/	/N86761/002/
	∂ LYPHOMED	1%	N86761 001
	∂	2%	N86761 002

JELLY; TOPICAL
LIDOCAINE HCL

AT	COPLEY	2%	N81318 001 APR 29, 1993

SOLUTION; ORAL
MYLOCAINE

AT	PENNEX PHARMS	2%	N87872 001 NOV 18, 1982
/AT/	/PHARM/BASICS/	/2%/	/N87872/001/ /NOV/18,/1982/

SOLUTION; TOPICAL
/MYLOCAINE/

/AT/	/PHARM/BASICS/	/4%/	/N87881/001/ /NOV/18,/1982/
	∂ PENNEX PHARMS	4%	N87881 001 NOV 18, 1982

LINDANE

LOTION; TOPICAL
LINDANE

AT	PENNEX PHARMS	1%	N88190 001 AUG 16, 1984

LINDANE

LOTION; TOPICAL
LINDANE

/AT/	/PHARM/BASICS/	/1%/	/N88190/001/ /AUG/16,/1984/

SHAMPOO; TOPICAL
LINDANE

AT	PENNEX PHARMS	1%	N88191 001 SEP 18, 1984
/AT/	/PHARM/BASICS/	/1%/	/N88191/001/ /SEP/18,/1984/

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25		
FOREST LABS	0.0125MG;0.0031MG	N16807 001
/RHONE/POULENC/RORER/	/0.0125MG;0.0031MG/	/N16807/001/
THYROLAR-0.5		
FOREST LABS	0.025MG;0.00625MG	N16807 005
/RHONE/POULENC/RORER/	/0.025MG;0.00625MG/	/N16807/005/
THYROLAR-1		
FOREST LABS	0.05MG;0.0125MG	N16807 004
/RHONE/POULENC/RORER/	/0.05MG;0.0125MG/	/N16807/004/
THYROLAR-2		
FOREST LABS	0.1MG;0.025MG	N16807 002
/RHONE/POULENC/RORER/	/0.1MG;0.025MG/	/N16807/002/
THYROLAR-3		
+ FOREST LABS	0.15MG;0.0375MG	N16807 003
/+//RHONE/POULENC/RORER/	/0.15MG;0.0375MG/	/N16807/003/
THYROLAR-5		
∂ FOREST LABS	0.25MG;0.0625MG	N16807 006
/∂/RHONE/POULENC/RORER/	/0.25MG;0.0625MG/	/N16807/006/

LISINOPRIL

TABLET; ORAL
ZESTRIL

/AB/	/IMPERIAL/CHEM/	/5MG/	/N19777/001/ /MAY/19,/1988/
/AB/		/10MG/	/N19777/002/ /MAY/19,/1988/
/AB/		/20MG/	/N19777/003/ /MAY/19,/1988/
/AB//+/		/40MG/	/N19777/004/ /MAY/19,/1988/

LISINOPRIL

TABLET; ORAL
ZESTRIL

AB	ZENECA	5MG	N19777 001 MAY 19, 1988
AB		10MG	N19777 002 MAY 19, 1988
AB		20MG	N19777 003 MAY 19, 1988
AB +		40MG	N19777 004 MAY 19, 1988
		2.5MG	N19777 005 APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL
/ESKALITH/

/AB/	/SMITHKLINE/BEECHAM/	/300MG/	/N17971/001/
	∂ SMITHKLINE BEECHAM	300MG	N17971 001

LITHANE

> DLT >	/AB/ /MILES/	/300MG/	/N18833/001/ /JUL/18,/1985/
> DLT >			
> ADD >	∂ MILES	300MG	N18833 001 JUL 18, 1985
> ADD >			
> DLT >	/∂/ROERIG/	/300MG/	/N16834/001/

LITHIUM CARBONATE

> ADD >	AB PFIZER	300MG	N16834 001

LITHIUM CITRATE

SYRUP; ORAL
LITHIUM CITRATE

AA	PENNEX PHARMS	EQ 300MG CARBONATE/5ML	N70755 001 MAY 21, 1986
/AA/	/PHARM/BASICS/	/EQ 300MG CARBONATE/5ML/	/N70755/001/ /MAY/21,/1986/

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC
ALOMIDE

+	ALCON	EQ 0.1% BASE	N20191 001 SEP 23, 1993

LORATADINE

TABLET; ORAL
CLARITIN

+	SCHERING	10MG	N19658 001 APR 12, 1993

LORAZEPAM

TABLET; ORAL
LORAZEPAM

> DLT >	/AB/ /PAR/	/0.5MG/	/N70675/001/ /DEC/01,/1986/
> DLT >			
> DLT >	/AB/	/1MG/	/N70676/001/ /DEC/01,/1986/
> DLT >			
> DLT >	/AB/	/2MG/	/N70677/001/ /DEC/01,/1986/
> DLT >			
> ADD >	∂ PAR	0.5MG	N70675 001 DEC 01, 1986
> ADD >			
> ADD >	∂	1MG	N70676 001 DEC 01, 1986
> ADD >			
> ADD >	∂	2MG	N70677 001 DEC 01, 1986
> ADD >			

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+	HICKAM /STERLING/	EQ 85MG BASE/GM /EQ/85MG/BASE/GM/	N16763 001 /N16763/001/

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE

	FUJISAWA /LYPHOMED/	EQ 0.1MG MANGANESE/ML /EQ/0.1MG/MANGANESE/ML/	N19228 001 MAY 05, 1987 /N19228/001/ /MAY/05,/1987/

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER

AP	MCGAW	10GM/100ML	N20006 002 JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP	MCGAW	15GM/100ML	N20006 003 JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION

MANNITOL 20% IN PLASTIC CONTAINER

AP	MCGAW	20GM/100ML	N20006 004 JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML	N20006 001 JUL 26, 1993

MASOPROCOL

CREAM; TOPICAL

ACTINEX + BLOCK DRUG	10%	N19940 001 SEP 04, 1992
/+//CHEMEX/	/10%/	/N19940/001/ /SEP/04,/1992/

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE + BRISTOL MYERS SQUIBB	40MG/ML	N20264 001 SEP 10, 1993

MENADIOL SODIUM DIPHOSPHATE

/INJECTABLE;/INJECTION/ /SYNKAYVITE/ /ROCHE/	/5MG/ML/ /10MG/ML/ /37.5MG/ML/	/N03718/004/ /N03718/006/ /N03718/008/
@ ROCHE	5MG/ML	N03718 004
@	10MG/ML	N03718 006
@	37.5MG/ML	N03718 008

/TABLET;/ORAL/ /SYNKAYVITE/ /ROCHE/	/5MG/	/N03718/010/
@ ROCHE	5MG	N03718 010

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

AP	ASTRA	10MG/ML	N81002 001 JUL 30, 1993
/AP/		/25MG/ML/	/N89781/001/ /MAR/31,/1989/
/AP/		/50MG/ML/	/N89782/001/ /MAR/31,/1989/
/AP/		/50MG/ML/	/N89783/001/ /MAR/31,/1989/
/AP/		/75MG/ML/	/N89785/001/ /MAR/31,/1989/
/AP/		/100MG/ML/	/N89786/001/ /MAR/31,/1989/
/AP/		/100MG/ML/	/N89787/001/ /MAR/31,/1989/
	@	25MG/ML	N89781 001 MAR 31, 1989
	@	50MG/ML	N89782 001 MAR 31, 1989
	@	50MG/ML	N89783 001 MAR 31, 1989
	@	75MG/ML	N89785 001 MAR 31, 1989
	@	100MG/ML	N89786 001 MAR 31, 1989
	@	100MG/ML	N89787 001 MAR 31, 1989
AP	INTL MEDICATION	10MG/ML	N81309 001 AUG 30, 1993

TABLET; ORAL

MEPERIDINE HCL

> ADD > AA	HALSEY	50MG	N80448 001
> ADD > AA		100MG	N80448 002
> DLT >	/PETHADOL/		
> DLT >/AA/	/HALSEY/	/50MG/	/N80448/001/
> DLT >/AA/		/100MG/	/N80448/002/

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

/AA/	/LEE/LABS/	/400MG/	/N89538/001/ /NOV/25,/1987/
	@ LEE LABS	400MG	N89538 001 NOV 25, 1987

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA
+ MARION MERRELL DOW 250MG N20049 001
MAY 10, 1993

MESTRANOL; NORETHINDRONE

/TABLET;/ORAL-28/
/NORINYL/
/SYNTEX/ /0.1MG;2MG/ /N13625/004/
∂ SYNTEX 0.1MG;2MG N13625 004

TABLET; ORAL-21
NORETHIN 1/50M-21
AB ROBERTS 0.05MG;1MG N71539 001
APR 12, 1988
/AB/ /SCHIAPPARELLI/SEARLE/0.05MG;1MG/ /N71539/001/
/APR/12,/1988/

TABLET; ORAL-28
NORETHIN 1/50M-28
AB ROBERTS 0.05MG;1MG N71540 001
APR 12, 1988
/AB/ /SCHIAPPARELLI/SEARLE/0.05MG;1MG/ /N71540/001/
/APR/12,/1988/

MESTRANOL; NORETHYNODREL

/TABLET;/ORAL/
/ENOVID/
/+//SEARLE/ /0.15MG;9.85MG/ /N10976/005/
/0.075MG;5MG/ /N10976/008/
∂ SEARLE 0.075MG;5MG N10976 008
∂ 0.15MG;9.85MG N10976 005

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE
∂ PENNEX PHARMS 5% N72190 001
JUN 07, 1988
/AN/ /PHARM/BASICS/ /5%/ /N72190/001/
/JUN/07,/1988/

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE
AA PENNEX PHARMS 10MG/5ML N71656 001
OCT 13, 1987
/AA/ /PHARM/BASICS/ /10MG/5ML/ /N71656/001/
/OCT/13,/1987/

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE
AP FUJISAWA EQ 10MG BASE/ML N80431 001
AP EQ 10MG BASE/ML N80722 001
/AP/ /LYPHOMED/ /EQ 10MG BASE/ML/ /N80431/001/
/AP/ /EQ 10MG BASE/ML/ /N80722/001/

METHADONE HYDROCHLORIDE

TABLET; ORAL
METHADOSE
AA MALLINCKRODT 5MG N40050 001
APR 15, 1993
AA 10MG N40050 002
APR 15, 1993

TABLET, DISPERSIBLE; ORAL
METHADONE HCL
AA LILLY 40MG N17058 001
METHADOSE
AA MALLINCKRODT 40MG N74184 001
APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
/METHAMPEX/
/AA/ /LEMMON/ /10MG/ /N83889/001/
∂ LEMMON 10MG N83889 001

METHAMPHETAMINE HCL
/AA/ /LEMMON/ /5MG/ /N86359/001/
∂ LEMMON 5MG N86359 001
/AA/ /REXAR/ /10MG/ /N84931/002/
REXAR 10MG N84931 002

METHANTHELINE BROMIDE

TABLET; ORAL
BANTHINE

ROBERTS	50MG	N07390 001
/SCHIAPPARELLI/SEARLE/	/50MG/	/N07390/001/

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE		
AB	COPLEY	25MG	N40001 001 JUN 30, 1993
AB		50MG	N40001 002 JUN 30, 1993
AB	GENEVA	25MG	N40036 001 JUN 30, 1993
AB		50MG	N40036 002 JUN 30, 1993
	NEPTAZANE		
AB	LEDERLE	25MG	N11721 002 NOV 25, 1991
AB +		50MG	N11721 001

METHICILLIN SODIUM

INJECTABLE; INJECTION
STAPHCILLIN

+ APOTHECON	EQ 900MG BASE/VIAL	N61449 001
+	EQ 3.6GM BASE/VIAL	N61449 002
+	EQ 5.4GM BASE/VIAL	N61449 003
/BRISTOL/	/EQ/900MG/BASE/VIAL/	/N61449/001/
	/EQ/3.6GM/BASE/VIAL/	/N61449/002/
	/EQ/5.4GM/BASE/VIAL/	/N61449/003/

METHOCARBAMOL

TABLET; ORAL

	/DELAXIN/		
/AA/	/FERNDALE/	/500MG/	/N85454/001/
	@ FERNDALE	500MG	N85454 001
	METHOCARBAMOL		
AA	NYLOS TRADING	750MG	N85033 001

METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL		
/AA/	/PIONEER/PHARMS/	/500MG/	/N88731/001/ /DEC/13,/1985/
/AA/		/750MG/	/N89082/001/ /DEC/13,/1985/
	@ PIONEER PHARMS	500MG	N88731 001 DEC 13, 1985
	@	750MG	N89082 001 DEC 13, 1985
/AA/	/TABLICAPS/	/750MG/	/N85033/001/
/AA/	/UPSHER/SMITH/	/500MG/	/N87453/001/
/AA/		/750MG/	/N87454/001/
	@ UPSHER SMITH	500MG	N87453 001
	@	750MG	N87454 001

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE SODIUM		
/AP/	/AKORN/	/EQ 25MG BASE/ML/	/N88648/001/ /MAY/09,/1986/
/AP/	/LYPHOMED/	/EQ 25MG BASE/ML/	/N89263/001/ /JUN/13,/1986/
	@ LYPHOMED	EQ 25MG BASE/ML	N89263 001 JUN 13, 1986
AP	NORBROOK	EQ 25MG BASE/ML	N88648 001 MAY 09, 1986

METHOXYFLURANE

/SOLUTION;/INHALATION/
/PENTHRANE/

/ABBOTT/	/99.9%/	/N13056/003/

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	METHYLDOPATE HCL		
/AP/	/LYPHOMED/	/50MG/ML/	/N70652/001/ /JUN/03,/1986/
	@ LYPHOMED	50MG/ML	N70652 001 JUN 03, 1986

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

/AB/	/CHELSEA/	/4MG/	/N86161/001/ /FEB/09,/1982/
B*	CHELSEA	4MG	N86161 001 FEB 09, 1982

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

/M-PREDROL/

/BP/	/BEL/MAR/	/40MG/ML/	/N86666/001/
/BP/		/80MG/ML/	/N87135/001/
	∂ BEL MAR	40MG/ML	N86666 001
	∂	80MG/ML	N87135 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

>DLT >/AP/	/ABBOTT/	/EQ 1GM BASE/VIAL/	/N89576/001/ /FEB/22,/1991/
>DLT >			
>ADD >	∂ ABBOTT	EQ 1GM BASE/VIAL	N89576 001 FEB 22, 1991
>ADD >			

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 40MG BASE/VIAL/	/N89143/001/ /MAR/28,/1986/
/AP/		/EQ 125MG BASE/VIAL/	/N89144/001/ /MAR/28,/1986/
/AP/		/EQ 500MG BASE/VIAL/	/N89187/001/ /MAR/28,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N89189/001/ /MAR/28,/1986/
	∂ LYPHOMED	EQ 40MG BASE/VIAL	N89143 001 MAR 28, 1986
	∂	EQ 125MG BASE/VIAL	N89144 001 MAR 28, 1986
	∂	EQ 500MG BASE/VIAL	N89187 001 MAR 28, 1986
	∂	EQ 1GM BASE/VIAL	N89189 001 MAR 28, 1986

METHYLTESTOSTERONE

CAPSULE; ORAL

/METHYLTESTOSTERONE/

/BP/	/HEATHER/	/10MG/	/N84967/001/
	∂ HEATHER	10MG	N84967 001

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

/BP/	/ICN/	/10MG/	/N83976/001/
	BP + ICN	10MG	N83976 001

TABLET; BUCCAL

>DLT >	/ANDROID/S/		
>DLT >	/ICN/	/5MG/	/N87222/001/
>ADD >	∂ ICN	5MG	N87222 001

TABLET; ORAL

METHYLTESTOSTERONE

>DLT > /BP/	/INWOOD/	/10MG/	/N80839/001/
>DLT > /BP/		/25MG/	/N80973/001/
>ADD >	∂ INWOOD	10MG	N80839 001
>ADD >	∂	25MG	N80973 001

METHYPRYLON

/CAPSULES;ORAL/

/NOLUDAR/

	/ROCHE/	/300MG/	/N09660/008/
	∂ ROCHE	300MG	N09660 008

/TABLET;ORAL/

/NOLUDAR/

	/ROCHE/	/200MG/	/N09660/004/
	∂ ROCHE	200MG	N09660 004

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

/AP/	/AKORN/	/EQ 10MG BASE/2ML/	/N70892/001/ /AUG/26,/1988/
/AP/	/FUJISAWA/	/EQ 10MG BASE/2ML/	/N70293/001/ /JAN/24,/1986/
	∂ FUJISAWA	EQ 10MG BASE/2ML	N70293 001 JAN 24, 1986
	∂ NORBROOK	EQ 10MG BASE/2ML	N70892 001 AUG 26, 1988

SOLUTION; ORAL

METOCLOPRAMIDE HCL

AA	LEMMON	EQ 5MG BASE/5ML	N71315 001 JUN 30, 1993

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HCL

AA	LIQUIPHARM	EQ 5MG BASE/5ML	N71402 001 JUN 25, 1993
AA	PENNEX PHARMS	EQ 5MG BASE/5ML	N70949 001 MAR 06, 1987
/AA/	/PHARM/BASICS/	/EQ 5MG BASE/5ML/	/N70949/001/ /MAR/06,/1987/

TABLET; ORAL

METOCLOPRAMIDE HCL

AB	BIOCRAFT	EQ 5MG BASE	N72801 001 JUN 15, 1993
AB	MUTUAL PHARM	EQ 10MG BASE	N71536 001 APR 28, 1993
/AB/	/PAR/	/EQ 10MG BASE/	/N70342/001/ /MAR/25,/1986/
	∂ PAR	EQ 10MG BASE	N70342 001 MAR 25, 1986

METRONIDAZOLE

TABLET; ORAL

	/SATRIC/		
/AB/	/SAVAGE/	/250MG/	/N70029/001/ /MAR/19,/1985/
/AB/		/500MG/	/N70731/001/ /JUN/08,/1987/
	∂ SAVAGE	250MG	N70029 001 MAR 19, 1985
	∂	500MG	N70731 001 JUN 08, 1987

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

	/MILES/	/EQ/1GM/BASE/VIAL/	/N62333/001/
> DLT >	∂ MILES	EQ 1GM BASE/VIAL	N62333 001
> ADD >		EQ 1GM BASE/VIAL	N62372 005 JAN 13, 1983
> DLT >		/EQ/2GM/BASE/VIAL/	/N62333/002/
> ADD >	∂	EQ 2GM BASE/VIAL	N62333 002
> DLT >		/EQ/3GM/BASE/VIAL/	/N62333/003/
> ADD >	∂	EQ 3GM BASE/VIAL	N62333 003
> DLT >		/EQ/4GM/BASE/VIAL/	/N62333/004/
> ADD >	∂	EQ 4GM BASE/VIAL	N62333 004

MICONAZOLE NITRATE

/CREAM;/VAGINAL/ /MONISTAT/7/ /JOHNSON/RW/	/2%/	/N17456/001/

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT DUAL-PAK + JOHNSON RW	2%;200MG	N18888 002 OCT 17, 1988

/LOTION;/TOPICAL/ /MONISTAT-DERM/ /+//JOHNSON/RW/	/2%/	/N17739/001/
∂ JOHNSON RW	2%	N17739 001

/SUPPOSITORY;/VAGINAL/ /MONISTAT/7/ /JOHNSON/RW/	/100MG/	/N18526/001/ /MAR/15,/1982/

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE + STERLING	EQ 1MG BASE/ML	N19436 001 DEC 31, 1987
/+/	/EQ/1MG/BASE/ML/	/N19436/001/ /DEC/31,/1987/

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVANTRONE
+ IMMUNEX — EQ 2MG BASE/ML — N19297 001 DEC 23, 1987
/LEDERLE/ — /EQ/2MG/BASE/ML/ — /N19297/001/ /DEC/23,/1987/

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
/DUPONT/ — /200MG/ — /N19753/001/ /JUN/19,/1990/
/250MG/ — /N19753/002/ /JUN/19,/1990/
/300MG/ — /N19753/003/ /JUN/19,/1990/
ROBERTS — 200MG — N19753 001 JUN 19, 1990
250MG — N19753 002 JUN 19, 1990
300MG — N19753 003 JUN 19, 1990

NABILONE

/CAPSULE;/ORAL/
/CESAMET/
/+//LILLY/ — /1MG/ — /N18677/001/ /DEC/26,/1985/
@ LILLY — 1MG — N18677 001 DEC 26, 1985

NADOLOL

TABLET; ORAL
CORGARD
> ADD > AB SQUIBB — 20MG — N18063 005 OCT 28, 1986
> ADD >
> ADD > AB — 40MG — N18063 001
> ADD > AB — 40MG — N18064 001
> ADD > AB — 80MG — N18063 002
> ADD > AB — 80MG — N18064 002

NADOLOL

TABLET; ORAL
NADOLOL
> ADD >
> ADD > AB MYLAN — 20MG — N74172 001 OCT 31, 1993
> ADD >
> ADD > AB — 40MG — N74172 002 OCT 31, 1993
> ADD >
> ADD > AB — 80MG — N74172 003 OCT 31, 1993
> ADD >

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL
AP APOTHECON — EQ 500MG BASE/VIAL — N62527 001 AUG 02, 1984
AP — EQ 1GM BASE/VIAL — N62527 002 AUG 02, 1984
AP — EQ 1GM BASE/VIAL — N62732 001 DEC 23, 1986
AP — EQ 2GM BASE/VIAL — N62527 003 AUG 02, 1984
AP — EQ 2GM BASE/VIAL — N62732 002 DEC 23, 1986
AP — EQ 10GM BASE/VIAL — N62527 004 AUG 02, 1984
/AP/ /BRISTOL/ — /EQ 500MG BASE/VIAL/ — /N62527/001/ /AUG/02,/1984/
/AP/ — /EQ 1GM BASE/VIAL/ — /N62527/002/ /AUG/02,/1984/
/AP/ — /EQ 1GM BASE/VIAL/ — /N62732/001/ /DEC/23,/1986/
/AP/ — /EQ 2GM BASE/VIAL/ — /N62527/003/ /AUG/02,/1984/
/AP/ — /EQ 2GM BASE/VIAL/ — /N62732/002/ /DEC/23,/1986/
/AP/ — /EQ 10GM BASE/VIAL/ — /N62527/004/ /AUG/02,/1984/

/POWDER/FOR/RECONSTITUTION;/ORAL/
/UNIPEN/
/+//WYETH/AYERST/ — /EQ/250MG/BASE/5ML/ — /N50199/001/
@ WYETH AYERST — EQ 250MG BASE/5ML — N50199 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

/AP/	/ASTRA/	/10MG/ML/	/N72071/001/ /APR/10,/1989/
/AP/		/10MG/ML/	/N72072/001/ /APR/10,/1989/
/AP/		/20MG/ML/	/N72074/001/ /APR/10,/1989/
/AP/		/20MG/ML/	/N72075/001/ /APR/10,/1989/
	∂ ASTRA	10MG/ML	N72071 001 APR 10, 1989
	∂	10MG/ML	N72072 001 APR 10, 1989
	∂	20MG/ML	N72074 001 APR 10, 1989
	∂	20MG/ML	N72075 001 APR 10, 1989
	NALBUPHINE HYDROCHLORIDE ABBOTT	1.5MG/ML	N20200 001 MAR 12, 1993

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

/AP/	/ASTRA/	/0.02MG/ML/	/N72082/001/ /APR/11,/1989/
/AP/		/0.02MG/ML/	/N72083/001/ /APR/11,/1989/
/AP/		/0.02MG/ML/	/N72084/001/ /APR/11,/1989/
/AP/		/0.02MG/ML/	/N72085/001/ /APR/11,/1989/
/AP/		/0.4MG/ML/	/N72087/001/ /APR/11,/1989/
/AP/		/0.4MG/ML/	/N72088/001/ /APR/11,/1989/
/AP/		/0.4MG/ML/	/N72089/001/ /APR/11,/1989/
/AP/		/0.4MG/ML/	/N72090/001/ /APR/11,/1989/
/AP/		/1MG/ML/	/N72092/001/ /APR/11,/1989/
/AP/		/1MG/ML/	/N72093/001/ /APR/11,/1989/
	∂ ASTRA	0.02MG/ML	N72082 001 APR 11, 1989
	∂	0.02MG/ML	N72083 001 APR 11, 1989
	∂	0.02MG/ML	N72084 001 APR 11, 1989
	∂	0.02MG/ML	N72085 001 APR 11, 1989
	∂	0.4MG/ML	N72087 001 APR 11, 1989
	∂	0.4MG/ML	N72088 001 APR 11, 1989
	∂	0.4MG/ML	N72089 001 APR 11, 1989
	∂	0.4MG/ML	N72090 001 APR 11, 1989
	∂	1MG/ML	N72092 001 APR 11, 1989
	∂	1MG/ML	N72093 001 APR 11, 1989
/AP/	/LYPHOMED/	/0.02MG/ML/	/N70661/001/ /NOV/17,/1986/
	∂ LYPHOMED	0.02MG/ML	N70661 001 NOV 17, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NARCAN		
/AP/	/DUPONT/	/0.4MG/ML/	/N71083/001/ /JUL/28,/1988/
/AP/		/1MG/ML/	/N71084/001/ /JUL/28,/1988/
/AP/		/1MG/ML/	/N71311/001/ /JUL/28,/1988/
	@ DUPONT	0.4MG/ML	N71083 001 JUL 28, 1988
	@	1MG/ML	N71084 001 JUL 28, 1988
	@	1MG/ML	N71311 001 JUL 28, 1988

NANDROLONE DECANOATE

INJECTABLE; INJECTION

	NANDROLONE DECANOATE		
/AO/	/LYPHOMED/	/100MG/ML/	/N88290/001/ /OCT/03,/1983/
/AO/		/200MG/ML/	/N88317/001/ /OCT/14,/1983/
	@ LYPHOMED	100MG/ML	N88290 001 OCT 03, 1983
	@	200MG/ML	N88317 001 OCT 14, 1983

NAPROXEN SODIUM

TABLET; ORAL

	ANAPROX		
AB	SYNTEX	275MG	N18164 001
	ANAPROX DS		
AB +	SYNTEX	550MG	N18164 003 SEP 30, 1987
	NAPROXEN SODIUM		
AB	HAMILTON	275MG	N74106 001 AUG 31, 1993
AB		550MG	N74106 002 AUG 31, 1993

NEOMYCIN SULFATE

TABLET; ORAL

	NEOMYCIN SULFATE		
/AA/	/EON/LABS/	/EQ 350MG BASE/	/N61586/001/
	@ EON LABS	EQ 350MG BASE	N61586 001

NIACIN

	/CAPSULE;/ORAL/		
	/WAMPOCAP/		
	/WALLACE/	/500MG/	/N11073/003/
	@ WALLACE	500MG	N11073 003

TABLET; ORAL

	NIACIN		
/AA/	/ZENITH/	/500MG/	/N83180/001/
	@ ZENITH	500MG	N83180 001

NIFEDIPINE

CAPSULE; ORAL

	NIFEDIPINE		
AB	FLEMINGTON	10MG	N72781 001 JUL 30, 1993

TABLET, EXTENDED RELEASE; ORAL

	ADALAT CC		
BC	MILES	30MG	N20198 001 APR 21, 1993
BC		60MG	N20198 002 APR 21, 1993
BC		90MG	N20198 003 APR 21, 1993
	PROCARDIA XL		
BC +	PFIZER	30MG	N19684 001 SEP 06, 1989
BC +		60MG	N19684 002 SEP 06, 1989
BC +		90MG	N19684 003 SEP 06, 1989
/+/		/30MG/	/N19684/001/ /SEP/06,/1989/
/+/		/60MG/	/N19684/002/ /SEP/06,/1989/
/+/		/90MG/	/N19684/003/ /SEP/06,/1989/

NITROFURANTOIN

TABLET; ORAL

	NITROFURANTOIN		
/AB/	/ZENITH/	/50MG/	/N80078/002/
/AB/		/100MG/	/N80078/001/
	@ ZENITH	50MG	N80078 002
	@	100MG	N80078 001

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

> ADD >	CAPSULE; ORAL			
> ADD >	MACROBID			
> ADD >	+ P AND G	75MG;25MG	N20064 001	
> ADD >			DEC 24, 1991	
> DLT >	/CAPSULE;/EXTENDED/RELEASE;/ORAL/			
> DLT >	/MACROBID/			
> DLT >	/+//P/AND/G/	/75MG;25MG/	/N20064/001/	
> DLT >			/DEC/24,/1991/	

NITROFURANTOIN, MACROCRYSTALLINE

	CAPSULE; ORAL		
	NITROFURANTOIN		
AB	ZENITH	50MG	N73671 001
			JAN 28, 1993
AB		100MG	N73652 001
			JAN 28, 1993

NITROGLYCERIN

	INJECTABLE; INJECTION		
	NITRO-BID		
	/MARION/MERRELL/DOW/	/10MG/ML/	/N71159/001/
			/FEB/28,/1990/
	∂ MARION MERRELL DOW	10MG/ML	N71159 001
			FEB 28, 1990

NORTRIPTYLINE HYDROCHLORIDE

	CAPSULE; ORAL		
	NORTRIPTYLINE HCL		
AB	MYLAN	EQ 10MG BASE	N74234 001
			JUL 26, 1993
AB		EQ 25MG BASE	N74234 002
			JUL 26, 1993
AB		EQ 50MG BASE	N74234 003
			JUL 26, 1993
AB		EQ 75MG BASE	N74234 004
			JUL 26, 1993

NYSTATIN

	CREAM; TOPICAL		
	NYSTATIN		
AT	BARRE	100,000 UNITS/GM	N62949 001
			JUN 13, 1988
/AT/	/NASKA/	/100,000 UNITS/GM/	/N62949/001/
			/JUN/13,/1988/
AT	TARO	100,000 UNITS/GM	N64022 001
			JAN 29, 1993

	OINTMENT; TOPICAL		
	NYSTATIN		
AT	BARRE	100,000 UNITS/GM	N62840 001
			NOV 13, 1987
/AT/	/NASKA/	/100,000 UNITS/GM/	/N62840/001/
			/NOV/13,/1987/

	POWDER; ORAL		
	/BARSTATIN 100/		
/AA/	/BARLAN/	/100%/	/N62489/001/
			/APR/27,/1988/
	∂ BARLAN	100%	N62489 001
			APR 27, 1988

	SUSPENSION; ORAL		
	MYCOSTATIN		
AA	APOTHECON	100,000 UNITS/ML	N61533 001
/AA/	/BRISTOL/MYERS/SQUIBB/	100,000 UNITS/ML/	/N61533/001/
	NYSTATIN		
AA	BARRE	100,000 UNITS/ML	N62571 001
			OCT 29, 1985
/AA/	/NASKA/	/100,000 UNITS/ML/	/N62571/001/
			/OCT/29,/1985/
AA	PENNEX PHARMS	100,000 UNITS/ML	N62512 001
			OCT 29, 1984
	∂	100,000 UNITS/ML	N62835 001
			NOV 19, 1987
/AA/	/PHARM/BASICS/	/100,000 UNITS/ML/	/N62512/001/
			/OCT/29,/1984/
/AA/		/100,000 UNITS/ML/	/N62835/001/
			/NOV/19,/1987/
/AA/	/PHARMADERM/	/100,000 UNITS/ML/	/N62518/001/
			/JUL/06,/1984/
	∂ PHARMADERM	100,000 UNITS/ML	N62518 001
			JUL 06, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	BARRE	100,000 UNITS/GM;0.1%	N63010 001 DEC 20, 1988
/AT/	/NASKA/	/100,000 UNITS/GM;0.1%/	/N63010/001/ /DEC/20,/1988/

NYSTATIN-TRIAMCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/100,000 UNITS/GM;0.1%/	/N62596/001/ /OCT/08,/1985/
	∂ PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001 OCT 08, 1985

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	TARO	100,000 UNITS/GM;0.1%	N63305 001 MAR 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN

/SANDOZ/	/EQ/50UGM/BASE/ML/	/N19667/001/ /OCT/21,/1988/
SANDOZ	EQ 0.05MG BASE/ML	N19667 001 OCT 21, 1988
	/EQ/100UGM/BASE/ML/	/N19667/002/ /OCT/21,/1988/
	EQ 0.1MG BASE/ML	N19667 002 OCT 21, 1988
	EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
	/EQ/500UGM/BASE/ML/	/N19667/003/ /OCT/21,/1988/
	EQ 0.5MG BASE/ML	N19667 003 OCT 21, 1988
	EQ 1MG BASE/ML	N19667 005 JUN 12, 1991

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

+	ALLERGAN	0.3%	N19921 001 JUL 30, 1993

OXACILLIN SODIUM

CAPSULE; ORAL

PROSTAPHLIN

AB	APOTHECON	EQ 250MG BASE	N61450 002
AB		EQ 500MG BASE	N61450 001
/AB/	/BRISTOL/	/EQ 250MG BASE/	/N61450/002/
/AB/		/EQ 500MG BASE/	/N61450/001/

POWDER FOR RECONSTITUTION; ORAL

PROSTAPHLIN

AA	APOTHECON	EQ 250MG BASE/5ML	N61457 001
/AA/	/BRISTOL/	/EQ 250MG BASE/5ML/	/N61457/001/

OXPRENOLOL HYDROCHLORIDE

/CAPSULE;/ORAL/

/TRASICOR/

/+//CIBA/	/160MG/	/N18166/004/ /DEC/28,/1983/
	/20MG/	/N18166/001/ /DEC/28,/1983/
	/40MG/	/N18166/002/ /DEC/28,/1983/
	/80MG/	/N18166/003/ /DEC/28,/1983/
∂ CIBA	20MG	N18166 001 DEC 28, 1983
∂	40MG	N18166 002 DEC 28, 1983
∂	80MG	N18166 003 DEC 28, 1983
∂	160MG	N18166 004 DEC 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

/AA/	/PARKE/DAVIS/	/100MG/5ML/	/N09268/012/ /NOV/27,/1984/
	PARKE DAVIS	100MG/5ML	N09268 012 NOV 27, 1984
	/OXTRIPHYLLINE/		
/AA/	/PHARM/BASICS/	/100MG/5ML/	/N88243/001/ /DEC/05,/1983/
	∂ PENNEX PHARMS	100MG/5ML	N88243 001 DEC 05, 1983

OXTRIPHYLLINE

SYRUP; ORAL
CHOLEDYL
/AA/ /PARKE/DAVIS/ /50MG/5ML/ /N09268/011/
PARKE DAVIS 50MG/5ML N09268 011
/OXTRIPHYLLINE PEDIATRIC/
/AA/ /PHARM/BASICS/ /50MG/5ML/ /N88242/001/
/DEC/05,/1983/
@ PENNEX PHARMS 50MG/5ML N88242 001
DEC 05, 1983

OXYPHENBUTAZONE

TABLET; ORAL
TANDEARIL
> ADD > @ GEIGY 100MG N12542 004
> ADD > SEP 03, 1982
> DLT > /@/RHONE/POULENC/RORER//100MG/ /N12542/004/
> DLT > /SEP/03,/1982/

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA
+ CIBA GEIGY 60MG/VIAL N20036 003
MAY 06, 1993
+ 90MG/VIAL N20036 004
MAY 06, 1993

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE
/AP/ /ASTRA/ /2MG/ML/ /N72212/001/
/MAR/31,/1988/
@ ASTRA 2MG/ML N72212 001
MAR 31, 1988

PARAMETHASONE ACETATE

TABLET; ORAL
HALDRONE
/+//LILLY/ /2MG/ /N12772/006/
/1MG/ /N12772/005/
@ LILLY 1MG N12772 005
@ 2MG N12772 006

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
/+//SMITHKLINE/BEECHAM/ /EQ/10MG/BASE/ /N20031/001/
/DEC/29,/1992/
/+/ /EQ/50MG/BASE/ /N20031/004/
/DEC/29,/1992/
@ SMITHKLINE BEECHAM EQ 10MG BASE N20031 001
DEC 29, 1992
/EQ/40MG/BASE/ /N20031/005/
/DEC/29,/1992/
@ EQ 40MG BASE N20031 005
DEC 29, 1992
@ EQ 50MG BASE N20031 004
DEC 29, 1992

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION
BICILLIN L-A
/+//WYETH/AYERST/ /300,000/UNITS/ML/ /N50131/001/
+ WYETH AYERST 300,000 UNITS/ML N50141 003
@ 300,000 UNITS/ML N50131 001
/300,000/UNITS/ML/ /N50141/003/

/TABLET;/ORAL/
/BICILLIN/
/+//WYETH/AYERST/ /200,000/UNITS/ /N50128/001/
@ WYETH AYERST 200,000 UNITS N50128 001

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN
/AA/ /BIOCRAFT/ /200,000 UNITS/5ML/ /N60307/002/
BIOCRAFT 200,000 UNITS/5ML N60307 002
/PENTIDS '200'/
/AA/ /SQUIBB/ /200,000 UNITS/5ML/ /N62149/001/
@ APOTHECON 200,000 UNITS/5ML N62149 001
/PENTIDS '400'/
/AA/ /SQUIBB/ /400,000 UNITS/5ML/ /N62149/002/
@ APOTHECON 400,000 UNITS/5ML N62149 002

TABLET; ORAL
PENICILLIN G POTASSIUM
@ APOTHECON 250,000 UNITS N60392 003
/AB/ /SQUIBB/ /250,000 UNITS/ /N60392/003/

PENICILLIN G POTASSIUM

TABLET; ORAL

	/PENITOS 200/		
/AB/	/SQUIBB/	/200,000 UNITS/	/N62155/001/
	@ APOTHECON	200,000 UNITS	N62155 001
	/PENITOS 250/		
/AB/	/SQUIBB/	/250,000 UNITS/	/N62155/002/
	@ APOTHECON	250,000 UNITS	N62155 002
	/PENITOS 400/		
/AB/	/SQUIBB/	/400,000 UNITS/	/N60392/004/
/AB/		/400,000 UNITS/	/N62155/003/
	@ APOTHECON	400,000 UNITS	N60392 004
	@	400,000 UNITS	N62155 003
	/PENITOS 800/		
/AB/	/SQUIBB/	/800,000 UNITS/	/N60392/005/
/AB/		/800,000 UNITS/	/N62155/004/
	@ APOTHECON	800,000 UNITS	N60392 005
	@	800,000 UNITS	N62155 004

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	/DURACILLIN A.S./		
/AP/	/LILLY/	/300,000 UNITS/ML/	/N60093/001/
	@ LILLY	300,000 UNITS/ML	N60093 001

PENICILLIN V

	/POWDER/FOR/RECONSTITUTION;/ORAL/		
	/V-CILLIN/		
	/*//LILLY/	/125MG/0.6ML/	/N60002/001/
	@ LILLY	125MG/0.6ML	N60002 001

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	/VEETIDS 125/		
/AA/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N61206/001/
/AA/		/EQ 125MG BASE/5ML/	/N62153/001/
	@ APOTHECON	EQ 125MG BASE/5ML	N61206 001
	@	EQ 125MG BASE/5ML	N62153 001
	/VEETIDS 250/		
/AA/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N61206/002/
/AA/		/EQ 250MG BASE/5ML/	/N62153/002/
	@ APOTHECON	EQ 250MG BASE/5ML	N61206 002
	@	EQ 250MG BASE/5ML	N62153 002

PENICILLIN V POTASSIUM

TABLET; ORAL

	BETAPEN-VK		
AB	APOTHECON	EQ 250MG BASE	N61411 001
AB		EQ 500MG BASE	N61411 002
/AB/	/BRISTOL/	/EQ 250MG BASE/	/N61411/001/
/AB/		/EQ 500MG BASE/	/N61411/002/
	/VEETIDS 250/		
/AB/	/SQUIBB/	/EQ 250MG BASE/	/N61164/001/
/AB/		/EQ 250MG BASE/	/N62156/002/
	@ APOTHECON	EQ 250MG BASE	N61164 001
	@	EQ 250MG BASE	N62156 002
	/VEETIDS 500/		
/AB/	/SQUIBB/	/EQ 500MG BASE/	/N61164/002/
/AB/		/EQ 500MG BASE/	/N62156/001/
	@ APOTHECON	EQ 500MG BASE	N61164 002
	@	EQ 500MG BASE	N62156 001

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

	/PENTOBARBITAL SODIUM/		
/AP/	/ELKINS/SINN/	/50MG/ML/	/N83270/001/
	@ ELKINS SINN	50MG/ML	N83270 001

PERFLUBRON

LIQUID; ORAL

	IMAGENT		
+	ALLIANCE PHARM	100%	N20091 001
			AUG 13, 1993

PERMETHRIN

	/LOTION;/TOPICAL/		
	/NIX/		
/AT/	/*//BURROUGHS/WELLCOME/	/1%/	/N19435/001/
			/MAR/31/1986/
	@ BURROUGHS WELLCOME	1%	N19435 001
			MAR 31, 1986

PERPHENAZINE

	/TABLET;/EXTENDED/RELEASE;/ORAL/		
	/TRILAFON/		
	/*//SCHERING/	/8MG/	/N11361/002/
	@ SCHERING	8MG	N11361 002

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

/STATODEX/
/AA/ /LEMMON/ /35MG/ /N85507/001/
@ LEMMON 35MG N85507 001

TABLET; ORAL

/ADDHEN/
/AA/ /FERNDALE/ /35MG/ /N83655/001/
@ FERNDALE 35MG N83655 001
> DLT > /MELFIAT/
> DLT >/AA/ /SOLVAY/ /35MG/ /N83790/002/
> ADD > @ SOLVAY 35MG N83790 002
/METRA/
/AA/ /FOREST/PHARMS/ /35MG/ /N83754/001/
@ FOREST PHARMS 35MG N83754 001

PHENDIMETRAZINE TARTRATE

/AA/ /ANABOLIC/ /35MG/ /N86020/001/
@ ANABOLIC 35MG N86020 001
/AA/ /FERNDALE/ /35MG/ /N86834/001/
/SEP/15/1983/
@ FERNDALE 35MG N86834 001
SEP 15, 1983
> DLT >/AA/ /GENEVA/ /35MG/ /N83993/001/
> ADD > @ SOLVAY 35MG N83993 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

/AA/ /LEMMON/ /30MG/ /N86911/001/
/QUESTIN-30/
/AA/ /FERNDALE/ /30MG/ /N87144/001/
@ FERNDALE 30MG N87144 001

PHENTERMINE HCL

@ LEMMON 30MG N86911 001
> DLT >/AA/ /PHARM/BASICS/ /30MG/ /N88430/001/
> DLT >
> ADD > @ PHARM BASICS 30MG N88430 001
> ADD >
MAR/27/1984
MAR 27, 1984
/AA/ /ZENITH/ /30MG/ /N86329/001/
@ ZENITH 30MG N86329 001

TABLET; ORAL

> DLT > /TORA/
> DLT >/AA/ /SOLVAY/ /8MG/ /N84035/001/
> ADD > @ SOLVAY 8MG N84035 001

PHENYLBUTAZONE

CAPSULE; ORAL

> DLT > /BUTAZOLIDIN/
> DLT >/AB//+//GEIGY/ /100MG/ /N08319/009/
> ADD > @ GEIGY 100MG N08319 009

PHENYLBUTAZONE

> DLT >/AB/ /BARR/ /100MG/ /N88994/001/
> DLT >
> ADD > + BARR 100MG
> ADD >
/DEC/04/1985/
N88994 001
DEC 04, 1985
> DLT >/AB/ /CHELSEA/ /100MG/ /N87756/001/
> DLT >
> ADD > @ CHELSEA 100MG
> ADD >
/DEC/17/1982/
N87756 001
DEC 17, 1982
> DLT >/AB/ /GENEVA/ /100MG/ /N87774/001/
> DLT >
> ADD > @ GENEVA 100MG
> ADD >
/JUN/16/1982/
N87774 001
JUN 16, 1982

TABLET; ORAL

> DLT > /BUTAZOLIDIN/
> DLT >/AB//+//GEIGY/ /100MG/ /N08319/008/
> ADD > @ GEIGY 100MG N08319 008

PHENYLBUTAZONE

> DLT >/AB/ /BARR/ /100MG/ /N88863/001/
> DLT >
> ADD > + BARR 100MG
> ADD >
/DEC/04/1985/
N88863 001
DEC 04, 1985
> DLT >/AB/ /CHELSEA/ /100MG/ /N86151/001/
> ADD > @ CHELSEA 100MG N86151 001
> DLT >/AB/ /DANBURY/PHARMA/ /100MG/ /N87674/001/
> DLT >
> ADD > @ DANBURY PHARMA 100MG
> ADD >
/APR/21/1982/
N87674 001
APR 21, 1982
> DLT >/AB/ /GENEVA/ /100MG/ /N84339/001/
> ADD > @ GENEVA 100MG N84339 001

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

@ PENNEX PHARMS 5MG/5ML;6.25MG/5ML N88897 001
JAN 04, 1985
/AA/ /PHARM/BASICS/ /5MG/5ML;6.25MG/5ML/ /N88897/001/
/JAN/04/1985/

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

/BP/	/MSD/	/10MG/ML/	/N12223/001/
BP +	MSD	10MG/ML	N12223 001

KONAKION

/BP/+	//ROCHE/	/10MG/ML/	/N11745/003/
BP	ROCHE	10MG/ML	N11745 003

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	GENEVA	5MG	N73608 001 MAR 29, 1993
AB		10MG	N73609 001 MAR 29, 1993
> ADD > AB	NOVOPHARM	5MG	N73661 001 OCT 31, 1993
> ADD > AB		10MG	N73661 002 OCT 31, 1993
AB	PUREPAC	5MG	N74125 001 APR 28, 1993
AB		10MG	N74125 002 APR 28, 1993
AB	ZENITH	5MG	N73687 001 FEB 26, 1993
AB		10MG	N73687 002 FEB 26, 1993

> ADD > PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

> ADD > INJECTABLE; INJECTION

> ADD > ZOSYN

> ADD >	+ LEDERLE	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N50684 001 OCT 22, 1993
> ADD >	+	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N50684 002 OCT 22, 1993
> ADD >	+	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N50684 003 OCT 22, 1993
> ADD >	+	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N50684 004 OCT 22, 1993

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	MEPHA AG	10MG	N74116 001 JUN 15, 1993
AB		20MG	N74118 001 JUN 15, 1993
AB	MUTUAL PHARM	10MG	N73535 001 MAR 12, 1993
AB		20MG	N73536 001 MAR 12, 1993
AB	ROXANE	10MG	N73651 001 FEB 26, 1993
AB		20MG	N73651 002 FEB 26, 1993

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

PEG-LYTE

AA	INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

/AB/	/ADRIA/	/8MEQ/	/N73398/001/ /JAN/28/1992/
/AB/		/10 MEQ/	/N72427/001/ /MAR/28/1990/
AB	SAVAGE	8MEQ	N73398 001 JAN 28, 1992
AB		10 MEQ	N72427 001 MAR 28, 1990

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N84290 001
AP		2MEQ/ML	N87787 001 APR 20, 1982
/AP/	/LUITPOLD/	/2MEQ/ML/	/N80221/001/
/AP/		/2MEQ/ML/	/N80736/001/
∂	LUITPOLD	2MEQ/ML	N80221 001
∂		2MEQ/ML	N80736 001

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

/AP/	/LYPHOMED/	/2MEQ/ML/	/N64296/001/
/AP/		/2MEQ/ML/	/N87787/001/
			/APR/20,/1982/

TABLET, EXTENDED RELEASE; ORAL
K+8

AB	ALRA	8MEQ	N70998 001 JAN 25, 1993
	KAON CL		
	/ADRIA/	/6.7MEQ/	/N17046/001/
	SAVAGE	6.7MEQ	N17046 001
	KAON CL-10		
/BC/	/ADRIA/	/10MEQ/	/N17046/002/
BC	SAVAGE	10MEQ	N17046 002

POTASSIUM CITRATE

/POWDER/FOR/RECONSTITUTION;/ORAL/
/POTASSIUM/CITRATE/

/+//UNIV/TX/	/20MEQ/PACKET/	/N19647/001/ /OCT/13,/1988/	
	/10MEQ/PACKET/	/N19647/002/ /OCT/13,/1988/	
∂ UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988	
∂	20MEQ/PACKET	N19647 001 OCT 13, 1988	

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

/+//UNIV/TX/	/5MEQ/	/N19071/001/ /AUG/30,/1985/	
+ UNIV TX	10MEQ	N19071 002 AUG 31, 1992	
	5MEQ	N19071 001 AUG 30, 1985	

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL

/+//BRISTOL/MYERS/SQUIBB/20MG/			/N19898/003/ /OCT/31,/1991/
+ BRISTOL MYERS SQUIBB	40MG		N19898 004 MAR 22, 1993
	20MG		N19898 003 OCT 31, 1991

PRAZEPAM

/TABLET;/ORAL/
/CENTRAX/

/+//PARKE/DAVIS/	/10MG/	/N17415/001/
∂ PARKE DAVIS	10MG	N17415 001

PREDNICARBATE

> ADD >	CREAM; TOPICAL DERMATOP HOECHST ROUSSEL	0.1%	N20279 001 OCT 29, 1993
> ADD >	OINTMENT; TOPICAL /DERMATOP/ /HOECHST/ROUSSEL/	/0.1%/	/N19568/001/ /SEP/23,/1991/
> ADD >	∂ HOECHST ROUSSEL	0.1%	N19568 001 SEP 23, 1991

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

> DLT >	/BX/ /PRIVATE/FORM/	/5MG/	/N80211/001/
> ADD >	∂ PRIVATE FORM	5MG	N80211 001
	/BX/ /WEST/WARD/	/5MG/	/N80324/001/
	∂ WEST WARD	5MG	N80324 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
CETAPRED

ALCON	0.25%;10%	N87771 001 AUG 06, 1993

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

> DLT >	/PREDSULFATE/		
> DLT >/AT/	/PHARMAFAIR/	/0.5%;10%/	/N88032/001/ /APR/15,/1983/
> DLT >			
> ADD >	∂ PHARMAFAIR	0.5%;10%	N88032 001 APR 15, 1983
> ADD >			

VASOCIDIN

> DLT >/AT/	/IOLAB/	/0.5%;10%/	/N88791/001/ /OCT/05,/1984/
> DLT >			
> ADD >	+ IOLAB	0.5%;10%	N88791 001 OCT 05, 1984
> ADD >			

SUSPENSION/DROPS; OPHTHALMIC

	/PREDSULFATE/		
/AT/	/PHARMAFAIR/	/0.5%;10%/	/N88007/001/ /APR/19,/1983/
	∂ PHARMAFAIR	0.5%;10%	N88007 001 APR 19, 1983

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

> DLT >	/PREDATE/		
> DLT >/AT/	/PHARMAFAIR/	/EQ 0.11% PHOSPHATE/	/N88415/001/ /FEB/29,/1984/
> DLT >			
> ADD >	∂ PHARMAFAIR	EQ 0.11% PHOSPHATE	N88415 001 FEB 29, 1984
> ADD >			

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.23% PHOSPHATE;10%	N73630 001 MAY 27, 1993

VASOCIDIN

AT	IOLAB	EQ 0.23% PHOSPHATE;10%	N18988 001 AUG 26, 1988

PREDNISONE

SOLUTION; ORAL

PREDNISONE

	∂ PENNEX PHARMS	5MG/5ML	N89726 001 AUG 02, 1988
/AA/	/PHARM/BASICS/	/5MG/5ML/	/N89726/001/ /AUG/02,/1988/

PREDNISONE

SOLUTION; ORAL

PREDNISONE

/AA/	/ROXANE/	/5MG/5ML/	/N88703/001/ /NOV/08,/1984/
	ROXANE	5MG/5ML	N88703 001 NOV 08, 1984

TABLET; ORAL

DELTASONE

AB	UPJOHN	2.5MG	N09986 005
/BX/		/2.5MG/	/N09986/005/

PREDNISONE

/AB/	/HEATHER/	/10MG/	/N84341/001/
/AB/		/20MG/	/N84417/001/
/AB/		/20MG/	/N85543/001/
/AB/		/50MG/	/N86946/001/
	∂ HEATHER	10MG	N84341 001
	∂	20MG	N84417 001
	∂	20MG	N85543 001
	∂	50MG	N86946 001
/BX/	/KV/	/5MG/	/N84236/001/
	∂ KV	5MG	N84236 001
BX	NYLOS TRADING	5MG	N85115 001
/BX/	/TABLICAPS/	/5MG/	/N85115/001/
/BX/	/UPSHER/SMITH/	/5MG/	/N87471/001/
/BX/		/20MG/	/N87470/001/
	∂ UPSHER SMITH	5MG	N87471 001
	∂	20MG	N87470 001

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PRONESTYL

AB	APOTHECON	250MG	N07335 001
AB		375MG	N07335 004
AB +		500MG	N07335 003
/AB/	/SQUIBB/	/250MG/	/N07335/001/
/AB/		/375MG/	/N07335/004/
/AB//+/		/500MG/	/N07335/003/

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

/AP/	/LYPHOMED/	/100MG/ML/	/N89415/001/ /NOV/17,/1986/
/AP/		/500MG/ML/	/N89416/001/ /NOV/17,/1986/
	@ LYPHOMED	100MG/ML	N89415 001 NOV 17, 1986
	@	500MG/ML	N89416 001 NOV 17, 1986

PRONESTYL

AP	+ APOTHECON	100MG/ML	N07335 002
AP	+	500MG/ML	N07335 005
/AP/	/SQUIBB/	/100MG/ML/	/N07335/002/
/AP/		/500MG/ML/	/N07335/005/

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINE HCL

/AP/	/BEL/MAR/	/1%/	/N80711/001/
/AP/		/2%/	/N80756/001/
	@ BEL MAR	1%	N80711 001
	@	2%	N80756 001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL
PROCHLORPERAZINE EDISYLATE

@ PENNEX PHARMS	EQ 10MG BASE/ML	N88598 001 OCT 25, 1984
/@/PHARM/BASICS/	/EQ/10MG/BASE/ML/	/N88598/001/ /OCT/25,/1984/

SYRUP; ORAL
PROCHLORPERAZINE EDISYLATE

@ PENNEX PHARMS	EQ 5MG BASE/5ML	N88597 001 OCT 25, 1984
/@/PHARM/BASICS/	/EQ/5MG/BASE/5ML/	/N88597/001/ /OCT/25,/1984/

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL
KEMADRIN

/BURROUGHS/WELLCOME/	/2MG/	/N09818/005/
@ BURROUGHS WELLCOME	2MG	N09818 005

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
SPARINE

/AP/	/WYETH/AYERST/	/25MG/ML/	/N10349/009/

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
PROMETHACON

/BR/	/ALCON/	/25MG/	/N84901/001/
/BR/		/50MG/	/N84902/001/
BR	POLYMEDICA	25MG	N84901 001
BR		50MG	N84902 001

SYRUP; ORAL
PROMETHAZINE PLAIN

@ PENNEX PHARMS	6.25MG/5ML	N87953 001 NOV 15, 1982
/AA/ /PHARM/BASICS/	/6.25MG/5ML/	/N87953/001/ /NOV/15,/1982/

TABLET; ORAL
PROMETHAZINE HCL

/BP/ /CIRCA/	/25MG/	/N83204/001/
@ CIRCA	25MG	N83204 001
/BP/ /ZENITH/	/50MG/	/N83613/001/
@ ZENITH	50MG	N83613 001

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN

/ICI/	/10MG/ML/	/N19627/001/ /OCT/02,/1989/
+ ZENECA	10MG/ML	N19627 001 OCT 02, 1989

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL
PROPRANOLOL HCL

@ PENNEX PHARMS	20MG/5ML	N71984 001 MAR 03, 1989
@	40MG/5ML	N71985 001 MAR 03, 1989

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL
PROPRANOLOL HCL

/$/	/PHARM/BASICS/	/20MG/5ML/	/N71984/001/ /MAR/03,/1989/
/$/		/40MG/5ML/	/N71985/001/ /MAR/03,/1989/

/SUSPENSION;/ORAL/
/INDERAL/

	/WYETH/AYERST/	/10MG/ML/	/N19536/001/ /DEC/12,/1986/
	@ WYETH AYERST	10MG/ML	N19536 001 DEC 12, 1986

TABLET; ORAL
PROPRANOLOL HCL

/AB/	/MYLAN/	/60MG/	/N72275/001/ /JUN/09,/1989/
	@ MYLAN	60MG	N72275 001 JUN 09, 1989

PROPYLIODONE

/SUSPENSION;/INTRATRACHEAL/
/DIONOSIL/OILY/

	/GLAXO/	/60%/	/N09309/002/
	@ GLAXO	60%	N09309 002

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/AP/	/QUAD/	/10MG/ML/	/N89306/001/ /MAY/30,/1986/
	@ QUAD	10MG/ML	N89306 001 MAY 30, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
/HISTAFED/

/AA/	/LIFE/LABS/	/30MG/5ML;1.25MG/5ML/	/N88283/001/ /APR/20,/1984/
	@ CENCI	30MG/5ML;1.25MG/5ML	N88283 001 APR 20, 1984

PYRANTEL PAMOATE

/SUSPENSION;/ORAL/
/ANTIMINTH/

	/+//ROERIG/	/EQ/250MG/BASE/5ML/	/N16883/001/

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

/AP/	/ICN/	/5MG/ML/	/N09830/001/
AP	ROCHE	5MG/ML	N09830 001

SYRUP; ORAL
MESTINON

	/ICN/	/60MG/5ML/	/N15193/001/
	ROCHE	60MG/5ML	N15193 001

TABLET; ORAL
MESTINON

/+//ICN/		/60MG/	/N09829/002/
+	ROCHE	60MG	N09829 002

TABLET, EXTENDED RELEASE; ORAL
MESTINON

/+//ICN/		/180MG/	/N11665/001/
+	ROCHE	180MG	N11665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
/HEXA-BETALIN/

/AP/	/LILLY/	/100MG/ML/	/N80854/001/
	@ LILLY	100MG/ML	N80854 001

PYRIDOXINE HCL

/AP/	/BEL/MAR/	/100MG/ML/	/N80761/001/
	@ BEL MAR	100MG/ML	N80761 001
AP	FUJISAWA	100MG/ML	N80618 001
/AP/	/LYPHOMED/	/100MG/ML/	/N80618/001/

QUAZEPAM

TABLET; ORAL
DORAL
/+//BAKER/NORTON/ /15MG/ /N18708/001/ /DEC/27,/1985/
/7.5MG/ /N18708/003/ /FEB/26,/1987/
+ WALLACE 15MG N18708 001 DEC 27, 1985
7.5MG N18708 003 FEB 26, 1987

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
/DURAQUIN/
/PARKE/DAVIS/ /330MG/ /N17917/001/
@ WARNER CHILCOTT 330MG N17917 001

QUINIDINE SULFATE

TABLET; ORAL
> DLT > /CIN-QUIN/
> DLT >/AB/ /SOLVAY/ /100MG/ /N85299/001/
> DLT >/AB/ /200MG/ /N84932/001/
> DLT >/AB/ /300MG/ /N85298/001/
> ADD > @ SOLVAY 100MG N85299 001
> ADD > @ 200MG N84932 001
> ADD > @ 300MG N85298 001

QUINIDINE SULFATE
/AB/ /PARKE/DAVIS/ /200MG/ /N83879/001/
@ WARNER CHILCOTT 200MG N83879 001

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUDIXIN
BP APOTHECON 50MG N08842 001
BP + 100MG N08842 002
/BP/ /SQUIBB/ /50MG/ /N08842/001/
/BP/+/ /100MG/ /N08842/002/

RESERPINE

TABLET; ORAL
RESERPINE
/BP/ /LEMMON/ /0.1MG/ /N89020/001/ /MAR/07,/1985/
/BP/ /0.25MG/ /N89019/001/ /MAR/07,/1985/
@ LEMMON 0.1MG N89020 001 MAR 07, 1985
@ 0.25MG N89019 001 MAR 07, 1985

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
/NAQUIVAL/
/BP/+//SCHERING/ /0.1MG;4MG/ /N12265/003/
@ SCHERING 0.1MG;4MG N12265 003

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL
FLUMADINE
+ FOREST LABS 50MG/5ML N19650 001 SEP 17, 1993

TABLET; ORAL
FLUMADINE
+ FOREST LABS 100MG N19649 001 SEP 17, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
/AP/ /QUAD/ /10MG/ML/ /N70700/001/ /OCT/06,/1986/
@ QUAD 10MG/ML N70700 001 OCT 06, 1986

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
@ PENNEX PHARMS 2.5% N88228 001 SEP 01, 1983

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
/AT/ /PHARM/BASICS/ /2.5%/ /N88228/001/ /SEP/01,/1983/

SERACTIDE ACETATE

/INJECTABLE;/INJECTION/
/ACTHAR/GEL-SYNTHETIC/
/ARMOUR/ /40/UNITS/ML/ /N17861/001/
/80/UNITS/ML/ /N17861/002/
@ ARMOUR 40 UNITS/ML N17861 001
@ 80 UNITS/ML N17861 002

SILVER SULFADIAZINE

/DRESSING;/TOPICAL/
/SILDIMAC/
@ BIOPLASTY 1% N19608 001 NOV 30, 1989

/SILDIMAC/
/ENQUAY/ /1%/ /N19608/001/ /NOV/30,/1989/

SODIUM BICARBONATE

/INJECTABLE;/INJECTION/
/SODIUM/BICARBONATE/IN/PLASTIC/CONTAINER/
/ABBOTT/ /0.9MEQ/ML/ /N19443/001/ /JUN/03,/1986/
/1MEQ/ML/ /N19443/002/ /JUN/03,/1986/
@ ABBOTT 0.9MEQ/ML N19443 001 JUN 03, 1986
@ 1MEQ/ML N19443 002 JUN 03, 1986

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP FUJISAWA 9MG/ML N88911 001 FEB 07, 1985
/AP/ /LYPHOMED/ /9MG/ML/ /N88911/001/ /FEB/07,/1985/

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
@ FUJISAWA 234MG/ML N19329 001 APR 22, 1987
/@/LYPHOMED/ /234MG/ML/ /N19329/001/ /APR/22,/1987/

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM
/SQUIBB/ /2MCI/VIAL/ /N13993/002/
@ SQUIBB 2MCI/VIAL N13993 002

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131
/@/CIS/ /50/UCI/ /N17316/001/
@ CIS 50 UCI N17316 001
/100/UCI/ /N17316/002/
100 UCI N17316 002

SOLUTION; ORAL
SODIUM IODIDE I 131
/CIS/ /50MCI/ML/ /N17315/001/
CIS 50MCI/ML N17315 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
@ PENNEX PHARMS 453.6GM/BOT N88786 001 SEP 11, 1984
/AA/ /PHARM/BASICS/ /453.6GM/BOT/ /N88786/001/ /SEP/11,/1984/

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
@ PENNEX PHARMS 15GM/60ML N88717 001 SEP 11, 1984
/AA/ /PHARM/BASICS/ /15GM/60ML/ /N88717/001/ /SEP/11,/1984/

SOYBEAN OIL

INJECTABLE; INJECTION
NUTRILIPID 10%
AP MCGAW 10% N19531 001 MAY 28, 1993

NUTRILIPID 20%
AP MCGAW 20% N19531 002 MAY 28, 1993

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
/AB/ /CHELSEA/ /25MG/ /N87078/001/
B* CHELSEA 25MG N87078 001
/AB/ /UPSHER/SMITH/ /25MG/ /N87554/001/
@ UPSHER SMITH 25MG N87554 001

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON
MEDI PHYSICS 1MCI/ML N20134 001 JUN 18, 1993

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
/SULFAIR 10/
/AT/ /PHARMAFAIR/ /10%/ /N88000/001/
@ PHARMAFAIR 10% /DEC/22,/1982/ N88000 001 DEC 22, 1982

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE
/ABBOTT/ /300MG/ /N04125/005/
@ ABBOTT 300MG N04125 005

SULFAMETHIZOLE

TABLET; ORAL
THIOSULFIL
/WYETH/AYERST/ /250MG/ /N08565/001/
@ WYETH AYERST 250MG N08565 001

SULFAMETHOXAZOLE

TABLET; ORAL
/GANTANOL-DS/
/ROCHE/ /1GM/ /N12715/003/
@ ROCHE 1GM N12715 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA
AB BARRE 200MG/5ML;40MG/5ML N72289 001 MAY 23, 1988
AB 200MG/5ML;40MG/5ML N72398 001 MAY 23, 1988
/AB/ /NASKA/ /200MG/5ML;40MG/5ML/ /N72289/001/ /MAY/23,/1988/
/AB/ /200MG/5ML;40MG/5ML/ /N72398/001/ /MAY/23,/1988/

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE
/AB/ /HEATHER/ /500MG/ /N80189/001/
@ HEATHER 500MG N80189 001

SULFISOXAZOLE ACETYL

/EMULSION;/ORAL/
/LIPO/GANTRISIN/
/ROCHE/ /EQ/1GM/BASE/5ML/ /N09182/009/
@ ROCHE EQ 1GM BASE/5ML N09182 009

SULFISOXAZOLE DIOLAMINE

/OINTMENT;/OPHTHALMIC/
/GANTRISIN/
/ROCHE/ /EQ/4%/BASE/ /N08414/002/
@ ROCHE EQ 4% BASE N08414 002

SULINDAC

TABLET; ORAL
SULINDAC

AB	MYLAN	150MG	N73038 001 JUN 22, 1993
AB		200MG	N73039 001 JUN 22, 1993

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

+	PARKE DAVIS	EQ 40MG BASE	N20070 004 SEP 09, 1993
		EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX

/+/	/STUART/	/EQ/10MG/BASE/	/N17970/001/
+	ZENECA	EQ 10MG BASE	N17970 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
/A-N/STANNOUS/AGGREGATED/ALBUMIN/

/BS/	/NORTH/AM/CHEM/	/N/A/	/N17916/001/
@	NORTH AM CHEM	N/A	N17916 001

AN-MAA

BS	SORIN	N/A	N17792 001
		/N/A/	/N17792/001/

/TECHNETIUM/TC/99M/MAA/

/BS/	/MEDI/PHYSICS/	/N/A/	/N17773/001/
@	MEDI PHYSICS	N/A	N17773 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
/AMERSCAN MDP KIT/

/AP/	/AMERSHAM/	/N/A/	/N18335/001/ /AUG/05,/1982/

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
/AMERSCAN MDP KIT/

@	AMERSHAM	N/A	N18335 001 AUG 05, 1982

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
/MINITEC/

	/SQUIBB/	/0.22-2.22CI/GENERATOR/	/N17339/001/
@	SQUIBB	0.22-2.22CI/GENERATOR	N17339 001

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

AB	DANBURY PHARMA	15MG	N71446 001 MAY 21, 1993
AB		30MG	N71447 001 MAY 21, 1993

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN

/+//ABBOTT/	/2MG/	/N19057/002/ AUG/07,/1987/	
+ ABBOTT	EQ 2MG BASE	N19057 002 AUG 07, 1987	
+	EQ 2MG/BASE	N20223 002 SEP 29, 1993	
	/1MG/	/N19057/001/ AUG/07,/1987/	
	EQ 1MG BASE	N19057 001 AUG 07, 1987	
	EQ 1MG BASE	N20223 001 SEP 29, 1993	
	/5MG/	/N19057/003/ AUG/07,/1987/	
	EQ 5MG BASE	N19057 003 AUG 07, 1987	
	EQ 5MG BASE	N20223 003 SEP 29, 1993	
	/10MG/	/N19057/004/ AUG/07,/1987/	
	EQ 10MG BASE	N19057 004 AUG 07, 1987	
	EQ 10MG BASE	N20223 004 SEP 29, 1993	

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
TESTODERM

>_ADD_>	+ ALZA	4MG/24HR	N19762 001 OCT 12, 1993
>_ADD_>	+	6MG/24HR	N19762 002 OCT 12, 1993

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION
TESTOSTERONE PROPIONATE

/AO/	/BEL/MAR/	/25MG/ML/	/N80741/001/
/AO/		/50MG/ML/	/N80742/001/
/AO/		/100MG/ML/	/N80743/001/
	∂ BEL MAR	25MG/ML	N80741 001
	∂	50MG/ML	N80742 001
	∂	100MG/ML	N80743 001

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION
TESTOSTERONE PROPIONATE

/AO/	/STERIS/	/25MG/ML/	/N80188/001/
/AO/		/25MG/ML/	/N85490/001/
/AO/		/100MG/ML/	/N80188/003/
/AO/		/100MG/ML/	/N83595/003/
	+ STERIS	25MG/ML	N80188 001
	+	100MG/ML	N80188 003
		25MG/ML	N85490 001
		100MG/ML	N83595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

/AB/	/ICN/	/250MG/	/N60471/001/
	∂ ICN	250MG	N60471 001

TABLET; ORAL
SUMYCIN

AB	APOTHECON	50MG	N61147 003
AB		100MG	N61147 002
AB		250MG	N61147 001
AB +		500MG	N61147 004
/AB/	/SQUIBB/	/50MG/	/N61147/003/
/AB/		/100MG/	/N61147/002/
/AB/		/250MG/	/N61147/001/
/AB//+/		/500MG/	/N61147/004/

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

/AP/	/SQUIBB/	/1MCI/ML/	/N18548/001/ DEC/30,/1982/
	∂ SQUIBB	1MCI/ML	N18548 001 DEC 30, 1982

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

>_DLT_>	/THEOBID/			
>_DLT_>	/BC/+//GLAXO/	/260MG/		/N85983/001/ MAR/20,/1985/
>_DLT_>	∂ WHITBY	260MG		N85983 001 MAR 20, 1985
>_ADD_>				
>_ADD_>				

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	/THEOBID/JR./		
> DLT >	/BC/+//GLAXO/	/130MG/	/N87854/001/
> DLT >			/MAR/20,/1985/
> ADD >	@ WHITBY	130MG	N87854 001
> ADD >			MAR 20, 1985
	THEOCLEAR L.A.-130		
> DLT >	/BC/ /CENTRAL/PHARMS/	/130MG/	/N86569/001/
> DLT >			/MAY/27,/1982/
> ADD >	BC + CENTRAL PHARMS	130MG	N86569 001
> ADD >			MAY 27, 1982
	THEOCLEAR L.A.-260		
> DLT >	/BC/ /CENTRAL/PHARMS/	/260MG/	/N86569/002/
> DLT >			/MAY/27,/1982/
> ADD >	BC + CENTRAL PHARMS	260MG	N86569 002
> ADD >			MAY 27, 1982

ELIXIR; ORAL

	/THEOPHYL-225/		
	/JOHNSON/RW/	/112.5MG/15ML/	/N86485/001/
	@ JOHNSON RW	112.5MG/15ML	N86485 001
	THEOPHYLLINE		
AA	BARRE	80MG/15ML	N89223 001
			MAY 27, 1988
/AA/	/NASKA/	/80MG/15ML/	/N89223/001/
			/MAY/27,/1988/
AA	PENNEX PHARMS	80MG/15ML	N86748 001
/AA/	/PHARM/BASICS/	/80MG/15ML/	/N86748/001/

TABLET; ORAL

	QUIBRON-T		
	/+//BRISTOL/MYERS/	/300MG/	/N88656/001/
			/AUG/22,/1985/
	+ ROBERTS	300MG	N88656 001
			AUG 22, 1985
	/THEOPHYL-225/		
	/JOHNSON/RW/	/225MG/	/N84726/001/
	@ JOHNSON RW	225MG	N84726 001
	/TABLET,/CHEWABLE,/ORAL/		
	/THEOPHYL/		
	/JOHNSON/RW/	/100MG/	/N86506/001/
			/SEP/12,/1985/
	@ JOHNSON RW	100MG	N86506 001
			SEP 12, 1985

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

	QUIBRON-T/SR		
/BC/	/BRISTOL/MYERS/	/300MG/	/N87563/001/
			/JUN/21,/1983/
BC	ROBERTS	300MG	N87563 001
			JUN 21, 1983

THEOPHYLLINE SODIUM GLYCINATE

	/ELIXIR,/ORAL/		
	/SYNOPHYLATE/		
	/CENTRAL/PHARMS/	/EQ/165MG/BASE/15ML/	/N06333/008/
	@ CENTRAL PHARMS	EQ 165MG BASE/15ML	N06333 008

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL		
/AP/	/BEL/MAR/	/100MG/ML/	/N80718/001/
/AP/		/200MG/ML/	/N80712/001/
	@ BEL MAR	100MG/ML	N80718 001
	@	200MG/ML	N80712 001
AP	FUJISAWA	100MG/ML	N80556 001
/AP/	/LYPHOMED/	/100MG/ML/	/N80556/001/
/AP/	/STERIS/	/200MG/ML/	/N80571/002/
/AP/		/200MG/ML/	/N83534/002/
	+ STERIS	200MG/ML	N80571 002
		200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	THIORIDAZINE HCL		
	@ PENNEX PHARMS	30MG/ML	N88258 001
			JUL 25, 1983
	@	100MG/ML	N88227 001
			JUL 05, 1983
/AA/	/PHARM/BASICS/	/30MG/ML/	/N88258/001/
			/JUL/25,/1983/
/AA/		/100MG/ML/	/N88227/001/
			/JUL/05,/1983/

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

/AB/	/PAR/	/10MG/	/N88351/001/ /DEC/05,/1983/
/AB/		/15MG/	/N88352/001/ /DEC/05,/1983/
/AB/		/25MG/	/N88336/001/ /DEC/05,/1983/
/AB/		/50MG/	/N88322/001/ /DEC/05,/1983/
/AB/		/100MG/	/N88480/001/ /DEC/29,/1983/
	a PAR	10MG	N88351 001 DEC 05, 1983
	a	15MG	N88352 001 DEC 05, 1983
	a	25MG	N88336 001 DEC 05, 1983
	a	50MG	N88322 001 DEC 05, 1983
	a	100MG	N88480 001 DEC 29, 1983
/AB/	/ZENITH/	/100MG/	/N88273/001/ /OCT/03,/1983/
	a ZENITH	100MG	N88273 001 OCT 03, 1983

THIOTEPA

INJECTABLE; INJECTION

	/THIO-TEPA/ /LEDERLE/	/15MG/VIAL/	/N11683/001/
	THIOTEPA + LEDERLE	15MG/VIAL	N11683 001

TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TICAR

+ SMITHKLINE BEECHAM	EQ 20GM BASE/VIAL	N50497 004
+	EQ 30GM BASE/VIAL	N50497 005 APR 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

+ SYNTEX	250MG	N19979 002 OCT 31, 1991
a	125MG	N19979 001 MAR 24, 1993
	/250MG/	/N19979/002/ /OCT/31,/1991/

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE

AB	NOVOPHARM	5MG	N72648 001 JUN 16, 1993
AB		10MG	N72649 001 JUN 16, 1993
AB		20MG	N72650 001 JUN 16, 1993

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM

AB	MYLAN	EQ 400MG BASE	N73393 001 MAY 27, 1993

TABLET; ORAL
TOLMETIN SODIUM

AB	GENEVA	EQ 600MG BASE	N74002 001 SEP 27, 1993

TORSEMIDE

INJECTABLE; INJECTION
DEMADEX

+ BOEHRINGER MANNHEIM	10MG/ML	N20137 002 AUG 23, 1993

TORSEMIDE

TABLET; ORAL
DEMADEX
+ BOEHRINGER MANNHEIM 100MG N20136 004 AUG 23, 1993
5MG N20136 001 AUG 23, 1993
10MG N20136 002 AUG 23, 1993
20MG N20136 003 AUG 23, 1993

TRANYLCYPROMINE SULFATE

TABLET; ORAL
PARNATE
+ SKF EQ 10MG BASE N12342 003 AUG 16, 1985

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL
AB APOTHECON 50MG N18207 001
AB + 100MG N18207 002
AB 150MG N18207 003 MAR 25, 1985
300MG N18207 004 NOV 07, 1988
/AB/ /BRISTOL/MYERS/ /50MG/ /N18207/001/
/AB/+/ /100MG/ /N18207/002/
/AB/ /150MG/ /N18207/003/ /MAR/25,/1985/
/300MG/ /N18207/004/ /NOV/07,/1988/

TRAZODONE HCL
AB MUTUAL PHARM 50MG N73136 001 MAR 24, 1993
AB 100MG N73137 001 MAR 24, 1993

TRETINOIN

/SWAB;/TOPICAL/
/RETIN-A/
/+//JOHNSON/RW/ /0.05%/ /N16921/002/
@ JOHNSON RW 0.05% N16921 002

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION
AZMACORT
+ RHONE POULENC RORER 0.1MG/INH N18117 001 APR 23, 1982
/+/ /0.25MG/INH/ /N18117/001/ /APR/23,/1982/

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
@ PENNEX PHARMS 0.025% N88094 001 SEP 01, 1983
@ 0.1% N88095 001 SEP 01, 1983
@ 0.5% N88096 001 SEP 01, 1983
/@/PHARM/BASICS/ /0.025%/ /N88094/001/ /SEP/01,/1983/
/@/ /0.1%/ /N88095/001/ /SEP/01,/1983/
/@/ /0.5%/ /N88096/001/ /SEP/01,/1983/
/AT/ /PHARMADERM/ /0.025%/ /N87990/001/ /JUL/07,/1983/
/AT/ /0.1%/ /N87991/001/ /JUL/07,/1983/
/AT/ /0.5%/ /N87992/001/ /JUL/07,/1983/
@ PHARMADERM 0.025% N87990 001 JUL 07, 1983
@ 0.1% N87991 001 JUL 07, 1983
@ 0.5% N87992 001 JUL 07, 1983
> DLT >/AT/ /PHARMAFAIR/ /0.025%/ /N87921/001/ /AUG/10,/1982/
> DLT >
> DLT >/AT/ /0.1%/ /N87912/001/ /AUG/10,/1982/
> DLT >
> DLT >/AT/ /0.5%/ /N87922/001/ /AUG/10,/1982/
> DLT >
> ADD > @ PHARMAFAIR 0.025% N87921 001 AUG 10, 1982
> ADD >
> ADD > @ 0.1% N87912 001 AUG 10, 1982
> ADD >
> ADD > @ 0.5% N87922 001 AUG 10, 1982
> ADD >

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	PENNEX PHARMS	0.025%	N88450 001 APR 01, 1985
AT		0.1%	N88451 001 APR 03, 1985
/AT/	/PHARM/BASICS/	/0.025%/	/N88450/001/ /APR/01,/1985/
/AT/		/0.1%/	/N88451/001/ /APR/03,/1985/

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	BARRE	0.5%	N89913 001 DEC 23, 1988
/AT/	/NASKA/	/0.5%/	/N89913/001/ /DEC/23,/1988/
	∂ PENNEX PHARMS	0.025%	N88090 001 SEP 01, 1983
	∂	0.1%	N88091 001 SEP 01, 1983
	∂	0.5%	N88092 001 SEP 01, 1983
	/∂/PHARM/BASICS/	/0.025%/	/N88090/001/ /SEP/01,/1983/
	/∂/	/0.1%/	/N88091/001/ /SEP/01,/1983/
	/∂/	/0.5%/	/N88092/001/ /SEP/01,/1983/
/AT/	/PHARMADERM/	/0.025%/	/N88692/001/ /AUG/02,/1984/
/AT/		/0.1%/	/N88690/001/ /AUG/02,/1984/
	∂ PHARMADERM	0.025%	N88692 001 AUG 02, 1984
	∂	0.1%	N88690 001 AUG 02, 1984

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

/TEP/

/AA/	/GENEVA/	/EQ 10MG BASE/ML/	/N85787/001/ /APR/15,/1982/

TRIFLUOPERAZINE HCL

AA	GENEVA	EQ 10MG BASE/ML	N85787 001 APR 15, 1982

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

TRIFLUOPERAZINE HCL

	∂ PENNEX PHARMS	EQ 10MG BASE/ML	N88143 001 JUL 26, 1983
/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N88143/001/ /JUL/26,/1983/

TABLET; ORAL

/TEP/

/AB/	/GENEVA/	/EQ 1MG BASE/	/N85785/001/
/AB/		/EQ 2MG BASE/	/N85786/001/
/AB/		/EQ 5MG BASE/	/N85789/001/
/AB/		/EQ 10MG BASE/	/N85788/001/

TRIFLUOPERAZINE HCL

AB	GENEVA	EQ 1MG BASE	N85785 001
AB		EQ 2MG BASE	N85786 001
AB		EQ 5MG BASE	N85789 001
AB		EQ 10MG BASE	N85788 001

TRIFLUPROMAZINE

/SUSPENSION;/ORAL/

/VESPRIN/

	/SQUIBB/	/EQ/50MG/HCL/5ML/	/N11491/004/
	∂ APOTHECON	EQ 50MG HCL/5ML	N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

AP +	APOTHECON	10MG/ML	N11325 004
AP +		20MG/ML	N11325 001
/AP/	/SQUIBB/	/10MG/ML/	/N11325/004/
/AP/		/20MG/ML/	/N11325/001/

/TABLET;/ORAL/

/VESPRIN/

	/+//SQUIBB/	/50MG/	/N11123/003/
		/10MG/	/N11123/001/
		/25MG/	/N11123/002/
	∂ SQUIBB	10MG	N11123 001
	∂	25MG	N11123 002
	∂	50MG	N11123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	NYLOS TRADING	5MG	N85622 001
/AA/	/TABLTCAPS/	/5MG/	/N85622/001/

TRIMEPRAZINE TARTRATE

SYRUP; ORAL
TRIMEPRAZINE TARTRATE

∂ PENNEX PHARMS	EQ 2.5MG BASE/5ML	N88285 001 APR 11, 1985
/∂/PHARM/BASICS/	/EQ/2.5MG/BASE/5ML/	/N88285/001/ /APR/11,/1985/

TRIOXSALEN

TABLET; ORAL
TRISORALEN

/ELDER/	/5MG/	/N12697/001/
ICN	5MG	N12697 001

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL

/AA/	/HEATHER/	/50MG/	/N83989/001/
	∂ HEATHER	50MG	N83989 001
AA	NYLOS TRADING	50MG	N85412 001
/AA/	/TABLTCAPS/	/50MG/	/N85412/001/

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

/AP/	/QUAD/	/3MG/ML/	/N89442/001/ /AUG/12,/1988/
	∂ QUAD	3MG/ML	N89442 001 AUG 12, 1988

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID

AB	PHARMACAPS	250MG	N73484 001 JUN 29, 1993

VALPROIC ACID

SYRUP; ORAL
MYPROIC ACID

AA	PENNEX PHARMS	250MG/5ML	N70868 001 JUL 01, 1986
/AA/	/PHARM/BASICS/	/250MG/5ML/	/N70868/001/ /JUL/01,/1986/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOCIN HCL IN PLASTIC CONTAINER

+ LILLY	EQ 500MG BASE/100ML	N50671 001 APR 29, 1993

POWDER FOR RECONSTITUTION; ORAL
VANCOCIN HCL

> ADD >	AB	LILLY	EQ 250MG BASE/5ML	N61667 002 JUL 13, 1983
> ADD >				
> ADD >	AB		EQ 500MG BASE/6ML	N61667 001
> ADD >		**VANCOLED**		
> ADD >	AB	LEDERLE	EQ 250MG BASE/5ML	N63321 001 OCT 15, 1993
> ADD >				
> ADD >	AB		EQ 500MG BASE/6ML	N63321 003 OCT 15, 1993
> ADD >				

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPTIN

/AP/	/KNOLL/	/2.5MG/ML/	/N18485/001/
AP	+ KNOLL	2.5MG/ML	N18485 001
	VERAPAMIL HCL		
AP	MARSAM	2.5MG/ML	N72233 001 FEB 26, 1993
AP		2.5MG/ML	N73485 001 SEP 27, 1993

TABLET; ORAL
VERAPAMIL HCL

AB	WATSON LABS	40MG	N72923 001 JUN 29, 1993
AB		40MG	N72924 001 JUN 29, 1993

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE
FUJISAWA 1MG/ML N89515 001
APR 29, 1987
/LYPHOMED/ /1MG/ML/ /N89515/001/
/APR/29,/1987/

VITAMIN A PALMITATE

CAPSULE; ORAL
AFAXIN
∂ STERLING EQ 50,000 UNITS BASE N83187 001
VITAMIN A
/AA/ /WHARTON/ /EQ 50,000 UNITS BASE/ /N83665/001/
∂ WHARTON EQ 50,000 UNITS BASE N83665 001
/AA/ /ZENITH/ /EQ 50,000 UNITS BASE/ /N83035/001/
/AA/ /EQ 50,000 UNITS BASE/ /N83190/001/
∂ ZENITH EQ 50,000 UNITS BASE N83035 001
∂ EQ 50,000 UNITS BASE N83190 001

INJECTABLE; INJECTION
AQUASOL A
/AP/ /ASTRA/ /EQ 50,000 UNITS BASE/ML/ /N06823/001/
ASTRA EQ 50,000 UNITS BASE/ML N06823 001
/VITAMIN A PALMITATE/
/AP/ /BEL/MAR/ /EQ 50,000 UNITS BASE/ML/ /N80819/001/
∂ BEL MAR EQ 50,000 UNITS BASE/ML N80819 001

WARFARIN SODIUM

TABLET; ORAL
COUMADIN
/BX/ /DUPONT/ /2MG/ /N09218/013/
/BX/ /2.5MG/ /N09218/018/
/BX/+/ /5MG/ /N09218/007/
/BX/+/ /10MG/ /N09218/005/
+ DUPONT 2MG N09218 013
5MG N09218 007
+ 10MG N09218 005
2.5MG N09218 018
4MG N09218 023
AUG 24, 1993

WARFARIN SODIUM

TABLET; ORAL
/PANWARFIN/
/BX/ /ABBOTT/ /2MG/ /N17020/001/
/BX/ /2.5MG/ /N17020/002/
/BX/ /5MG/ /N17020/003/
/BX/ /7.5MG/ /N17020/004/
/BX/ /10MG/ /N17020/005/
∂ ABBOTT 2MG N17020 001
∂ 2.5MG N17020 002
∂ 5MG N17020 003
∂ 7.5MG N17020 004
∂ 10MG N17020 005

XENON, XE-133

GAS; INHALATION
XENON XE 133
/AA/ /DUPONT/ /30MCI/VIAL/ /N17284/004/
/AA/ /40MCI/VIAL/ /N17284/005/
/AA/ /50MCI/VIAL/ /N17284/006/
/AA/ /60MCI/VIAL/ /N17284/007/
/AA/ /100MCI/VIAL/ /N17284/003/
AA MEDI PHYSICS 10MCI/VIAL N17687 002
AA 20MCI/VIAL N17687 003

XYLOSE

POWDER; ORAL
XYLO-PFAN
/AA/ /ADRIA/ /25GM/BOT/ /N17605/001/
AA SAVAGE 25GM/BOT N17605 001

ZINC SULFATE

/INJECTABLE;/INJECTION/
/ZINC/SULFATE/
/LYPHOMED/ /EQ/1MG/ZINC/ML/ /N19229/002/
/MAY/05,/1987/
∂ LYPHOMED EQ 1MG ZINC/ML N19229 002
MAY 05, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL
NEOPAP
/ALCON/ /120MG/ /N16401/001/ > DLT >
POLYMEDICA 120MG N16401 001 > DLT >
> ADD >
> ADD >

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
DRIXORAL PLUS
> DLT > /SCHERING/ /500MG;3MG;60MG/ /N19453/001/
> DLT > /MAY/22,/1987/
> ADD > + SCHERING PLOUGH 500MG;3MG;60MG N19453 001
> ADD > MAY 22, 1987

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
/ALUMINUM/HYDROXIDE/AND/MAGNESIUM/TRISILICATE/
/PENNEX/ /80MG;20MG/ /N89449/001/ > DLT >
/NOV/27,/1987/ > DLT >
@ PENNEX 80MG;20MG N89449 001 > DLT >
NOV 27, 1987
> ADD >
> ADD >

BACITRACIN; POLYMYXIN B SULFATE

/AEROSOL;/TOPICAL/
/LANABIOTIC/
/COMBE/ /500/UNITS/GM;/
/5,000/UNITS/GM/ /N50598/001/
/SEP/22,/1986/ > DLT >
@ COMBE 500 UNITS/GM; > ADD >
5,000 UNITS/GM N50598 001
SEP 22, 1986

CHLORHEXIDINE GLUCONATE > DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

SOLUTION; TOPICAL
HIBISTAT
/STUART/ /0.5%/ /N18300/001/
+ ZENECA 0.5% N18300 001

TINCTURE; TOPICAL
HIBITANE
/@/STUART/ /0.5%/ /N18049/001/
@ ZENECA 0.5% N18049 001

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL
CHLOR-TRIMETON
/SCHERING/ /8MG/ /N07638/001/
> DLT > /12MG/ /N07638/002/
> ADD > + SCHERING PLOUGH 8MG N07638 001
> ADD > + 12MG N07638 002

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DEMAZIN
/SCHERING/ /4MG;25MG/ /N18556/001/
> DLT > /MAY/14,/1984/
> ADD > + SCHERING PLOUGH 4MG;25MG N18556 001
> ADD > MAY 14, 1984

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
/ISOCLOR/
/CIBA/ /8MG;120MG/ /N18747/001/
> DLT > /MAR/06,/1986/
@ FISONS 8MG;120MG N18747 001
> ADD > MAR 06, 1986
> ADD >

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CHLOR-TRIMETON
/SCHERING/ /8MG;120MG/ /N18397/001/
> DLT > + SCHERING PLOUGH 8MG;120MG N18397 001
> ADD >

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

/SUSPENSION,/EXTENDED/RELEASE;/ORAL/
/PENNTUSS/
/FISONS/ /EQ/4MG/MALEATE/5ML;/
/EQ/10MG/BASE/5ML/ /N18928/001/
> DLT > /AUG/14,/1985/
@ FISONS EQ 4MG MALEATE/5ML;
> ADD > EQ 10MG BASE/5ML N18928 001
> ADD > AUG 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

>_DLT_>	/SUSPENION;/EXTENDED/RELEASE;/ORAL/		
>_DLT_>	/CORSYM/		
>_DLT_>	/FISONS/	/EQ/4MG/MALEATE/5ML;/	
>_DLT_>		/EQ/37.5MG/HCL/5ML/	/N18050/001/
>_DLT_>			/JAN/04,/1984/
>_ADD_>	@ FISONS	EQ 4MG MALEATE/5ML;	
>_ADD_>		EQ 37.5MG HCL/5ML	N18050 001
>_ADD_>			JAN 04, 1984

CLEMASTINE FUMARATE

	TABLET; ORAL		
	CLEMASTINE FUMARATE		
>_ADD_>	GENEVA	1.34MG	N73458 001
>_ADD_>			OCT 31, 1993

CLOTRIMAZOLE

	CREAM; TOPICAL		
	CLOTRIMAZOLE		
	TARO	1%	N72640 002
			AUG 31, 1993
	LOTRIMIN AF		
>_DLT_>	/SCHERING/	/1%/	/N17619/002/
>_DLT_>			/OCT/27,/1989/
>_ADD_>	+ SCHERING PLOUGH	1%	N17619 002
>_ADD_>			OCT 27, 1989
	CREAM; VAGINAL		
	CLOTRIMAZOLE		
	NMC	1%	N74165 001
			JUL 16, 1993
	GYNE-LOTRIMIN		
>_DLT_>	/SCHERING/	/1%/	/N18052/002/
>_DLT_>			/NOV/30,/1990/
>_ADD_>	+ SCHERING PLOUGH	1%	N18052 002
>_ADD_>			NOV 30, 1990
	CREAM, SUPPOSITORY; TOPICAL, VAGINAL		
	GYNE-LOTRIMIN COMBINATION PACK		
	+ SCHERING PLOUGH	1%;100MG	N20289 002
			APR 26, 1993

CLOTRIMAZOLE

	LOTION; TOPICAL		
	LOTRIMIN AF		
>_ADD_>	+ SCHERING	1%	N18813 002
>_ADD_>			OCT 27, 1989
>_DLT_>		/1%/	/N18813/002/
>_DLT_>			/OCT/27,/1989/
	SOLUTION; TOPICAL		
	LOTRIMIN AF		
>_DLT_>	/SCHERING/	/1%/	/N17613/002/
>_DLT_>			/OCT/27,/1989/
>_ADD_>	+ SCHERING PLOUGH	1%	N17613 002
>_ADD_>			OCT 27, 1989

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

	TABLET, EXTENDED RELEASE; ORAL		
	DISOPHROL		
>_DLT_>	/SCHERING/	/6MG;120MG/	/N13483/004/
>_DLT_>			/SEP/13,/1982/
>_ADD_>	SCHERING PLOUGH	6MG;120MG	N13483 004
>_ADD_>			SEP 13, 1982
	DRIXORAL		
>_DLT_>	/SCHERING/	/6MG;120MG/	/N13483/003/
>_DLT_>			/SEP/13,/1982/
>_ADD_>	+ SCHERING PLOUGH	6MG;120MG	N13483 003
>_ADD_>			SEP 13, 1982

DIPHENHYDRAMINE HYDROCHLORIDE

	SYRUP; ORAL		
	DIPHEN		
	PENNEX PHARMS	12.5MG/5ML	N70118 001
			OCT 01, 1985
	/PHARM/BASICS/	/12.5MG/5ML/	/N70118/001/
			/OCT/01,/1985/
	DIPHENHYDRAMINE HCL		
	BARRE	12.5MG/5ML	N70497 001
			APR 25, 1989
	/NASKA/	/12.5MG/5ML/	/N70497/001/
			/APR/25,/1989/

IBUPROFEN

TABLET; ORAL
IBUPROFEN
/LUCHEM/ /200MG/ /N72901/001/ /DEC/19,/1991/
/200MG/ /N72903/001/ /DEC/19,/1991/

IBUPROFEN
NORTON HN 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991

/IBUPROFEN/
/OHM/ /200MG/ /N71214/001/ /DEC/01,/1986/

IBUPROFEN
/ZENITH/ /200MG/ /N71154/001/ /OCT/27,/1987/ > DLT > > DLT >
@ ZENITH 200MG N71154 001 OCT 27, 1987 > ADD > > ADD >

IBUPROHM
OHM 200MG N71214 001 DEC 01, 1986

/NEUVIL/
/LUCHEM/ /200MG/ /N71144/001/ /JAN/20,/1987/ > DLT > > DLT > > DLT > > ADD >

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

/INJECTABLE;/INJECTION/
/PROTAMINE,/ZINC/&/ILETIN/I/(BEEF-PORK)/
/LILLY/ /40/UNITS/ML/ /N17932/001/
/100/UNITS/ML/ /N17932/002/
@ LILLY 40 UNITS/ML N17932 001
@ 100 UNITS/ML N17932 002

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
WATSON LABS 1MG/5ML N73062 001 MAY 28, 1993 > DLT > > DLT > > DLT > > ADD > > ADD >

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL
LOPERAMIDE HCL
NOVOPHARM 2MG N73254 001 JUL 30, 1993

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT 7 COMBINATION PACK
+ ADVANCED CARE 2%;100MG N20288 002 APR 26, 1993

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUCLEAR
/SCHERING/ /0.025%/ /N18471/001/ /MAY/30,/1986/
SCHERING PLOUGH 0.025% N18471 001 MAY 30, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/SUDAFED/12/HOUR/
/BURROUGHS/WELLCOME/ /120MG/ /N17941/002/
@ BURROUGHS WELLCOME 120MG N17941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/CAPSULE;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N19268/001/ /JAN/15,/1985/

CAPSULE, EXTENDED RELEASE; ORAL
/ACTIFED/
/BURROUGHS/WELLCOME/ /120MG;5MG/ /N18996/001/ /JUN/17,/1985/
@ BURROUGHS WELLCOME 120MG;5MG N18996 001 JUN 17, 1985

/SYRUP;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /30MG/5ML;1.25MG/5ML/ /N11935/003/ /NOV/26,/1982/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/SYRUP;/ORAL/
/TRIOFED/
/BARRE/ /30MG/5ML;1.25MG/5ML/ /N88115/001/
/MAR/04,/1983/

/TRIPOSED/
/HALSEY/ /30MG/5ML;1.25MG/5ML/ /N88213/002/
/MAR/30,/1984/

/TABLET;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N11936/002/
/NOV/26,/1982/

/TRI-SUDO/
/MD/PHARM/ /60MG;2.5MG/ /N85024/002/
/JAN/10,/1984/

/TRIPODRINE/
/DANBURY/PHARMA/ /60MG;2.5MG/ /N88112/001/
/JAN/26,/1983/

/TRIPOSED/
/HALSEY/ /60MG;2.5MG/ /N88192/002/
/MAY/01,/1984/

/TRIPROLIDINE/HCL/AND/PSEUDOEPHEDRINE/HCL/
/CHELSEA/ /60MG;2.5MG/ /N88118/002/
/JAN/26,/1984/

PSEUDOEPHEDRINE POLISTIREX

> DLT > /SUSPENION;/EXTENDED/RELEASE;/ORAL/
> DLT > /PSEUDO-12/
> DLT > /FISONS/ /EQ/60MG/HCL/5ML/ /N19401/001/
> DLT > /JUN/19,/1987/
> ADD > @ FISONS EQ 60MG HCL/5ML N19401 001
> ADD > JUN 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
AFRINOL
> DLT > /SCHERING/ /120MG/ /N18191/001/
> ADD > + SCHERING PLOUGH 120MG N18191 001

TRIPROLIDINE HYDROCHLORIDE

> DLT > /SYRUP;/ORAL/
> DLT > /ACTIDIL/
> DLT > /BURROUGHS/WELLCOME/ /1.25MG/5ML/ /N11496/002/
> DLT > /JUL/01,/1983/

TRIPROLIDINE HYDROCHLORIDE

> DLT > /SYRUP;/ORAL/
> DLT > /ACTIDIL/
> ADD > @ BURROUGHS WELLCOME 1.25MG/5ML N11496 002
> ADD > JUL 01, 1983

> DLT > /TABLET;/ORAL/
> DLT > /ACTIDIL/
> DLT > /BURROUGHS/WELLCOME/ /2.5MG/ /N11110/002/
> DLT > /JUL/01,/1983/
> ADD > @ BURROUGHS WELLCOME 2.5MG N11110 002
> ADD > JUL 01, 1983

INDIUM^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR
AMERSHAM N/A N19862
DEC 29, 1992

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January thru October 1993]

NAME *Generic/Chemical* *TN=Trade Name*	***INDICATION DESIGNATED***	***SPONSOR & ADDRESS*** *DD=Date Designated* *MA=Marketing Approval*
2-O-DESULFATED HEPARIN TN= AEROPIN	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs. 7702 PARHAM ROAD RICHMOND VA 23294 DD 09/17/93 MA / /
8-METHOXSALEN TN= UVADEX	FOR USE IN CONJUNCTION WITH THE UVAR PHOTOPHERESIS TO TREAT DIFFUSE SYSTEMIC SCLEROSIS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 06/22/93 MA / /
9-[3-PYRIDYLMETHYL]-9-DEAZAGUANINE TN=	TREATMENT OF CUTANEOUS T-CELL LYMPHOMA.	BIOCRYST PHARMACEUTICALS, INC. 2190 PARKWAY LAKE DRIVE BIRMINGHAM AL 35244 DD 10/05/93 MA / /
AMINOSALICYLATE SODIUM TN=	TREATMENT OF CROHN'S DISEASE.	SYNCOM PHARMACEUTICALS, INC. 155 PASSAIC AVENUE FAIRFIELD NJ 07004 DD 04/06/93 MA / /
AMINOSIDINE TN= GABBROMICINA	TREATMENT OF TUBERCULOSIS.	KANYOK, THOMAS P. PHARM.D. UNIVERSITY OF RHODE ISLAND PROVIDENCE RI 02908-4735 DD 05/14/93 MA / /
AMIODARONE TN= AMIO-AQUEOUS	TREATMENT OF INCESSANT VENTRICULAR TACHYCARDIA.	ACADEMIC PHARMACEUTICALS, IN 25720 SAUNDERS ROAD NORTH LAKE FOREST IL 60045 DD 08/17/93 MA / /
ANTI-THYMOCYTE SERUM TN= NASHVILLE RABBIT ANTI-THYMOCYTE SERUM	TREATMENT OF ALLOGRAFT REJECTION, INCLUDING SOLID ORGAN (KIDNEY, LIVER, HEART, LUNG, AND PANCREAS) AND BONE MARROW TRANSPLANTATION.	APPLIED MEDICAL RESEARCH 1600 HAYES STREET NASHVILLE TN 37203 DD 06/02/93 MA / /
APOMORPHINE HCL INJECTION TN=	TREATMENT OF THE ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	BRITANNIA PHARMACEUTICALS LTD FORUM HOUSE, BRIGHTON ROAD REDHILL, SURREY UK DD 04/22/93 MA / /
ATOVAQUONE TN= MEPRON	TREATMENT AND SUPPRESSION OF TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
ATOVAQUONE TN= MEPRON	PRIMARY PROPHYLAXIS OF HIV-INFECTED PERSONS AT HIGH RISK FOR DEVELOPING TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
BISPECIFIC ANTIBODY 520C9x22 TN=	IN VIVO SEROTHERAPY OF PATIENTS WITH OVARIAN CANCER.	MEDAREX 12 COMMERCE AVENUE WEST LEBANON NH 03784 DD 10/05/93 MA / /
BLEOMYCIN SULFATE TN= BLENOXANE	TREATMENT OF MALIGNANT PLEURAL EFFUSION.	BRISTOL-MYERS SQUIBB PO BOX 4000 PRINCETON NJ 08543-4000 DD 09/17/93 MA / /
BOVINE WHEY PROTEIN CONCENTRATE TN= IMMUNO-C	TREATMENT OF CRYPTOSPORIDIOSIS CAUSED BY THE PRESENCE OF CRYPTOSPORIDIUM PARVUM IN THE GASTROINTESTINAL TRACT OF PATIENTS WHO ARE IMMUNODEFICIENT/IMMUNOCOMPROMISED OR IMMUNOCOMPETENT.	BIOMUNE SYSTEMS, INCORPORATED 40 EAST SOUTH TEMPLE SUITE 310 SALT LAKE CITY UT 84111 DD 09/30/93 MA / /
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF NON-HODGKIN'S LYMPHOMA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202 SOUTH, P.O. BOX 300 RARITAN NJ 08869-0602 DD 04/19/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
COLFOSCERIL PALMITATE, CETYL ALCOHOL, TYLOXAPOL TN= EXOSURF	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 01/11/93 MA / /
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TN=	TREATMENT OF CYSTIC FIBROSIS.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 01/08/93 MA / /
DEPOFOAM ENCAPSULATED CYTARABINE TN=	TREATMENT OF NEOPLASTIC MENINGITIS.	KIM, SINIL M.D. UCSD CANCER CENTER/0812 SAN DIEGO CA 92103 DD 06/02/93 MA / /
DISODIUM CLODRONATE TN=	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY.	DISCOVERY EXPERIMENTAL & DEVELOPMENT,INC 29949 S.R. 54 WEST WESLEY CHAPEL FL 33543 DD 06/16/93 MA / /
FACTOR XIII, RECOMBINANT TN=	TREATMENT OF CONGENITAL FACTOR XIII DEFICIENCY.	ZYMOGENETICS, INC. 4225 ROOSEVELT WAY SEATTLE WA 98105 DD 04/22/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE FOLLOWING BONE MARROW TRANSPLANTATION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA / /
INTERFERON BETA (RECOMBINANT HUMAN) TN=	TREATMENT OF PRIMARY BRAIN TUMORS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 01/13/93 MA / /
INTERLEUKIN-3, HUMAN, RECOMBINANT TN=	FOR SEQUENTIAL ADMINISTRATION WITH SARGRAMOSTIM TO ACCELERATE NEUTROPHIL AND PLATELET RECOVERY IN PATIENTS UNDERGOING AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF HODGKIN'S DISEASE OR NON-HODGKIN'S LYMPHOMA.	SANDOZ PHARMACEUTICALS CORP. 59 ROUTE 10 EAST HANOVER NJ 07936-1080 DD 09/30/93 MA / /
LIPOSOMAL DAUNORUBICIN TN= DAUNOXOME	TREATMENT OF PATIENTS WITH ADVANCED HIV-ASSOCIATED KAPOSI'S SARCOMA.	VESTAR, INC. 650 CLIFFSIDE DRIVE SAN DIMAS CA 91773 DD 05/14/93 MA / /
METHOTREXATE TN= RHEUMATREX	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	LEDERLE LABORATORIES 401 N. MIDDLETOWN ROAD PEARL RIVER NY 10965-1299 DD 08/23/93 MA / /
MODAFINIL	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY.	CEPHALON, INC. 145 BRANDYWINE PARKWAY WEST CHESTER PA 19380-4245 DD 03/15/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD= Date Designated MA= Marketing Approval
MONOCLONAL ANTIBODY FOR IMMUNIZATION AGAINST LUPUS NEPHRITIS TN=	TREATMENT OF LUPUS NEPHRITIS.	MEDCLONE, INC. 2435 MILITARY AVENUE LOS ANGELES CA 90064 DD 01/07/93 MA / /
MONOLAURIN TN= GLYLORIN	TREATMENT OF CONGENITAL PRIMARY ICHTHYOSIS.	CELLEGY PHARMACEUTICALS, INC. 371 BEL MARIN KEYS, SUITE 210 NOVATO CA 94949 DD 04/29/93 MA / /
MYTOMYCIN-C TN=	TREATMENT OF REFRACTORY GLAUCOMA AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY.	IOP INCORPORATED 3100 AIRWAY AVENUE COSTA MESA CA 92626 DD 08/20/93 MA / /
NITRIC OXIDE TN=	TREATMENT OF PERSISTENT PULMONARY HYPERTENSION IN THE NEWBORN.	ANAQUEST, INCORPORATED 110 ALLEN ROAD LIBERTY CORNER NJ 07938 DD 06/22/93 MA / /
PRIMAQUINE PHOSPHATE TN=	FOR USE IN COMBINATION WITH CLINDAMYCIN HYDROCHLORIDE IN THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	STERLING WINTHROP INC. 90 PARK AVENUE NEW YORK NY 10016 DD 07/23/93 MA / /
PROSTAGLANDIN E1 ALPHA-CYCLODEXTRIN TN= VASOPROST	TREATMENT OF SEVERE PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (CRITICAL LIMB ISCHEMIA) IN PATIENTS WHERE OTHER PROCEDURES, GRAFTS OR ANGIOPLASTY, ARE NOT INDICATED.	SCHWARZ PHARMA 5600 WEST COUNTY LINE ROAD MEQUON WI 53092 DD 10/20/93 MA / /
PROTEIN C CONCENTRATE TN= PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR USE IN THE PREVENTION AND TREATMENT OF PURPURA FULMINANS IN MENINGOCOCCEMIA.	IMMUNO CLINICAL RESEARCH CORP. 750 LEXINGTON AVENUE, 19TH FLOO NEW YORK NY 10022 DD 04/22/93 MA / /
PROTIRELIN TN=	PREVENTION OF INFANT RESPIRATORY DISTRESS SYNDROME ASSOCIATED WITH PREMATURITY.	UCB PHARMACEUTICALS, INC. 5505-A ROBIN HOOD ROAD NORFOLK VA 23513 DD 08/24/93 MA / /
PULMONARY SUFACTANT REPLACMENT, PORCINE TN= CUROSURF	FOR THE TREATMENT AND PREVENTION OF RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS.	CHIESI PHARMACEUTICALS, INC. 150 DANBURY ROAD RIDGEFIELD CT 06877 DD 08/02/93 MA / /
RII RETINAMIDE TN=	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	SPARTA PHARMACEUTICALS, INCORPORATED PO BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 05/06/93 MA / /
RILUZOLE TN=	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA / /
ROQUINIMEX TN= LINOMIDE	TO PROLONG TIME TO RELAPSE IN LEUKEMIA PATIENTS WHO HAVE UNDERGONE AUTOLOGOUS BONE MARROW TRANSPLANTATION.	KABI PHARMACIA, INC. 800 CENTENNIAL AVENUE PISCATAWAY NJ 08855-1327 DD 07/01/93 MA / /
SECALCIFEROL TN= OSTEO-D	TREATMENT OF FAMILIAL HYPOPHOSPHATEMIC RICKETS.	LEMMON COMPANY 650 CATHILL ROAD SELLERSVILLE PA 18960 DD 07/26/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN-Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD-Date Designated MA-Marketing Approval
SOMATROPIN TN= BIOTROPIN	TREATMENT OF CACHEXIA ASSOCIATED WITH AIDS.	BIO-TECHNOLOGY GENERAL CORPORATION 1250 BROADWAY, 20th FLOOR NEW YORK NY 10001 DD 02/12/93 MA / /
SUCRALFATE TN=	TREATMENT OF ORAL MUCOSITIS AND STOMATITIS FOLLOWING RADIATION THERAPY FOR HEAD AND NECK CANCER.	FUISZ TECHNOLOGIES, LTD. 3810 CONCORDE PARKWAY, SUITE 100 CHANTILLY VA 22021 DD 07/15/93 MA / /
THALIDOMIDE TN=	TREATMENT OF THE CLINICAL MANIFESTATIONS OF MYCOBACTERIAL INFECTION CAUSED BY MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIA.	CELGENE CORPORATION 7 POWDER HORN DRIVE WARREN NJ 07059 DD 01/12/93 MA / /
TOREMIFENE TN= ESTRINEX	TREATMENT OF DESMOID TUMORS.	ADRIA LABORATORIES P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 08/17/93 MA / /
RETINOIN TN= TRETINOIN LF, IV	TREATMENT OF ACUTE AND CHRONIC LEUKEMIA.	ARGUS PHARMACEUTICALS, INC. 3400 RESEARCH FOREST DRIVE THE WOODLANDS TX 77381 DD 01/14/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN 1 TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN II TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
VASOACTIVE INTESTINAL POLYPEPTIDE TN=	TREATMENT OF ACUTE ESOPHAGEAL FOOD IMPACTION.	RESEARCH TRIANGLE PHARMACEUTICALS 200 WESTPARK CORPORATE CENTER DURHAM NC 27713 DD 06/23/93 MA / /

NAME *Generic/Chemical* *TN=Trade Name*	***INDICATION DESIGNATED***	***SPONSOR & ADDRESS*** *DD=Date Designated* *MA=Marketing Approval*

Orphan Drug Approvals

ANTIHEMOPHILIC FACTOR (RECOMBINANT) TN= KOGENATE	PROPHYLAXIS AND TREATMENT OF BLEEDING IN INDIVIDUALS WITH HEMOPHILIA A OR FOR PROPHYLAXIS WHEN SURGERY IS REQUIRED IN INDIVIDUALS WITH HEMOPHILIA A.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94701 DD 09/25/89 MA 02/25/93
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF HAIRY CELL LEUKEMIA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 11/15/90 MA 02/26/93
FELBAMATE TN= FELBATOL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	WALLACE LABORATORIES 301B COLLEGE ROAD EAST PRINCETON NJ 08540 DD 01/24/89 MA 07/29/93
INTERFERON BETA, RECOMBINANT HUMAN TN=BETASERON	TREATMENT OF MULTIPLE SCLEROSIS.	CHIRON CORPORATION 4560 HORTON STREET EMERYVILLE CA 94608 DD 11/17/88 MA 07/23/93
LEUPROLIDE ACETATE TN= LUPRON INJECTION	TREATMENT OF CENTRAL PRECOCIOUS PUBERTY.	TAP PHARMACEUTICALS, INC. 2355 WAUKEGAN ROAD DEERFIELD IL 60015 DD 07/25/88 MA 04/16/93
LEVOMETHADYL ACETATE HYDROCHLORIDE TN=ORLAAM	TREATMENT OF HEROIN ADDICTS SUITABLE FOR MAINTENANCE ON OPIATE AGONISTS.	BIODEVELOPMENT CORPORATION 1300 NORTH 17TH STREET, SUITE 300 ARLINGTON VA 22209-2306 DD 01/24/84 MA 07/09/93
LODOXAMIDE TROMETHAMINE TN= ALOMIDE OPHTHALMIC SOLUTION	TREATMENT OF VERNAL KERATOCONJUNCTIVITIS.	ALCON LABORATORIES, INC. 6201 SOUTH FREEWAY FORT WORTH TX 76134 DD 10/16/91 MA 09/23/93
MEGESTROL ACETATE TN= MEGACE	TREATMENT OF PATIENTS WITH ANOREXIA, CACHEXIA, OR SIGNIFICANT WEIGHT LOSS (=/>10% OF BASELINE BODY WEIGHT) AND CONFIRMED DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	BRISTOL-MYERS SQUIBB 2400 WEST LLOYD EXPRESSWAY EVANSVILLE IN 47721-0001 DD 04/13/88 MA 09/10/93

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1993 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

BUMETANIDE (TABLET)	APR 23, 1993
BUSIPRONE HYDROCHLORIDE (TABLET)	AUG 13, 1993
CEFACLOR (CAPSULE AND SUSPENSION)	APR 23, 1993
CAPTOPRIL (TABLET)	MAY 13, 1993
CHOLESTRYRAMINE (POWDER)	JUL 15, 1993
GLIPIZIDE (TABLET)	APR 23, 1993
GLYBURIDE (TABLET)	APR 23, 1993
GUANABENZ ACETATE (TABLET)	APR 23, 1993
INDAPAMIDE (TABLET)	APR 23, 1993
KETOPROFEN (CAPSULE)	APR 23, 1993
ORAL EXTENDED (CONTROLLED RELEASE)	SEP 09, 1993
PINDOLOL (TABLET)	APR 23, 1993
RANITIDINE HYDROCHLORIDE (TABLET)	APR 23, 1993
TRIAZOLAM (TABLET)	DEC 24, 1992

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

AMINOSALICYLIC ACID GRANULES, ENTERIC-COATED; ORAL	4GM/PACKET	92 P-0356/ CP1	JACOBUS	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 03, 1993
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 50MG BASE/ML (10ML/VIAL) (20ML/VIAL)	92 P-0468/ CP1	BULL	NEW DOSAGE FORM	APPROVED SEP 01, 1993
CARBOPLATIN INJECTABLE; INJECTION	10MG/ML (5ML/VIAL) (15ML/VIAL) (45ML/VIAL)	92 P-0467/ CP1	BULL	NEW DOSAGE FORM	APPROVED MAY 20, 1993
CHLORPROMAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0284/ CP1	UDL	NEW STRENGTH	APPROVED JAN 07, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (40ML/VIAL)	92 P-0365/ CP1	LYPHOMED	NEW STRENGTH	APPROVED FEB 11, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (100ML/CONTAINER)	92 P-0045/ CP1	MARSAM	NEW STRENGTH	APPROVED SEP 01, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (12.5MG/VIAL)	92 P-0355/ CP1	LEDERLE	NEW STRENGTH	APPROVED JAN 07, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/CONTAINER)	91 P-0460/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 11, 1993
LACTULOSE CRYSTAL; ORAL	10GM/PACKET	92 P-0370/ CP1	BENNETT AND COMPANY	NEW DOSAGE FORM	APPROVED JAN 07, 1993
METHYLPHENIDATE HYDROCHLORIDE; TABLET, EXTENDED RELEASE; ORAL	10MG	92 P-0400/ CP1	MD PHARM	NEW STRENGTH	APPROVED MAR 22, 1993
PREDNISOLONE SYRUP; ORAL	10MG/5ML	92 P-0439/ CP1	WE PHARMS	NEW STRENGTH	APPROVED MAY 20, 1993
PROPRANOLOL HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	10MG 20MG 60MG 80MG 90MG	93 P-0049/ CP1	FLEMINGTON PHARM	NEW DOSAGE FORM NEW STRENGTH	APPROVED SEP 01, 1993
TRIMETHOPRIM SOLUTION; ORAL	25MG/5ML	92 P-0500/ CP1	ASCENT PHARMS	NEW DOSAGE FORM	APPROVED MAY 20, 1993

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-20	SINGLE 32MG DOSE

REFERENCES
NEW INDICATION

I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT

REFERENCES
PATENT USE CODE

U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18473 001	ALBUTEROL; VENTOLIN				I-93	JUL 20, 1996
19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS				I-93	JUL 20, 1996
19604 001	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4751071	JUN 14, 2005			
19604 002	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4751071	JUN 14, 2005		NS	DEC 23, 1995
18276 004	ALPRAZOLAM; XANAX	5061494	OCT 29, 2008			
20258 001	APRACLONIDINE HYDROCHLORIDE; IOPIDINE	4517199	MAY 14, 2002	U-15	NS	JUL 30, 1996
19402 001	ASTEMIZOLE; HISMANAL	4219559	AUG 26, 1999		NCE	DEC 29, 1993
20045 001	AVOBENZONE; SHADE UVAGUARD	4522807	JUN 11, 2002		NC	DEC 07, 1995
		4387089	JUN 07, 2002			
19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
20186 001	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
					NC	FEB 26, 1996
20186 002	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
					NC	FEB 26, 1996
20186 003	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
					NC	FEB 26, 1996
18343 001	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
18343 002	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
18343 003	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
18343 005	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
20210 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
20210 002	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
20229 001	CLADRIBINE; LEUSTATIN				NCE	FEB 26, 1998
					ODE	FEB 26, 2000
19287 001	DIAZEPAM; DIZAC	RE32393	SEP 18, 1996		NDF	JUN 18, 1996
18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
19680 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
18651 001	DRONABINOL; MARINOL				ODE	DEC 22, 1999
18651 002	DRONABINOL; MARINOL				ODE	DEC 22, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18651 003	DRONABINOL; MARINOL				ODE	DEC 22, 1999
>ADD>	19879 002	EFLORNITHINE HYDROCHLORIDE; ORNIDYL	4399151	AUG 16, 2000		NCE	NOV 28, 1995
>DLT>	~~19879 002~~	~~EFLORNITHINE HYDROCHLORIDE; ORNIDYL~~	~~4339151~~	~~AUG 16, 2000~~		~~NCE~~	~~NOV 28, 1995~~
	19616 004	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	19616 005	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	20164 001	ENOXAPARIN SODIUM; LOVENOX				NCE	MAR 29, 1998
	20189 001	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20189 002	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20189 003	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20073 001	FLUMAZENIL; MAZICON	4316839	MAR 03, 2003		NCE	DEC 20, 1996
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003			
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003			
			4314081	FEB 02, 2001			
			4194009	APR 19, 1994			
			4018895	APR 19, 1994	U-12		
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4215113	JUN 06, 2000	U-64	NCE	SEP 27, 1996
	20123 001	GADODIAMIDE; OMNISCAN	4687659	AUG 18, 2004	U-76	NCE	JAN 08, 1998
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4957939	MAR 03, 2004		I-94	AUG 17, 1996
	17783 003	GLIPIZIDE; GLUCOTROL				NCE	MAY 08, 1994
	20051 003	GLYBURIDE; GLYNASE	4916163	APR 10, 2007		NP	MAR 04, 1995
			4735805	APR 05, 2005		NCE	MAY 01, 1994
	20051 004	GLYBURIDE; GLYNASE	4916163	APR 10, 2007		NP	MAR 04, 1995
			4735805	APR 05, 2005		NCE	MAY 01, 1994
	19726 001	GOSERELIN ACETATE; ZOLADEX				I-88	FEB 02, 1996
	19032 001	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19032 002	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19891 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	19892 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	18538 002	INDAPAMIDE; LOZOL				NS	APR 29, 1996
						NCE	JUL 06, 1993
>ADD>	18956 001	IOHEXOL; OMNIPAQUE 180	4250113	DEC 26, 1999		I-97	JUL 13, 1996
>ADD>			4021481	MAY 03, 1994		NR	JUL 13, 1996
	19710 005	IOVERSOL; OPTIRAY 350				I-48	JUL 27, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20228 001	IPRATROPIUM BROMIDE; ATROVENT				NDF	SEP 29, 1996
	20215 001	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
	20215 002	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
	20225 001	ISOSORBIDE MONONITRATE; IMDUR				NS	JUN 30, 1996
						NCE	DEC 30, 1996
	20225 002	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
						NCE	DEC 30, 1996
	19084 001	KETOCONAZOLE; NIZORAL				NDF	AUG 12, 1996
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4335125	JUN 15, 1999		I-30	JAN 27, 1996
			5110493	MAY 05, 2009	U-75	NCE	NOV 30, 1994
			4454151	JUN 12, 2001	U-75	NDF	NOV 09, 1995
	20263 001	LEUPROLIDE ACETATE; LUPRON	4089969	MAY 16, 1997	U-75		
			4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
			4005063	JAN 25, 1996		ODE	APR 16, 2000
	20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
			4005063	JAN 25, 1996		ODE	APR 16, 2000
	20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
			4005063	JAN 25, 1996		ODE	APR 16, 2000
	20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			4005063	JAN 25, 1996		ODE	APR 16, 2000
	18948 001	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
						ODE	DEC 16, 1999
	18948 002	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
						ODE	DEC 16, 1999
	20315 001	LEVOMETHADYL ACETATE HYDROCHLORIDE; ORLAAM				NCE	JUL 09, 1998
						ODE	JUL 09, 2000
	19558 001	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 002	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 003	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 004	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 001	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 002	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 003	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 004	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 005	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	20191 001	LODOXAMIDE TROMETHAMINE; ALOMIDE				NCE	SEP 23, 1998
						ODE	SEP 23, 2000
>ADD>	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	MAY 05, 2005	U-36	NCE	FEB 21, 1997
	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 1998	U-77	NCE	APR 12, 1998
>ADD>	20264 001	MEGESTROL ACETATE; MEGACE				ODE	SEP 10, 2000
	20049 001	MESALAMINE; PENTASA	4980173	DEC 25, 2007	U-78		
			4496553	JAN 29, 2002	U-78	NP	MAY 10, 1996
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
	19356 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 2000		NCE	MAR 01, 1993
	20150 001	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 002	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 003	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20066 001	NICOTINE POLACRILEX; NICORETTE DS				NCE	JAN 13, 1994
	20198 001	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 002	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 003	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	19921 001	OFLOXACIN; OCUFLOX	4551456	NOV 05, 2002	U-80	NDF	JUL 30, 1996
			4382892	MAY 10, 2000			
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		D-20	FEB 02, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						I-9	AUG 13, 1996
>ADD>	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		NCE	JAN 04, 1996
>DLT>	~~20103 001~~	~~ONDANSETRON HYDROCHLORIDE; ZOFRAN~~	~~4695578~~	~~SEP 22, 2004~~		~~NCE~~	~~JAN 04, 1996~~
>ADD>	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		NCE	JAN 04, 1996
>DLT>	~~20103 002~~	~~ONDANSETRON HYDROCHLORIDE; ZOFRAN~~	~~4695578~~	~~SEP 22, 2004~~		~~NCE~~	~~JAN 04, 1996~~
	20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996	U-53		
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
	20091 001	PERFLUBRON; IMAGENT				NCE	AUG 13, 1998
	20014 001	PIRBUTEROL ACETATE; MAXAIR	4664107	MAY 12, 2004			
	19795 001	PODOFILOX; CONDYLOX				NCE	DEC 13, 1995
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NE	SEP 23, 1994
>ADD>	20279 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NE	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN				I-90	MAR 08, 1996
	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4996061	FEB 26, 2008			
			4929605	MAY 29, 2007	U-81		
			4254129	MAR 03, 1998	U-81		
>ADD>	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
>ADD>	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
>ADD>	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
>ADD>	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
	50689 001	RIFABUTIN; MYCOBUTIN				ODE	DEC 23, 1999
	19649 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
	19650 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	20134 001	STRONTIUM CHLORIDE, SR-89; METASTRON				NCE	JUN 18, 1998
	19050 001	SUFENTANIL CITRATE; SUFENTA				NR	MAR 19, 1996
						I-89	MAR 19, 1996
	20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	MAR 28, 2006	U-72		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
	20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
	20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
	20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
	19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3				I-87	NOV 27, 1995
	20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
	20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
	18163 003	TEMAZEPAM; RESTORIL	5211954	MAY 18, 2010			
			5030632	JUL 09, 2008	U-70	NS	OCT 25, 1994
	20223 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
			4112097	SEP 05, 1995			
			4026894	MAY 31, 1994		I-96	SEP 29, 1996
	20223 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
			4112097	SEP 05, 1995			
			4026894	MAY 31, 1994		I-96	SEP 29, 1996
	20223 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
			4112097	SEP 05, 1995			
			4026894	MAY 31, 1994		I-96	SEP 29, 1996
	20223 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
			4112097	SEP 05, 1995			
			4026894	MAY 31, 1994		I-96	SEP 29, 1996
	18949 001	TERFENADINE; SELDANE	4254129	MAR 03, 1998	U-81		
>ADD>	19762 001	TESTOSTERONE; TESTODERM				NDF	OCT 12, 1996
>ADD>	19762 002	TESTOSTERONE; TESTODERM				NDF	OCT 12, 1996
	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
			4051141	SEP 27, 1996		NCE	OCT 31, 1996
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
			4051141	SEP 27, 1996		NCE	OCT 31, 1996
	20136 001	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			
	20136 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			
	20136 003	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20136 004	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
		4018929	APR 19, 1994		NCE	AUG 23, 1998
		RE30633	APR 19, 1994			
20137 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
		4018929	APR 19, 1994		NCE	AUG 23, 1998
		RE30633	APR 19, 1994			
18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
18776 003	VECURONIUM BROMIDE; NORCURON	4215104	JUL 29, 1997			
		4297351	OCT 27, 1998			
19908 001	ZOLPIDEM TARTRATE; AMBIEN	4237126	DEC 02, 1997		NCE	APR 30, 1994
19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997
		4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997

*U.S. Government Printing Office: 1993 — 301-037/80004

New 14th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7229

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

(Company or personal name)

(Additional address/attention line)

(Street address)

(City, State, ZIP Code)

(_____)
(Daytime phone including area code)

(Purchase Order No.)

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents

☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐

☐ VISA or MasterCard

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(04/93)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 783-3238.

RM301.45 .A66 1985-

Approved drug products with
therapeutic equivalence
C:368627 M:154953 O:12771735

Library Use Only

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110

ST. LOUIS COLLEGE OF PHARMACY
3 2201 90036 5095

RM301.45 .A66 1993 Oct Suppl

Approved drug products with therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only